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Abstract
Proteins are the primary functional units of biology and the direct targets of most drugs,
yet there is limited knowledge of the genetic factors determining inter-individual variation
in protein levels (protein quantitative trait loci (pQTLs)). Limitations in high-throughput
proteomic measurement technology have meant well-powered genome-wide association
studies for large number of proteins so far have lagged behind many of the other "omic"
studies such as transcriptomics and metabolomics. This is made more challenging by
the complexity of human plasma, characterised by high dynamic range spanning several
magnitudes of concentrations and a large number of low abundance proteins.
By using an expanded high-throughput multiplex aptamer-based proteomic assay with
more than twice the proteome coverage of previous studies, I am able to greatly expand on
existing knowledge on genetic determinants of human plasma proteins through testing 10.6
million DNA variants against levels of 2,994 proteins in 3,301 individuals. I identify 1,927
genetic associations with 1,478 proteins, replicating many previous associations as well as
gaining novel insights into the genetic architecture of the human plasma proteome.
I use several approaches to highlight the application of pQTLs to biology and disease. I
show several examples linking distant pQTLs to biologically plausible genes and demonstrate
the mediation of distant pQTL by local protein levels, highlighting the role of protein-protein
interactions. In addition, I find epistatic effects of genetically determined phenotypes (blood
group and secretor status) on protein levels. Through linking previous disease associations,
I show that disease associated variants are enriched for pQTLs and I provide insights into
possible mechanisms underpinning some of the disease loci. Finally, I identify causal roles for
protein biomarkers in disease through multivariable Mendelian randomisation (MR) analysis,
leveraging on the simultaneous measurement of multiple functionally related proteins in a
locus to account for potential pleiotropic effects. Whereas MR studies of plasma proteins
have been constrained by availability of few suitable genetic instruments, the data generated
here remedy this bottleneck by furnishing an extensive toolkit.
Overall, the work within this thesis foreshadows major advances in post-genomic science
through increasing application of novel bioassay technologies to major population biobanks.
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Chapter 1
Introduction and literature review
The dynamic interplay of different components within the human body drives the biological
processes needed for its normal functioning. This system of interplay between genes and
their products, proteins, forms the core underpinnings of these processes. Variation in any
component of this complex network can lead to population differences in risk of developing
certain diseases. Connecting genetic variation with protein levels and the risk of disease or
other clinical phenotypes can help inform targets for treatment - this is the motivation and
focus for this thesis. In this chapter, I will first introduce the background and key concepts in
genetics and proteomics which underpin the work in this thesis, with a focused review of
the relevant literature. This will be followed by the specific aims and objectives with a brief
outline of the structure for subsequent chapters.
1.1 Structure and variation of the human genome
The human genome consists of ∼ 3 billion pairs of deoxyribonucleic acid (DNA) packed into
23 pairs of chromosomes (22 autosomal and 1 sex-determining) within the nuclei of cells; a
small amount of genetic material is found within the mitochondria. The order of four DNA
nucleotides, adenine (A), cytosine (C), guanine (G) and thymine (T), make up the "genetic
code". On average only ∼ 0.1% of the sequences differ between individuals with most of
the variation having no direct effect on protein structure/function since only ∼ 1.5% of the
genome is protein-coding [1, 2].
Human genetic variation can be broadly categorised into single nucleotide polymorphisms
(SNPs) and structural variation which is a broad category consisting of insertions/deletions
(indels), block substitutions, inversions, translocations and copy number variations. The
former makes up the majority of the source of variation [3] and has been the main focus in
genome-wide association studies (GWAS) and the work within this thesis. A SNP is the
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substitution of a single nucleotide by another in a stretch of DNA. These typically occur every
300 bases along the genome [4] with > 7 million common variations (defined from here on
as having a minor allele frequency (MAF) > 5% unless otherwise specified) across the entire
genome [5]. In addition, small indels ranging from one to several thousands base pairs in
length are also highly common (∼ 2 million) in human populations [6]. Large structural
variations also play important functional roles but will not be the main focus of this thesis; a
detailed review of this topic can be found in [7, 8]. The variation within the human genome
determines the heritable differences between individuals.
1.2 Genetic basis of disease and complex traits
For centuries it has been observed that despite differences between individuals, many traits
and diseases tend to cluster within families. Mendel’s work on inheritance along with
elucidation of DNA as the genetic material have paved the way towards understanding how
genetic variation contributes to the hereditary elements of human traits.
Early studies have revolved around genetic linkage studies. During meiosis, maternal and
paternal chromosome pairs crossover and exchange parts of the chromosome in a process
called homologous recombination. Alleles that lie in close proximity to each other are
more likely to be inherited together during homologous recombination and are said to be in
linkage. Genetic markers which co-segregate with the gene(s) of interest are tracked across
a few generations within a family with a phenotype such as disease. If the disease is more
frequently passed along with specific markers, then the gene(s) close to the markers are likely
to be responsible for the disease.
Linkage analyses have been successful in identifying genetic regions with large effects
associated with diseases which are mostly rare and follow Mendelian inheritance. Successful
examples include identification of mutations in the CFTR gene as the cause of cystic fibrosis
[9] and the HD gene as the cause of Huntington disease [10, 11]. However, for most common
diseases, linkage studies have had limited success [12], despite exceptions in a few cases
where variants in genes have substantial effects on disease such as: NOD2 in Crohn’s
disease, BRCA1 and BRCA2 genes in breast cancer and APOE in Alzheimer’s disease [13].
Furthermore, linkages analysis is less powerful compared to association mapping, which
assesses correlation between genetic variants and traits, in identifying common genetic
variants with moderate effects [14, 15].
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The idea of GWAS, association mapping on the whole genome scale, was proposed as early
as in 1996 where association testing was found to have greater power to detect variants
with modest effects compared to linkage studies and a high density genome-wide map of
polymorphic markers could allow well-powered association testings to be performed across
the genome [14]. Current GWAS designs are mostly suited for discovery of common variants
in the context of the common disease common variant (CDCV) hypothesis where a large
proportion of genetic contribution to phenotypic variance in complex diseases and traits can
be attributed to a small number of common variants [16, 17]. The high frequency of these
variants means that they exert small net negative selective pressure either due to small effects,
balancing selection or associations with post-reproductive diseases. Many robust GWAS,
replicated in several independent studies, have shown that common variants can contribute
to common disease risk. However, genome-wide significant variants only explain a small
proportion of heritability estimated from family-based studies in what is called "missing
heritability" [18]. This led to a modified version of CDCV, known as the infinitesimal
model, whereby the genetic contribution to disease risk is due to a large number of common
variants with small effects across the allele frequency spectrum not detected at the genome-
wide significance level (p < 5×10−8) [19, 20]. This model is supported by looking at the
phenotypic variance explained using all nominally significant variants (p < 0.05) [21, 22] or
using a multivariate approach which regresses phenotypic similarity on genetic relatedness
using all common variants [23], both of which suggest common variants explain most of the
genetic variance. However, the extent to which genetic variance is explained by common
variants varies between different traits and diseases.
1.3.1 Linkage disequilibrium (LD)
Both linkage and association between two loci are related to the concept of recombination
(Fig. 1.1). Linkage, as described earlier whereby alleles lying in proximity tend to get co-
inherited, is essentially tracking the recombinations over a few generations within a family.
Association studies rely on the statistical non-independence of two or more loci occurring
together within a population - linkage equilibrium (LD). Regions of co-inherited alleles are
often referred to as haplotype blocks. Over many generations since the initial disease causing
mutation occurred, large numbers of unobserved recombination events take place which tend
occur closer and closer to the causal locus such that the measurable distance between the
variant and the locus, on average, extends over relatively short distances of up to 100kb [24].
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As a result, alleles of the variant can be used to tag the causal locus for a trait/disease in
association mapping.
Fig. 1.1 Linkage and linkage disequilibrium. Within a family, linkage occurs when two genetic
markers remain linked on a chromosome rather than being broken apart by recombination events
during meiosis, shown as red lines. In a population, contiguous stretches of founder chromosomes
from the initial generation are sequentially reduced in size by recombination events over many
generations. (Figure taken from Bush and Moore [25]).
1.3.2 Entering the GWAS era
The completion of the human genome in 2001 [1, 2] along with the availability of chip-
based genome-wide SNP microarrays [26] and reference genetic variation maps [27] laid
the foundations for GWAS. The International HapMap Project [27] systematically examined
the variation and LD structure among four population groups. The extent of LD is such
that a subset of variants can capture the majority of common variation within the genome
and LD structure varies between population groups reflecting population history; the range
of LD is shorter among Africans compared to Europeans [27, 28]. This information has
helped in the parallel efforts in developing genome-wide SNP microarray chips for different
population groups. For example, a carefully chosen set of ∼ 500,000 SNPs could cover 80%
of common variation in European populations [29].
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The first GWAS was performed in 2005 [30] and the number of published GWAS has
been increasing greatly since (Fig. 1.2). As of September 2016, the National Human Genome
Research Institute-European Bioinformatics Institute GWAS Catalog lists > 24,000 SNP-
trait associations from > 2,500 publications [31]. Typical GWAS usually type hundreds
of thousands of SNPs in a relatively large sample size depending on the phenotype. The
association between each SNP and the trait is usually tested independently using logistic (for
dichotomous traits such as cases and controls) or linear (for quantitative traits) regression
assuming additive genetic effects [32]. Loci (regions of the genome) containing variants
associated with quantitative traits as often called quantitative trait loci (QTLs), for example,
those associated with gene expression are called eQTLs and those associated with protein
levels are called pQTLs. The statistical tests are usually adjusted for additional factors which
may correlate with the trait such as age, gender, study specific factors and known clinical
covariates.
Fig. 1.2 Number of published GWAS between 2005 and 2013. (Figure adapted from NHGRI-EBI
GWAS Catalog available at https://www.genome.gov/gwastudies/).
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Important considerations when performing GWAS
Two important statistical issues need to be considered in GWAS: accounting for population
stratification and correcting for multiple testing.
Population stratification occurs as a result of differences in allele frequencies between
individuals (e.g. cases and controls) due to systematic differences in ancestry. This can
result in spurious associations if not accounted for [33, 34]. Genomic control which assesses
inflation in test statistics compared to the null distribution has often been used to estimate
and control for global population stratification [35, 36]. Although this does not account for
differences for each individual SNPs leading to over-correction for some SNPs and under-
correction for others [37]. Adjustments for global genomic inflation are often performed on
the test statistics after addressing population structure. Principal component analysis (PCA)
and its related method multidimensional scaling (MDS) have been commonly used to capture
population structure [38, 39]. In general, both PCA and MDS reduce the high-dimensional
data into a smaller number of orthogonal components which capture most of the variance.
The top components are then used as covariates to correct for population structure [38].
Other methods have also been employed to account for population stratification and cryptic
population structure such as structured association [40], and increasingly mixed models
owing to computational advances [39, 41].
Statistical tests are generally called significant if the p-value falls below a predefined
value, which is commonly set to 0.05. This means the null hypothesis is wrongly rejected (i.e.
a false positive) 5% of the time for a single statistical test. In GWAS, hundreds of thousands
to millions of tests are performed, and thus the chance of finding one or more false positives
over the entire GWAS analysis is much higher. Therefore, GWAS results must meet stringent
levels of significance to account for multiple testing in order to minimise false positives.
The widely accepted genome-wide significance threshold of p< 5×10−8 is commonly used
which is based on the Bonferroni-corrected threshold (α = 0.05) assessing ∼ 1 million
effective independent common variants in the human genome [42]. Empirical estimation
using newer reference panels also find thresholds of similar magnitude [43]. Other methods
to limit false positive findings include false discovery rate (FDR), permutation testing and
Bayesian approaches [44]. In addition to the use of stringent significance thresholds, the
associations should also be replicated in an independent sample to account for non-random
biases (e.g. technical bias) in a study.
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1.3.3 Improve power through pooling GWAS data
Most variants discovered by GWAS have relatively small effects [45]. The power to detect
associations depends on sample size, effect size, allele frequency and correlation between the
marker and the causal variant [32]. Major research groups often form a consortium to pool
samples, increasing power to detect associations. Through pre-defined analysis protocols,
which look to reduce the amount of heterogeneity between studies, results can be pooled
either at individual-levels or, more often, using summary data via meta-analysis [46]. GWAS
meta-analysis for many phenotypes have been successfully employed, increasing both the
number of discovered and replicated associations; some of the high profile examples are
listed in [46]. Pooling associations together requires the estimates for the same variant to be
available across all the studies which may not be the case if different studies use different
genotyping arrays. This problem has been largely addressed through genotype imputation.
Imputation
Imputation describes the process of predicting genotypes that were not directly measured
through making use of LD information in detailed population specific reference haplotype
panels (Fig. 1.3). In addition to facilitating cross-study meta-analyses, imputation also
helps to correct genotyping errors, increases power and the genetic resolution which in turn
facilitates fine-mapping studies [47]. Many algorithms for imputation exist [47] which all
essentially involve first phasing (i.e. resolving the genotypes into the two parental haplo-
types) each individual at observed SNPs; the resulting phased haplotypes consist of mosaics
of individual reference haplotypes (Fig. 1.3). Missing genotypes are then imputed, with
uncertainty, using the matching reference haplotypes (Fig. 1.3). The phasing and matching
are not 100% certain, and the uncertainty are represented by probability distributions over
the three possible genotypes. The uncertainty needs to be accounted for in downstream
analysis using imputed data [48]. The accuracy of imputed genotypes for common variants
is typically very high [49] and decreases for rare and low-frequency (defined from here on
as having a 1% <MAF< 5% unless otherwise specified) variants, although the accuracy is
increasing with the availability of larger and denser reference panels. Early imputations often
used reference panels generated from HapMap [27] whilst the 1000 Genomes reference panel
is currently widely adopted due to its larger sample size, more diverse populations and denser
genome coverage via whole-genome sequencing [50, 51]. Even larger reference panels,
especially for European ancestry and sub-populations, with higher sequencing coverage, are
also emerging. Examples include efforts from UK10K Consortium [52], consisting mainly of
the UK population, and the Haplotype Reference Consortium [53] which combines data from
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multiple cohorts (including UK10K and 1000 Genomes), currently consisting individuals of
mostly European ancestry.
Fig. 1.3 Principles of imputation. (Figure adapted from Marchini and Howie [47]).
1.3.4 Non-coding variation and GWAS findings
Despite the vast haul of associations, the majority of variants found in GWAS have been
non-coding and are not in LD with variants in coding regions [54]. Therefore, this infers that
most of the GWAS variants have regulatory roles affecting gene and in turn protein expres-
sion. Extensive efforts, such as Encyclopedia of DNA Elements (ENCODE) and Roadmap
Epigenomics projects, have led to systematic mapping of regulatory (both genetic and epi-
genetic) functions to regions of the genome, including promoters, enhancers, Transcription
factor binding site (TFBS), DNaseI hypersensitive sites (DHSs), chromatin accessibility and
interactions across various cell types [55, 56]. In addition, directly assessing allelic effects
on gene expression - eQTL mapping, have also helped in biological interpretation of GWAS
hits.
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eQTLs
It has been shown that GWAS variants are enriched for eQTLs [57]. For example, type 2
diabetes (T2D) SNPs are enriched in the set of eQTL SNPs in liver and fat tissues [58]. As a
complementary resource, eQTLs can aid in prioritisation of the causal gene in a GWAS locus;
a GWAS hit that is also an eQTL for a given gene provides the hypothesis that the expression
of this gene influences the disease. For example, a GWAS identified a locus in chromosome
17q23 associated with childhood asthma which contained 19 genes, none of which had
evident roles in the disease [59]. Through cross-referencing eQTLs in lymphoblastoid cell
lines (LCLs) derived from the same families, it was shown that the GWAS variants explained
∼ 30% of variance in the levels of one of the 19 genes, ORMDL3 [59]. Further functional
studies suggest the role of ORMDL3 as the leading candidate in the region in the aetiology
of childhood asthma [60]. Another prominent example is the association between a variant,
rs12740374, in the 3’untranslated region (UTR) of CELSR2 in the CELSR2-PSRC1-SORT1
locus on 1p13 and risk of myocardial infarction (MI) and low-density lipoprotein (LDL)
cholesterol; a well known risk factor for MI [61]. Expression studies showed that the
variant leads to differential expression of SORT1 by creating a C/EBP TFBS and subsequent
knockdown and overexpression of SORT1 in mouse liver confirmed the effect of SORT1
levels on LDL cholesterol [61]. Therefore, this showed that the gene closest in proximity to
the strongest associated variant is not necessarily the best candidate and eQTL data can help
inform likely candidate causal gene(s).
There have been many eQTL studies performed across many different tissues and cell
lines [62]. eQTLs tend to be highly tissue specific [63, 64]. Systematic eQTL mapping across
multiple tissues in hundreds of samples by the Genotype-Tissue Expression (GTEx) project
is providing novel insights into the sharing and tissue specificity of eQTLs and discovery
of novel eQTLs [65]. Typically most of the discovered eQTLs have been in cis (i.e. the
associated variant lies close to the gene encoding the messenger ribonucleic acid (mRNA),
conventionally within 1Mb of the gene), although trans (i.e. non-cis variants not in proximity
of the gene) eQTLs are less common, partly owing to the increased multiple testing penalty
and less power.
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1.4 Combining the human plasma proteome with human
genetics
It has been shown that changes in expression have attenuated downstream effects on protein
levels [66, 67]. This may be a result of post-transcriptional regulation and protein interactions
not captured at the transcriptional level. Given that proteins are the functional units in
biological processes, examining the effects of genetic variation on the proteome rather
than the transcriptome may provide additional layer of information in linking the causal
gene/protein with disease.
1.4.1 The human plasma proteome and composition
Human blood is a typical medium for biological measurements for a variety of reasons.
It is easily obtainable and stored through standardised venepuncture protocols and is in
exchange with most tissues within the body and thus acts as an integrative representation
of the physiological and pathological state of an individual. Blood is relatively simple to
process and handle compared with many other tissue specimens and does not suffer from
significant degradation over relatively long periods. Plasma is derived from whole blood
through removal of blood cells by centrifugation.
The human plasma is a complicated matrix containing many thousands of proteins
integrated from various sources. There are secreted proteins which perform functions within
the circulation such as albumin and immunoglobulins. Some proteins such as cytokines and
endocrine hormones act as chemical messengers linking functions of local and distant tissues
with either relatively short acting or long acting effects. Proteins may leak into the circulation
as a result of cellular damage such as cardiac troponin released from myocardial tissue during
MI. Dysregulated response from cells and tumour cells in general can also result in aberrant
protein secretion. Finally, non-human proteins (e.g. proteins released by bacteria, viruses and
parasites) may also enter the circulation. The composition of the human plasma proteome
results from the interplay between these various sources.
A small number of proteins make up the majority of the plasma composition. (Fig. 1.4). A
handful of∼ 22 protein species make up nearly all (∼ 99%) of the total weight. Albumin and
immunoglobulins alone account for around three quarters of the total weight. The remainder
of the plasma proteome, which consists of thousands to more than ten thousand proteins
that are low abundance, collectively only make up ∼ 1% of the total weight in plasma [68].
This small percentage of the plasma composition includes some physiologically important
proteins such as cytokines, chemokines and peptide hormones.
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Fig. 1.4 Composition of the human plasma proteome. (Figure taken from Jaros et al [68]).
1.4.2 Challenges in measuring the plasma proteome at scale
Whilst microarray and ribonucleic acid (RNA) sequencing technologies have enabled high-
throughput and high coverage measurement of the human transcriptome [62], comprehensive
high-throughput measurement of the human plasma proteome has proved much more difficult.
The plasma proteome stretches over a large dynamic range of around 12 orders of
magnitude [69]. Whilst proteins such as albumin and haptoglobulin are present in mg/ml
ranges, the majority of the low abundance proteins including cytokines are present in pg/ml
ranges - beyond the sensitivities and dynamic ranges of many of the mass spectrometry
(MS) approaches. Masking of low abundance proteins by high abundance ones may also
complicate their reliable detection (discussed next in Section 1.4.3). Furthermore, unlike
RNA measurements where low abundance transcripts can be amplified through polymerase
chain reaction (PCR) approaches, there is currently no analogous method for proteins.
1.4.3 Overview of current proteomic technologies
Current methods used to measure the proteome can be broadly categorised into two categories:
MS and affinity-based methods.
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Mass spectrometry approaches
MS is an extensive topic, here I give a brief outline of the main MS proteomic methods
without going into specific technical details which is beyond the focus of this thesis and has
been extensively reviewed elsewhere in [70–72].
The central idea behind MS is making use of the signatures of the mass-to-charge ratios
of ionised fragmented peptides to detect the proteins. The mass and charge of the fragment
together determine the amount of deflection when accelerated through an electromagnetic
field. The general workflow for MS proteomics is summarised in Fig. 1.5. In summary,
proteins are extracted from the sample by fractionation (1), which reduces its complexity
and dynamic range for analysis by separating proteins based on their biophysical properties
(e.g. size, charge and solubility). One-dimensional or two-dimensional gel electrophoresis
may also be carried out to define a "sub-proteome" to be analysed. The proteins are typically
digested by trypsin into smaller peptides (2) and ionised (3). Electrospray ionisation (ESI) or
matrix-assisted laser desorption/ionisation (MALDI) is used to ionise the peptides with the
former readily coupled to liquid chromatography (LC) (3) and is more commonly employed
for complex sample matrices [71]. The resulting ionised peptides are passed through the mass
spectrometer to generate mass spectra of the ionised peptides (4). Certain ionised peptide
ions are selected (precursor selection) for fragmentation by collision-induced dissociation
(CID) and recording of the fragment ion spectra (5) for protein identification. Quantification
can be done either on the absolute or relative scale using spiked in standard peptides,
chemical/metabolic/enzymatic isotope labelling or label free approaches such as ion intensity
and spectrum counting [73].
The presence of high abundance proteins such as albumin and immunoglobulins in plasma
can mask the presence of low abundance ones. As a result, additional sample pre-processing
is often needed to improve sensitivity by enriching for interested sub-proteome in the low
abundance range and reducing high dynamic range into manageable "chunks". Usually, high
abundances proteins are removed by targeted depletion using affinity-based approaches. The
top 7 or 14 abundant proteins are often removed [74] and has been shown to increase protein
detection [75].
There are two main MS-based proteomic strategies commonly used: discovery (shotgun)
and targeted approaches. In addition, a recent emerging strategy called Sequential Window
Acquisition of all THeoretical Mass Spectra (SWATH-MS) is also becoming more commonly
employed. The key principles of these three MS approaches are summarised in Fig. 1.6 and
are discussed below.
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Fig. 1.5 General workflow of MS-based proteomics experiment. (1) The proteins to be analysed are
extracted by fractionation or affinity selection. This often includes a final step of one-dimensional
gel electrophoresis, and defines the "sub-proteome" to be analysed. (2) Proteins are degraded
enzymatically to peptides, usually by trypsin, leading to peptides. (3) Peptides are separated high-
pressure liquid chromatography and eluted into an electrospray ion (ESI) source where they are
nebulised in small, highly charged droplets. After evaporation, multiply protonated peptides enter
the mass spectrometer and, in (4), a mass spectrum of the peptides eluting at this time point is taken
(MS1 spectrum). The computer generates a prioritized list of these peptides for fragmentation and a
series of tandem mass spectrometric or ’MS/MS’ experiments ensues (5). These consist of isolation
of a given peptide ion, fragmentation by energetic collision with gas, and recording of the tandem or
MS/MS spectrum. (Figure adapted from Aebersold and Mann [70]).
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Fig. 1.6 MS instrumental principles of (A) shotgun proteomics, (B) selected/multiple reaction moni-
toring (SRM/MRM) and (C) SWATH MS. (A) The purpose of shotgun proteomics is the generation of
fragment ion spectra for the identification of the amino acid sequence of peptides. The first analyser
(MS1) is set to scan all the precursor ions at a time and then to select one specific precursor (based
on the intensity) for fragmentation. The selected ion undergoes collision-induced dissociation in the
collision cell, and the resulting fragments are analysed by the second analyser (MS2). The process is
repeated for different precursors, yielding the MS2 spectra (far right). (B) In SRM, precursor ions
of a specific peptide are selected in MS1. After fragmentation step, a specific fragment ion from the
target peptide (transition) is selected and guided to the detector. Finally, a SRM trace corresponding
to the specific fragment(s) of the peptide monitored over time is generated. (C) SWATH-MS is
a data-independent acquisition method in which the MS2 spectra generation is not guided by the
real-time intensity of precursor ions. Here, the MS2 data are acquired by repeatedly cycling through
32 consecutive 25 Da precursor isolation windows (swaths) and monitoring all fragment ions. (Figure
taken from Liu et al [72]).
Discovery proteomics also called shotgun proteomics, has been commonly used for global
protein identification by LC tandem MS (LC-MS/MS) operated in data-dependent acquisition
(DDA) mode. The precursor selection of ions for fragmentation by CID is performed based
on an initial survey scan (MS1) on the fly by the MS instrument. Unfortunately, the selection
is highly stochastic, driven by the intensity of peptide ions, leading to poor reproducibility of
protein identification and quantification as well as limited sensitivity to detect low abundance
proteins [76].
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Targeted MS allows more reproducible peptide quantification of a predetermined set of
precursor and fragment ions with higher sensitivities and throughput compared to shotgun
MS. Selected reaction monitoring (SRM), also known as multiple reaction monitoring, is
currently the most widely used approach and is commonly performed using triple quadruple
instruments which allow mass filtering and selective monitoring of specific ions. The first
quadrupole filters the pre-selected peptide ion, the second performs CID whilst the third
filters and measures the pre-defined fragment ion of the peptide. The fragment ion spectrum
of pre-selected target peptides are defined a priori often using resources such as SRMAtlas
which is a catalogue containing SRM parameters for a wide range of peptides for different
proteins [77]. However, SRM can only measure around a hundred proteins each run compared
to more than 1000 identifiable proteins (albeit with missing data for many) using shotgun
approaches.
Recently, an implementation of data-independent acquisition (DIA) MS called SWATH-
MS is emerging to address the limitations of shotgun and SRM MS. As the name implies,
the instrument is run in DIA mode which fragments all precursor ions in a pre-defined
mass-to-charge window producing a spectral map of all the fragment ions. Recursive scans
through consecutive mass-to-charge windows allow a spectral map to be generated across
all fragment ions within a wide range of retention times and mass-to-charge windows [78].
The resulting data can then be analysed and re-analysed independently of data acquisition
using targeted data extraction strategies through specialised tools [79]. Although the data
analysis relies on generation of sample-specific assay libraries currently generated in-house
using the same instrument in DDA mode, generic libraries with comparable performance are
also beginning to become available [80].
Affinity-based approaches
Affinity-based methods have different variations but all rely on the underlying principle of
detecting an assayable reagent which specifically binds its target protein epitope (Fig. 1.7).
Antibody based immunoassays such as enzyme-linked immunosorbent assays (ELISAs) are
commonly used in detection and quantification of soluble proteins as antibodies have high
diversity, specificity and sensitivity. ELISAs are highly reproducible, easy to implement
and can be automated to allow high throughput measurements at epidemiological scales
of thousands to tens of thousands samples. However, traditional ELISAs measure only
one protein at a time and thus multiplexing of binding reagents is required to enable large
proteomic measurements in a reasonable sample volume.
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Fig. 1.7 Common affinity-based assay setup formats. The antigen (Ag) of interest is immobilized
by direct adsorption to the assay plate or by first attaching a capture antibody to the plate surface
("sandwich" setup). Detection of the antigen can then be performed using an enzyme (E)-conjugated
primary antibody (direct detection) or a matched set of unlabelled primary and conjugated
secondary antibodies (indirect detection). (Figure taken from ThermoFisher available at https:
//www.thermofisher.com/uk/en/home/life-science/protein-biology/protein-biology-learning-center/
protein-biology-resource-library/pierce-protein-methods/overview-elisa.html).
Currently two main formats for multiplex immunoassays are widely used: planar assays
and microbead suspension assays [81], using the "sandwich" setup (Fig. 1.7 (right)). In
planar assays, capture antibodies are immobilised on a solid-phase 2D support either in
microtitre plates or glass slides. The antibodies are subsequently exposed to the sample
and detection antibodies coupled to a labelled reporter system for quantification in a similar
manner to DNA microarrays (Fig. 1.8 (left)). The suspension format involves immobilisation
of capture antibodies on micrometre sized fluorescent activated beads suspended in liquid
phase which are then exposed to the sample and detection antibodies. The fluorescent
beads corresponding to different targets are sorted by flow-cytometry based methods and
the reporter system on the detection antibodies are used for quantification (Fig. 1.8 (right)).
The planar and microbead assays can also be used in direct or indirect assay setups (Fig. 1.7
(left and middle)), termed reverse-phase protein array, which involves proteins extracted
from the sample being immobilised instead of capture ligands and subsequently probed
with specific antibodies. There is a wide range of commercially available assays stemming
from the principles described above, targeting proteins within various biological and clinical
domains; a comprehensive list of these assays have been detailed in [81].
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Fig. 1.8 Workflow of two commonly used multiplex assay formats. In both assays, (i) samples
are extracted from blood. Planar assays (left) can be produced in either slide based or microtitre
based formats (ii). (iii) The sample matrix is applied and discrete assays are spatially separated
by a frame and gasket, whereby they may be subsequently treated as individual microtitre wells,
subject to blocking, washing, etc. (iv) Detection results from application of a composite of specific
secondary antibodies coupled to chemiluminescent/fluorescent reporter systems (iv). (v) Microtitre-
based immunoassays harbour regularly printed antibody sets within the confines of the wells of a
standard protein-binding plate. Suspension assays (right) employs thousands of micrometre-sized
plastic microbeads infused with a single (or several) chemiluminescent/fluorescent dyes prior to
linking with a specific capture antibody. Numerous sets of such beads are prepared, each maintaining
separate capture antibodies according to the cognate analyte and a unique fluorescent signature
enabling identification (ii). (iii) Sets of detection antibodies, all of which are individually labelled with
a single chemiluminescent/fluorescent reporter (separate from those contained within the beads) are
added upon completion of incubation and washing stages. Each bead thus accommodates a ‘sandwich’
consisting of the captured target analyte and the cognate reporter-conjugated detection antibody (iv).
(v) Bead analyte reporter constructs are subject to analysis in a flow chamber implementing individual
bead separation, whereby lasers excite the chemiluminescent/fluorescent reporters and emitted light is
collected by a series of detectors for quantitative analysis. (Figure adapted from Tighe et al [81]).
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Within one run, the extent of multiplexing is often limited by the issue of specificity due
to cross-reactivity of antibodies and also by the limited repertoire of specific high-quality
antibodies. This has limited multiplex assays mostly to fewer than 100 proteins being
measured at any one time, although several panels can be "pieced together" to increase
coverage but this comes at the cost of increased sample volume demands.
Recently, short sequences of single-stranded DNA called aptamers, first synthesised
in 1990 by two independent groups [82, 83], have been used to improve specificity and
proteome coverage of affinity-based assays.
First, proximity ligation assays (PLAs) and proximity extension assays (PEAs) have
been used to improve specificity of immunoassays (Fig. 1.9) [84–86]. Both involve the
covalent attachment of an aptamer to streptavidin linked to biotinylated antibodies. Usually
this involves two detection antibodies for two different epitopes of a target, each with a
different aptamer attached, one via the 5’ end the other via the 3’ end, both of which are
brought together into close proximity when the antibodies bind to the target. In PLAs, a
bridging aptamer with complementary sequences to both ends of the antibody linked aptamers
binds the two ends which are ligated together, forming the template for amplification and
quantification using PCR or other DNA quantification methods (Fig. 1.9 (left)). Instead of
ligating the two aptamer ends together, the two antibody linked aptamers used in PEAs have
ends with complimentary sites for the end of the other aptamer, allowing direct hybridisation
(Fig. 1.9 (right)). The ends of the aptamers are then extended by DNA polymerases using the
alternate aptamer as template and subsequently amplified and quantified as described above.
The current largest available multiplex assay, from Olink Bioscience (Uppsala, Sweden)
measures ∼ 700 unique proteins (∼ 200 in 2014 at the start of this thesis) spread across 9
92-plex panels. The low sample volume requirement (∼1 µl) of these assays enables multiple
panels to be used.
The second approach involves the use of fluorescent tagged aptamers instead of antibodies
as ligands for protein targets. Aptamers can fold into defined 3D configurations specific
to a protein epitope. As ligands they have several advantages compared to antibodies: (1)
they are more versatile as there are effectively endless sequence combinations producible
in vitro, selected by the investigator rather than relying on the immune system; (2) the
specificity can be modified and fine-tuned through sequence modifications; (3) they are
relatively stable to temperature insults and have a long shelf life when dehydrated and so far
there have been limited reports of immune reactions to them. Aptamers specific to protein
targets are selected through a process called systematic evolution of ligands by exponential
enrichment (SELEX) [83], of which there are now several variations of the original protocol
summarised in [88]. The core principles of SELEX revolve around the screening of aptamer
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Fig. 1.9 Principles of PLA and PEA. In PLA (left), biotinylated antibodies bind pairwise to dif-
ferent epitopes on target proteins bound to a capture antibody. This brings the two streptavidin-
oligonucleotide tails, one coupled through its 5’-end, the other through its 3’-end, into close proximity.
The connector oligonucleotide (splint) hybridises to ends of both oligonucleotides. The gap is ligated
and the resulting continuous DNA strand can be amplified and quantified. In PEA (right), binding
stages are as in PLA. The streptavidin-oligonucleotides ends hybridise directly to each other followed
by extension by DNA polymerase, amplification and quantification. (Figure adapted from Geenwood
et al [87]).
libraries against a potential target and amplifying specifically bound aptamers iteratively to
retain only a small subset of aptamers with high specificity and high affinity for the target in
question. Aptamers have been successfully used as an alternative to antibodies in various
applications such as Western and dot blots [89, 90], flow cytometry and therapeutics [91,
92]. In addition, aptamers have huge scope for multiplexing; the latest multiplexed aptamer-
based proteomic array (SOMAscan) from SomaLogic, is able to measure more than 3,000
unique proteins (Fig. 1.10). The SOMAscan platform makes use of Slow Off-rate Modified
Aptamers (SOMAmers®), aptamers chemically modified to enhance binding affinity and
specificity to protein epitopes. The main limitations to the extent of multiplexing are the
availability of purified protein targets and the increasing chance of cross-reactivity with
increased multiplexing despite the high specificity of aptamers.
19
Introduction and literature review
Fig. 1.10 Principles of SOMAmer affinity assay. (A) SOMAmers and samples are mixed. Cognate
and non-cognate SOMAmer-target complexes form. (B) DNA-based SOMAmers (gold, blue, and
green) contain biotin ("B"), a photo-cleavable linker ("L") and a fluorescent tag at the 5’ end. Most
SOMAmers (gold and green) bind to cognate proteins (red), but some (blue) form non-cognate
complexes. (C) SOMAmers are captured onto a bead coated with streptavidin ("SA"). Uncomplexed
proteins are washed away. (D) Proteins are tagged with biotin. (E) UV light ("hv") cleaves the
linker and SOMAmers are released. Samples are challenged with anionic competitor and non-
cognate complexes preferentially dissociate. (F) SOMAmer-protein complexes are captured onto new
streptavidin coated beads with free SOMAmers washed away. (G) SOMAmers are released from
complexes into solution at high pH. (H) Relative protein quantification via hybridization to microarray
containing complementary oligonucleotides to SOMAmers. (Figure taken from Gold et al [93]).
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1.4.4 Evaluation of proteomic technologies for discovering pQTLs
Many human plasma proteins are heritable [94–96] and this is not correlated with pro-
tein abundance [96], suggesting many of the genetic contributions to proteins in the low-
abundance end are still left to be discovered in larger powered studies. Therefore, to extend
the pQTL discovery space, ideally we want to perform the study in as large as possible
sample size across as many proteins as possible.
Whilst MS approaches can provide proteomic measurements in a relatively unbiased
manner with high specificity, they are currently limited in terms of throughput for measuring
the human plasma proteome prohibiting timely measurements at epidemiological scales
(thousands to tens of thousands of samples). Even with depletion, MS methods generally
have lower sensitivity compared to affinity-based methods. Whilst SRM with depletion can
achieve sensitivities comparable to the lower end of affinity-based methods, they are limited
in terms of proteome coverage. In addition, MS quantifies specific peptides fragments of a
protein as a proxy for the whole protein but not all peptides of the same protein correlate
well with each other [94, 97]. Therefore selecting representative peptides that are reflective
of the protein levels also play a role in accurate and reproducible quantification. Selecting
multiple peptides of a protein can improve reproducibility but this comes at a cost of reduced
number of proteins that can be measured.
Affinity-based approaches offer superior sensitivities, higher dynamic ranges and more
reproducible quantifications compared to MS methods in addition to being readily geared for
large scale measurements. Whilst traditional affinity-based methods have been limited in
terms of proteome coverage, recent developments in multiplexing technologies combined
with the use of aptamers have significantly enhanced proteome coverage by overcoming
some of the limitations such as specificity and ligand generation.
1.4.5 Review of previous pQTL studies for soluble proteins in humans
There have been many studies so far looking at the effect of genetic variation on soluble
protein level concentrations in plasma or serum. Some of these were performed in non-human
species such as mice [98–100] and yeast [101–103]. In humans, the association between ABO
blood groups, which is genetically determined by variations in the ABO gene on chromosome
9 [104], and plasma levels of proteins involved in coagulation such as von Willebrand factor
(VWF) and factor VIII (F8), reproduced in several studies [105], were effectively some of the
earliest examples of mapping genetic determinants of human plasma protein levels. However,
these are not pQTLs in the conventional sense that they are not determined through testing
the direct association between plasma protein levels and genome-wide genetic variants or
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a dense array of variants in cis regions. There have been various studies looking at lipids,
non-protein hormones and metabolites (comprehensively reviewed in [106] and [107]) which
are small molecules distinct from proteins and are considered part of the metabolomics space
rather than proteomics.
With the emergence of genomic technologies and GWAS since 2005, many studies
looking at genetic variation on protein levels have been within the context of a wider clinical
or biological focus. The earliest examples, using samples from the Framingham Heart Study
(FHS), included looking at the genetic association of proteins involved in thrombosis and
coagulation (fibrinogen, factor VII (F7), VWF, tissue-type plasminogen activator (tPA),
plasminogen activator inhibitor-1 (PAI-1) and haemoglobin) within a haematological context
[108–110]; insulin and glycated haemoglobin in the context of diabetes [111, 112]; cystatin C
and thyroid stimulating hormone (TSH) with kidney function and endocrine traits respectively
[113]. Most of the efforts at pQTL mapping have followed similar themes of examining
candidate protein levels in relation to clinical traits or measurements, or proteins with well
established biological roles; a comprehensive list is summarised in Table 1.1.
Table 1.1 List of proteins analysed in previous singleplex pQTL studies examined in human blood
under various biological/clinical contexts.
Protein Trait context Reference1
AAT AAT deficiency and COPD [114], [115]
Adiponectin Metabolic and diabetes [116], [117], [118], [119], [120], [121]
(HMW adiponectin), [122], [123], [124],
[125], [126]
Albumin Haematological [127], [128], [129], [130], [131]
ALP Clinical biochemistry (liver) [128], [132], [133]
ALT Clinical biochemistry (liver) [128], [129], [134], [132], [135]
ANGPT2 Vascular [136]
APOH Haematological [137]
AST Clinical biochemistry (liver) [128], [138], [129], [134], [135]
Antithrombin Haematological [139]
B2M Immunological and renal [140]
BCHE Metabolic [134]
BNP Cardiovascular [141] (N-terminal pro BNP), [142]
C3 Haematological [143]
C4 Haematological [143]
C4BP Haematological [144]
CC16 COPD [145]
Ceruloplasmin Inflammation and cardiovascular [146]
CHI3L1 Asthma [147]
CK Clinical biochemistry [128], [148]
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Clusterin Alzheimer’s disease [149]
CRP Inflammation and cardiovascular [150], [151], [152], [153], [154], [134],
[155], [156], [157], [158], [159], [145],
[160], [161], [162]
Cystatin C Renal [113]
D-dimer Haematological [163]
F7 Haematological [109]C, [110], [164]
E-selectin Haematological [165], [166], [167]
F11 Haematological [168], [169]
Ferritin Iron metabolism [134], [170], [171], [172]
Fibrinogen Haematological, inflammation, cardio-
vascular
[109]C, [110], [127], [173], [174], [175],
[145], [176], [177], [162]
FSH Endocrine [178], [179]
Haptoglobin Haematological and inflammation [180]
Haemoglobin Haematological [110], [181], [182], [128], [183], [184]
(HbA2), [185] (HbA2), [186] (HbA1,
HbA2, HbF)
Hepcidin Iron metabolism [187]
Galectin 3 Inflammation [188]
GGT Clinical biochemistry (liver) [128], [129], [134], [132], [189]
Glycated
haemoglobin
Diabetes [111], [112]
ICAM1 Metabolic and inflammation [190], [191], [192]
IgA Immunological [193], [194]
IgE Immunological [195], [196], [197], [198], [199], [200],
[201]
IgG Immunological [202]
IgM Immunological [203]
IGF1 Metabolic [204]
IGFBP3 Metabolic [204]
IL1RA Inflammation [205]
IL1RL1 Inflammation, cardiovascular, asthma [206]
IL2Rα Cardiovascular [207]
IL6 Inflammation [156], [145]
IL8 Inflammation [145]
IL18 Inflammation [208], [205]
Insulin (fasting) Diabetes [111], [112], [209], [210] (pro-insulin),
[134], [211], [212]
Leptin Metabolic [151], [213]
LEPR Metabolic [214]
LH Endocrine [178], [179]
LPA Cardiovascular [215], [216], [217], [218]
Lp-PLA2 Cardiovascular [219], [220], [221]
MCP1 Inflammation [156], [222]
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MMP1 Cardiovascular [223]
MPO Cardiovascular [224]
PAI-1 Haematological [108]C, [110], [225]
OPG Bone [226]
Plasminogen Haematological [227]
P-selectin Haematological [191]
Prolactin Endocrine [179]
Protein C Haematological [228], [229]
Protein S Haematological [139]
RETN Metabolic, cardiovscular, diabetes [230], [231]
SAA Amyloidosis [232]
SHBG Endocrine and breast cancer [233], [234], [178], [179]
SP-D COPD [145]
TM Haematological [162]
TIE2 Vascular [136]
TNFa Inflammation [145]
TPA Haematological [109]C, [110], [151], [235]
Transferrin Iron metabolism [171]
Troponin T Cardiovascular [236]
TSH Endocrine (thyroid) [113], [237], [238], [239], [240]
VDBP Nutrition [241]
VEGFA Cardiovascular [242], [243]
VEGFR2 Vascular [244]
VWF Haematological [110], [164]
1 C: cis; genome-wide studies if not specified.
AAT (α1-antitrypsin); ALP (alkaline phosphatase); ALT (alanine aminotransferase); APOH (apolipoprotein
H); AST (aspartate aminotransferase); B2M (β2-microglobulin); BCHE (butyrylcholinesterase); BNP (B-type
natriuretic peptide); C3/4 (complement component 3/4); C4BP (C4b-binding protein); CC16 (Clara cell
protein); CHI3L1 (chitinase-3-like protein 1); CK (creatine kinase); COPD (chronic obstructive pulmonary
disease); CRP (C-reactive protein); GGT (gamma glutamyl transferase); HbA1/A2/F (haemoglobin A1/A2/fetal);
HMW (high molecular weight); ICAM1 (intercellular Adhesion Molecule 1); IgA/E/G/M (immunoglobulin
A/E/G/M); IGF1 (insulin-like growth factor 1); IGFBP3 (insulin-like growth factor-binding protein 3); IL1RA
(interleukin 1 receptor antagonis); IL1RL1 (interleukin 1 receptor-like 1); IL2Rα (interleukin 2 receptor α);
IL6/8/18 (interleukin 6/8/18); LEPR (leptin receptor); Lp-PLA2 (lipoprotein-associated phospholipase A2);
LPA (lipoprotein(a)); MCP1 (monocyte chemotactic protein 1); MMP1 (matrix metalloproteinase 1); MPO
(myeloperoxidase); OPG (osteoprotegerin); RETN (resistin); SAA (serum amyloid A); SHBG (sex hormone-
binding globulin); SP-D (surfactant protein D); TM (Thrombomodulin); TNFa (tumor necrosis factor α); TIE2
(tyrosine-protein kinase receptor); VDBP (vitamin D-binding protein); VEGFA (vascular endothelial growth
factor A); VEGFR2 (Vascular endothelial growth factor receptor 2).
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The majority of these pQTL studies have focused only on single or small specific set of
proteins, in either healthy or non-healthy cohorts in various ethnicities with varying sample
sizes. There are relatively few studies that have assessed many (more than 10) proteins
in the same individuals. Studies by Benjamin et al [245] and Melzer et al [246] were the
first attempts at extensive pQTL mapping which looked at 22 and 42 proteins respectively
across various biological domains. Solomon et al [247] recently used a sample efficient
immunoassay to map cis (±500kb of the gene) pQTLs for 20 cardiovascular related proteins.
These studies adopted single-plex affinity based measurements separately for each protein
which required a relatively large sample volume in the ml range or a large number of separate
single-plex reagents and therefore offered limited potential for scaling up to much larger
number of proteins as well as being technically cumbersome. There have also been a small
number of pQTL studies performed in human LCLs using MS [248, 249] or multiplex
immunoarray [250] methods to measure multiple proteins simultaneously.
To date, there has only been a handful of pQTL studies which used a multiplex assay
approach (Table 1.2).
Table 1.2 List of multiplex pQTL studies in human blood.
Year Assay type
Sample No. of No. of proteins
Reference2size proteins with pQTLs
2012 Aptamer 96 813 42 [251]C
2013 MS 687 163 12 [94]C
2013 Antibody 521 132 26 [252]C
2014 Antibody with aptamer (PEA) 687 77 12 [95]
20151 MS 113 303 13 [96]C
20161 Antibody 818 146 32 [253]
20161 Antibody 1,340 88 38 [254]
20171 Antibody 8,293 41 16 [255]
20171 Aptamer 51 1,128 41 [256]
20171 Aptamer 1000 1,124 276 [257]
1 Study emerged during the course of this thesis.
2 C: cis region only; genome-wide studies if not specified.
Many pQTL studies which measured many proteins simultaneously have only examined
SNPs in cis of the gene encoding the protein. Johansson et al [94] and Liu et al [96]
used MS to perform pQTL) mapping for 163 and 303 proteins in plasmas of 687 and 113
individuals respectively. However these two studies only examined SNPs within ±100kb
[94] or ±1kb [96] of the gene in cis. Lourdusamy et al [251] also performed cis pQTL
mapping (±300kb of the gene in cis) across much larger number of proteins (813) using an
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aptamer-based proteomics array (SOMAscan, SomaLogic) but in a much smaller sample size
of 96 elderly individuals. Using a larger sample size of 521 elderly adults, Kim et al [252]
used a microbead-based multiplex immunoassay (Human DiscoveryMAP v1.0, Myriad Rules
Based Medicine (RBM)) to look for genetic associations with 132 proteins, but they only
assessed SNPs within the cis genes. However, there have been a small number of genome-
wide pQTL studies emerging which also measured many proteins simultaneously. Deming
et al [253] used the same platform as Kim et al [252] to perform GWAS for 146 proteins
in 818 individuals of Alzheimer’s disease cases and controls. Sun et al [254] employed a
custom multiplex panel using the RBM microbead-based immunoassay to assess levels of
88 proteins in 1,340 individuals consisting of current and former smokers. Ahola-Olli el
al [255] used a combination of two multiplexed assays using similar methods as Kim et al
[252] and Deming et al [253] (Bio-Plex Pro Human Cytokine, Bio-Plex) to test 41 cytokines
in 8,293 individuals. Enroth et al [95] used the PEA proteomics approach (Olink Proseek
Multiplex Oncology I, Olink) to perform GWAS on 77 proteins in a discovery cohort of 687
individuals. Recently, Di Narzo et al [256] used the aptamer-based SOMASscan assay to
assess levels of 1,128 proteins in a small cohort of 51 Crohn’s disease patients. Subsequently
in an independent study using the same assay platform, Suhre et al performed pQTL mapping
in a much large discovery cohort of 1000 participants. Results of studies from 2015 onwards
[96, 253–257] emerged during the course of this thesis.
The pQTL studies so far have shown that variation of levels of many proteins in blood
(plasma or serum) are partly genetically driven and many novel SNPs associated with levels
of different proteins have been discovered. Potentially many more novel pQTLs are still
left undiscovered owing to limited proteome coverage as the majority of existing studies
have only examined a limited subset of proteins often within a specific biological or clinical
context. The small handful of multiplexed studies have either had limited sample size, limited
proteome coverage or have only assessed cis variants (especially those published prior to
the start of this thesis). In addition, some of the studies were not performed in a sample
representative of a healthy population and thus may be confounded by reverse causation
where the disease or disease risk factors lead to changes in protein levels. Currently, there
have been no large scale systematic genome-wide pQTL mapping efforts across a large
number of soluble blood proteins in samples from a healthy population. This has been largely
limited by the lack of high-throughput proteomic technologies for complex matrices such as
plasma. But, with the emergence of aptamer-based methods which allow quantification of
thousands of proteins with throughput for thousands of samples, this type of study is now
becoming feasible.
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1.5 Motivation for pQTL discovery - causal inference
Observational epidemiology has been limited in identifying causal associations between
risk factor and outcomes as correlation does not necessarily mean causation. There are
two main limitations to observational studies when assessing causality: confounding and
reverse causation. Confounding occurs when the association seen between a risk factor and
outcome is not conditionally independent of other factors due to correlations between the
confounder and the risk factor-outcome relationship. Confounders can be adjusted for if they
have been measured and to some extent this is almost far from exhaustive - some unmeasured
confounding will remain in a real-world system in epidemiology. Reverse causation occurs
as a result of outcome having an effect on the risk factor rather than the other way around
which cannot be empirically distinguished in cross-sectional studies. Genetic variants can be
used to assess the causal impact of an intermediate on an outcome and overcome limitations
of observational associations through the principle of Mendelian randomisation (MR).
1.5.1 Mendelian randomisation principles
The concept of MR stems from instrumental variable (IV) analysis frequently used in
econometrics [258]. MR is effectively IV analysis applied in the genetic epidemiology
domain where genetic variant(s) are used as IVs to proxy for the effect of the risk factor.
Whilst not explicitly stated, the first applied description of MR by Katan [259] proposed
using variants in the APOE gene, which was biologically implicated in regulating cholesterol
levels, to instrument serum cholesterol for its effect on cancer risk. By Mendel’s second law,
the genotype at a locus is randomly assorted at conception from the parental genotypes, hence
the name "Mendelian randomisation". On a population level, many confounding factors, such
as socio-economic and lifestyle factors, should be randomly distributed between respective
genotype groups. In addition, disease processes do not affect germline genotypes, therefore
any genotype disease association will not be affected by reverse causation. Due to these
properties, MR can be also be viewed as the natural analogue of randomised controlled trials
(RCTs) [260] (Fig. 1.11).
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Fig. 1.11 Conceptual parallels between a randomised controlled trial and Mendelian randomisation to
assess the causal effect of changes in protein biomarker levels on disease risk.
Randomised controlled trial Mendelian randomisation
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In order for a genetic variant or a combination of independent genetic variants to act
as suitable instruments for MR analyses, three assumptions must be met. (1) The variant
needs to be associated with the biological intermediate (risk factor) of interest; (2) the
variant must be independent of the confounders of the intermediate-outcome relationship
(independence assumption); and (3) the variant exerts its effects on the outcome only through
the intermediate of interest. The MR paradigm can be summarised by a directed acyclic
graph (DAG) in Fig. 1.12. Under this specification, MR can be used to estimate the causal
effect of the intermediate on the outcome free from confounding and reverse causation. A
detailed discussion of all the IV methods and type of MR set-ups are beyond the scope of
this thesis; I will focus on some of the key concepts and areas relevant to the thesis below
and in Chapter 6. Comprehensive reviews can be found in [261] for IV estimators and [262]
for MR strategies.
MR estimates typically use the Wald method or two-stage least squares (2SLS) [263].
The Wald method is the simplest which is obtained by the coefficient of the outcome on
the IV divided by the coefficient of the exposure on the IV with the standard error (SE)
typically calculated using the delta method [261] (see Section 6.2.5 for details). In 2SLS,
there is a first stage regression of the exposure on the IVs and a second stage regression of
the outcome on the fitted values of the exposure from the first stage with uncertainty derived
using robust SEs. Unlike 2SLS which can be extended to include multiple instruments, the
Wald method can only be used with single instruments. However, multiple independent
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Fig. 1.12 Directed acyclic diagram showing the the causal relationships between the genetic variant
(instrument), biological intermediate or risk factor of interest, outcome and (measured or non-
measured) confounders which satisfy the assumptions of Mendelian randomisation.
IVs can be combined into a univariate score to improve power [264], commonly known as
allelic or genetic risk score, which can be either unweighted or weighted by the effect of the
corresponding genetic variant on the exposure [265]. This can be done using summarised
data in which ratio estimates for each IV are combined using inverse-variance weighted
(IVW) meta-analysis [266] or likelihood-based methods [267], which can also be extended
to account for correlated variants [268] (see Section 6.2.5 for details).
The main advantage with the Wald ratio or combined ratio approaches compared to
2SLS in the context of genetic epidemiology is that the former can be performed using
summarised data. Furthermore for the ratio approaches, the genetic-exposure and genetic-
outcome summary estimates can be obtained from separate samples from a population or
subsamples; this is known as two-sample MR (2SMR) and subsample MR respectively
[269]. In large genetic association studies, it may not be possible nor practical to obtain
individual-level data but summary level data on the other hand are often publically available.
Additionally, genetic associations are often performed independently for the exposure and
outcome using different samples, making 2SMR a particularly powerful approach in view of
the increasing wealth of publically available GWAS summary data (Fig. 1.2). The confidence
interval of MR is typically much larger compared to observational estimates due to lower
power and large sample sizes are required to obtain precise estimates [268, 270]. For example,
an instrument which explains 2.5% of the variation in exposure requires ∼ 9,000 cases and
controls to achieve 80% power to detect an odds ratio (OR) of 1.3 per standard deviation
(SD) change in the exposure, assuming a p-value threshold of 0.05 for significance [271].
To an extent, this problem is alleviated in the 2SMR setting due to the combined large scale
(tens to hundreds of thousands of samples) GWAS efforts from various consortia across
many diseases and traits [31] allowing much more precise and robust estimates. Caution
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should be taken in ensuring that the two samples used should come from the same underlying
population especially in terms of ethnicity to avoid false positive findings due to population
stratification (see Section 1.3.2).
GWAS discovery estimates tend to over-estimate the effect due to "winner’s curse"; if
genetic variants are chosen due to their association with the exposure in the dataset under
analysis, then the association with the exposure is likely to be overestimated [272]. Weak
instruments (i.e. if the genetic variant only explains a small proportion of the variance in the
intermediate) are more likely to be affected by this [273]. The R2 or F statistic of the genetic-
exposure regression are two related measures often used to estimate instrument strength with
a F < 10 often being used as a rule of thumb to indicate weak instruments [264, 274]. In finite
samples, if the genetic-exposure and genetic-outcome estimates are obtained from the same
sample, weak instrument bias acts in the direction of the observed association between the
exposure and the outcome [275]. In a two-sample setting where the samples are independent
or largely non-overlapping, weak instrument bias acts in the direction of the null [269].
This can be viewed using the Wald ratio where in the two-sample setting, the coefficients
for the numerator and denominator are independently derived and overestimation of the
denominator due to winner’s curse will result in an underestimation of the ratio. Therefore,
in the two-sample setting, bias towards the null leads to more conservative estimates and will
reduce false positive findings which may be desirable from a robust discovery perspective.
1.5.2 Application of MR in practice
Through robust and careful selection of genetic instruments guided by biological plausibility,
MR has been successfully applied in the field of genetic epidemiology. A thorough recent
review of past MR studies can be found in [276] and [277]. I will highlight in detail some
of the high profile examples and how they have helped inform causal inference and drug
targeting in the context of coronary heart disease (CHD) where MR has been extensively
applied.
Observationally, plasma levels of two main components of cholesterol LDL and high-
density lipoprotein (HDL)-cholesterol have been repeatedly been positively and inversely
associated respectively with risk of CHD/MI [278, 279]. LDL has been widely recognised
to play a causal role in CHD/MI [280] and this has been supported by various efficacious
LDL lowering drugs [281]. The protective role of HDL on the other hand has been less
clear [279] as Mendelian forms of high or low HDL have not been robustly associated with
increased CHD/MI risk [282]. In a large scale MR study, Voight et al [283] used a single
functional variant in the endothelial lipase (LIPG) gene and a 14-SNP genetic risk score
specifically associated with HDL (i.e. no evidence of association with LDL and triglycerides)
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to instrument HDL for its effect on MI risk. In contrast to observational estimate, the MR
results did not find evidence of HDL being associated with MI risk using both MR approaches.
As a positive control, using a 13-SNP genetic score specifically associated with LDL, the
MR estimates were concordant with observational associations of increased LDL leading
to increased MI risk. Other MR studies using variants in the genes related to HDL/LDL
pathways [284–287], or allelic scores for HDL and LDL, have also shown similar results [288,
289]. For example the causal effect of LDL and risk of CHD is convincingly demonstrated
using 9 independent SNPs for 6 genes independently which have prior biological evidence of
being involved in the LDL regulation pathway; all 9 instruments gave similar causal effect
estimates as shown in Fig. 1.13 [288].
Fig. 1.13 Effect of per unit long term exposure to lower LDL-cholesterol (LDL-C) on risk of CHD.
Boxes represent the proportional risk reduction (1-OR) of CHD for each exposure allele plotted
against the absolute magnitude of lower LDL-C (mg/dl) associated with that allele. Vertical lines
represent 1 SE above and below the point estimate of proportional risk reduction. The line (which is
forced to pass through the origin) represents the increase in proportional risk reduction of CHD per
unit lower long-term exposure to LDL-C. (Figure adapted from Ference et al [288]).
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Amongst protein biomarkers associated with CHD, fibrinogen and C-reactive protein
(CRP) levels have been associated with increased CHD risk in observational epidemiology
[290–295]. Large scale MR studies using a functional variant in the promoter of the FGB
gene which encodes the β component of fibrinogen to instrument for the effect of fibrinogen
levels on CHD risk showed no causal evidence of fibrinogen levels on CHD risk [296, 297].
Similarly, several MR studies [152, 298–302], including a large scale combined effort in
nearly 200,000 participants across 47 studies [303], using variants within the CRP gene
which were specifically associated with CRP levels, have shown no significant evidence for a
causal association between CRP levels and CHD risk. These results suggest that the positive
observational associations of plasma/serum levels of fibrinogen and CRP on risk of CHD
could be due to reverse causation or unmeasured confounding and that drugs targeting these
proteins are unlikely to be efficacious in reducing CHD risk.
MR studies have also been applied on other protein intermediates targeted by pharmaco-
logical agents to mimic their effects, which could help inform drug targeting. Metabolomic
profiling showed that metabolomic effects of statins, which inhibits HMG-CoA reductase
(HMGCR), could be mirrored by a genetic variant in the HMGCR gene [304]. Association
between variant(s) affecting an intermediate and the outcome can be used to provide evidence
of potential efficacy in targeting this intermediate. For example, a known functional variant
(D358A) in interleukin-6 receptor (IL6R) was used to show causal associations between IL6R
related pathways and CHD risk [305]. This suggests drugs targeting IL6R (e.g. tocilizumab),
currently used for treating rheumatoid arthritis (RA), can also reduce CHD risk. In addi-
tion, association between variants and outcomes considered as potential side effects could
suggest whether the side-effect is likely to be due to on-target or off-target effects. This
is exemplified in a recent MR study which used two independent variants associated with
interleukin-1 receptor antagonist (IL1RA) levels, an endogenous inhibitor of IL-1α and
IL-1β , as instruments and showed a causal effect of increased IL1RA levels on decreased
risk of RA, decreased levels of IL-6, CRP and increased LDL levels, CHD and abdominal
aortic aneurysm (AAA) risks [306]. This suggests drugs with dual inhibition of both IL-1α
and IL-1β , such as anakinra (a recombinant IL1RA currently licensed for RA) [307] could
potentially lead to increased CHD and AAA risk as a result of on-target effects. A recent
large scale randomised controlled trial of the monoclonal IL-1β inhibitor canakinumab has
also shown a reduction in CRP and IL-6, echoing the effects seen in the MR study [308].
Interestingly the trial showed no change in the drug’s effect on LDL levels and a decreased
MI risk which was not predicted through MR, although endogenous IL1RA inhibits both
IL-1α and IL-1β . This may suggest that pro-lipid effects on increased LDL levels and in
turn CHD risk could be mediated through IL-1α inhibition whilst the anti-inflammatory and
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cardio-protective effects could be mediated through IL-1β inhibition. On the other hand,
torcetrapib, a first-in-class cholesteryl ester transfer protein (CETP) inhibitor which raises
HDL-cholesterol, unexpectedly failed phase 3 clinical trials due to an unexpected increase
in blood pressure and cardiovascular events [309]. A MR study using SNPs in the CETP
gene, found concordant effects on lipid levels but no evidence of CETP inhibition causally
increasing blood pressure; this suggests the side-effect of torcetrapib on blood pressure is
unlikely to be due to on-target effects [310]. The recent randomised clinical trial looking
at the effects of another CETP inhibitor, anacetrapib, on atherosclerotic disease (88% of
patients had CHD) showed reduced major coronary events with no significant differences
in rates of serious adverse events attributed to hypertension [311]. There was effect of only
a slight increase in blood pressure (0.7 mmHg), much smaller compared to that seen in
torcetrapib (5 mmHg), providing support to the MR results that the effect of torcetrapib on
blood pressure is likely off-target.
MR can provide a complementary and cost-effective tool in assessing drug efficacy and
possible on and off-target side effects before embarking on potentially costly (tens of millions
of pounds) clinical trials [312] as well as monitoring for previous unconsidered side-effects
such as in the case of anakinra.
1.5.3 pQTLs as instruments for MR
The reliability of the findings from MR depends on the validity of the instruments used. In the
case of lipids above, the variants used are in or near genes that are biologically implicated in
the regulation of those lipids, which in MR assumes that effect of the variant acts on the lipids
via those genes only and the gene/gene product does not have effects on CHD risk other than
via the lipids - no pleiotropy effects (MR assumption 3 described in Section 1.5.1). Rather
than using genetic variants to instrument risk factors far distal downstream to the genetic
code such as metabolites and lipids (e.g. metabolite quantitative trait loci (mQTLs)), it may
be more robust to use genetic variants to instrument the gene-encoding protein products.
Therefore, cis pQTLs have several desirable characteristics for MR.
First, proteins are the functional unit of biological processes. Protein expression and
structure therefore are placed closer to the functional processes than gene expression, which
are often used as proxy for protein expression. As already discussed, changes in gene
expression may not reflect changes in protein levels [66, 67] - directly assessing protein
expression is therefore more representative than assessing RNA levels. In addition, most
pharmacological interventions target proteins rather than upstream RNAs or downstream
metabolites [313]. Therefore, pQTLs are better than eQTLs or mQTLs in terms of mimicking
the inhibitory/activatory effect of a pharmacological agent on a target.
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Second, cis pQTLs are often biologically plausible and specific for the encoded protein in
cis; this is exemplified in the genetic instruments associated with CRP [303]. Any pleiotropy
effects are likely to be vertical (acting via the protein) rather than horizontal (acting on the
outcome not via the protein but through alternate pathways); though horizontal pleiotropy is
still possible (e.g. through long-range chromosomal interactions or through cis micro RNA
effects on other protein levels), these can be excluded using available bioinformatic data
[314]. Vertical pleiotropy is less problematic because MR gives consistent causal estimates
[315] whilst horizontal pleiotropy directly violates the third MR assumption discussed in
Section 1.5.1 and leads to biased estimates. The likelihood of horizontal pleiotropy is also
dependent on the complexity of the locus. In the CRP example where the region does
not contain any similar functioning genes in the same pathway, there is unlikely to be any
horizontal pleiotropy. On the other hand, in regions where there are several genes potentially
in similar pathways (e.g. the MMP12 and IL1RL1-IL18R1 loci), there is a much higher
chance of horizontal pleitropy through the effects genetic variants on one or more of the
alternate genes in that locus (see Chapter 6 for more details). Methods such as multivariable
MR and MR-Egger have been recently proposed to address the issue of horizontal pleiotropy
albeit with certain limitations such as requiring multiple instruments and reduced power.
Multivariable MR essentially allows for pleiotropy among a pre-specified set of risk factors
(e.g. protein levels) for which the genetic effects of the instruments on these have been
measured [315] but this requires effects of multiple proteins to be measured, especially
those encoded by functionally related genes near the pQTL(s) selected as instrument(s), to
minimise the chance of horizontal pleiotropy via unmeasured biomarkers. MR-Egger tests for
directional pleiotropy by regression of the gene-outcome on the gene-exposure associations
with the intercept unconstrained to pass through the origin [272]. The intercept from the
MR-Egger regression indicates the presence of non-balanced (directional) pleiotropy whilst
the slope corresponds to the causal effect adjusted for the pleiotropy. However, this method
assumes the strength of the gene-exposure association do not correlate with the strength of
bias from pleitropy (the InSIDE assumption) and has a reduced power to detect causal effects
[272].
Third, cis pQTLs make relatively strong instruments compared to those used for some of
"downstream intermediates" such as body mass index (BMI), thus allowing reduced bias due
to weak instruments and increased power in MR. On average, the lead pQTLs explain∼ 8.5%
[96] of the protein variance with some studies reporting higher estimates for some proteins
[95, 254]. In comparison, instruments used to assess the causal effect of BMI (obtained from
recent BMI GWAS of much larger samples) on various traits together explained less than 3%
of the variance in BMI [316–319].
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1.6 This thesis
Understanding the causes of diseases is important in developing treatment for them and
genetics have contributed hugely to this motivation. Genetics can be used to provide causal
evidence of protein risk factors on disease and inform drug targeting through the MR
paradigm. pQTLs, especially cis ones, have desirable properties that make them ideal
instrumental variables. However, the pQTL space has been largely under-explored due to a
combination of limited proteome coverage, relatively small sample size and particularly in
early studies, low resolution genome coverage; most of the shortcomings have been a result
of technological limitations.
1.6.1 Aims and outline of this thesis
In this thesis, I am looking to use state of the art tools (an apatamer-based proteomics assay
measuring >3,300 proteins combined with densely imputed genetic variants using a recent
large-scale reference panel and a large sample (n>3,300)), which largely overcome several of
the limitations described above, to:
1. Identify novel genetic determinants of the human plasma proteome with the secondary
aim of characterising the genetic architecture of pQTLs.
2. Identify examples that highlight biological relevance of identified pQTLs.
3. Highlight the disease relevance of the pQTLs and use them to test causal relationships
between proteins levels and disease risk through MR.
The thesis will be structured as follows:
• Chapter 2: Description of the study cohort, the technical details of protein and genetic
measurements along with their quality control, and setting up the analysis strategy for
large scale GWAS. Specific methods used are presented within the relevant chapters.
• Chapter 3: Identifying the genetic determinants of protein levels.
• Chapter 4: Characterisation of pQTLs.
• Chapter 5: Examples of biological relevance of pQTLs.
• Chapter 6: Disease relevance of pQTLs and their application in MR.
• Chapter 7: Conclusion: summary of work, discussion of limitations and future direc-
tions.
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Chapter 2
Study cohort characteristics,
measurements and QC
2.1 Introduction
The ability for GWAS to detect genetic associations largely depends on the data quality
going into the analyses. Performing analyses on data that have not been properly cleaned
could potentially lead to increased false negatives and particularly, false positives, which
could be carried into further downstream studies at the expense of wasted time and resources.
Therefore, prior to genetic analyses, stringent quality control (QC) measures need to be
performed both in the genetic and phenotype (i.e. protein measurements) data to ensure that
only high quality data serve as inputs for analyses.
In recent years, there have been major improvements in our resolution to measure variants
across the genome owing to advances in terms of methods, size and quality of reference
genetic data and computational power [51–53, 320]. Recent 1000 Genomes Phase 3 and
UK10K reference panels have allowed imputation of a larger number of variants and im-
proved imputation quality, especially for lower frequency variants among UK and European
populations [51, 52]. In contrast to traditional GWAS which looked at a small handful of
phenotypes and often assessed less than 1 million genotyped variants, current GWAS are
getting bigger in terms of sample sizes, number of genetic variants and dimensionality of
phenotypic data as we enter the "omics" era and this poses significant computational as
well as file storage and access challenges. The scale of the data makes running all GWAS
infeasible using a single desktop machine. Therefore, there is a need to parallelise the process,
making use of computing clusters to reduce the time needed for analysis to within reasonable
time frames.
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This chapter introduces the study cohort, proteomics and genetic data used in this thesis.
I will briefly describe the study participants used and then proceed to give an in-depth
description and a detailed overview of the QC procedures of the proteomic and genetic data.
This includes assessing the proteomic data for repeatability of the assay, proteomic profile
of the samples and technical factors contributing to protein variability, standardisation of
quantification outputs between the cohorts and looking at how the proteomic data replicate
previously known biological associations. For genetic data QC, I largely follow previous well-
established QC stages with additional QC measures pertaining to the INTERVAL samples
[321, 322]. Finally, I first compare the time it took to run one GWAS using different existing
tools and using two commonly used methods to account for imputation uncertainty. I then
assess the results from these different tools and methods to see if they give sensible results.
The post-QC’d data and optimised GWAS computational set-up form the basis of analyses in
subsequent chapters.
2.2 Methods
2.2.1 Study Participants
The INTERVAL study is a prospective cohort study of approximately 50,000 participants
nested within a randomised trial of blood donors. Between 2012 and 2014, blood donors
18 years and older were consented and recruited from 25 National Health Service Blood
and Transplant static donor centres across England, UK [323]. Men were randomised to 12,
10 and 8-week donation intervals whilst women were randomised to 16, 14 and 12-week
intervals. Participants were predominantly healthy individuals at the time of recruitment since
people with major disease were ineligible for donation, as were those who reported being
unwell or having had recent illness or infection. Participants completed online questionnaires
containing basic lifestyle and health-related information at enrolment and are scheduled to
be reassessed at two years post-baseline.
The INTERVAL study was approved by the Cambridge (East) Research Ethics Committee.
Informed consent was obtained from all participants. Participants who have subsequently
withdrawn from the study were removed at the time of analysis.
2.2.2 Blood sample collection
At baseline and two-year time-points, research blood samples were collected in tubes of
ethylenediaminetetraacetic acid (EDTA) using standard venepuncture protocols. The tubes
were inverted three times and transferred in temperature-controlled shipping boxes to UK
37
Study cohort characteristics, measurements and QC
Biocentre (Stockport, UK) for processing. 800 µl plasma, serum and buffy coat aliquots were
extracted from the EDTA sample by centrifugation and subsequently stored at −80 ◦C prior
to use.
2.2.3 Proteomic measurements and QC
SOMAscan™ proteomic assay
Aliquots of 150 µl plasma were sent to SomaLogic (Boulder, Colorado, USA) for protein
quantification using the expanded SOMAscan multiplex proteomics assay platform (see
Fig. 1.10 for details). The samples were diluted into three dilutions (40%, 1% and 0.005%)
and incubated with dilution specific collections of bead-immobilised SOMAmers linked to
fluorophore tags. Plasma proteins binding to the SOMAmers are biotinylated, then the bound
complexes are released from the bead by photocleavage and non-specific SOMAmer-protein
pairs are disrupted. Subsequently, the biotinylated proteins are recaptured on streptavidin
beads where after washing, SOMAmers are eluted and the fluorophore-tagged aptamers are
quantified through hybridisation to SOMAmer-complimentary arrays. Protein concentrations
are relatively quantified as relative fluorescent units (RFUs). Specific technical details can be
found in the technical white paper at the manufacturer’s website (http://http://info.somalogic.
com/lp_campaign_somascan-white-paper_jan-2016[accessed01/2017]).
Multiplex protein measurements in INTERVAL
The SOMAscan assay was used to measure 4,034 unique SOMAmer targets in INTERVAL
samples totalling 3,562 individuals randomly drawn from a set of approximately 4,500
INTERVAL participants who have also been whole exome sequenced in addition to genome-
wide genotyping (see Section 2.2.6). The participants who had whole exome sequencing
were randomly drawn from the 50,000 INTERVAL participants. For pragmatic reasons,
selection of samples for proteomic assays was carried out in two cohorts. In cohort 1, 2,664
baseline samples (including 4 pairs of duplicates), 71 paired baseline-2 year samples and
30 pooled plasma samples were measured. In cohort 2, 831 baseline samples and 10 pooled
plasma samples were measured. The pooled samples were identical within each cohort and
obtained through pooling together plasma of a random sub-sample of individuals within each
cohort and splitting the pooled plasma into 30 and 10 aliquots, randomised across the plates,
for cohorts 1 and 2 respectively. The laboratory staff were blinded to the type of samples
measured to avoid any experimenter bias.
Protein mapping to UniProt identifiers and gene names were provided by SomaLogic.
Mapping to Ensembl gene IDs and genomic positions was performed using Ensembl Variant
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Effects Predictor (VEP) v83 [324]. Protein subcellular locations were determined by export-
ing the subcellular location annotations from UniProt [325]. If the term "membrane" was
included in the descriptor, the protein was considered to be a membrane protein, whereas
if the term "secreted" (but not "membrane") was included in the descriptor, the protein was
considered to be a secreted protein. Proteins not annotated as either membrane or secreted
proteins were classified (by inference) as intracellular proteins. Proteins were mapped to
molecular functions using gene ontology annotations [326] from UniProt. The same approach
was used to map all proteins in the Human Protein Atlas [327].
SomaLogic proteomic QC
Data normalisation and calibration were performed at the sample and SOMAmer level to
adjust for within-run and between-run variabilities respectively. It involved the use of control
SOMAmers and calibrator samples. The three main data standardisation steps: hybridisation
and median normalisations, and calibration scaling are summarised in Fig. 2.1 below.
At the sample level, a set of hybridisation control sequences were added to each sample
to correct for systematic variability during hybridisation - hybridisation normalisation. There
was a predefined global reference RFU for each hybridisation control based on a number
of independently run assays. A ratio was calculated by dividing the global reference RFU
of each control by its measured RFU in the sample. The median of the ratios determines
the sample-based hybridisation scaling factor. All SOMAmer RFUs within a sample were
multiplied by the scaling factor.
In addition, median normalisation was performed to remove sample or assay biases
that may be due to differences between samples in overall protein concentration, pipetting
variation, variation in reagent concentrations, assay timing, and any other source of systematic
variability within a single plate run. Each SOMAmer was assigned to one of three dilution
sets (40%, 1% and 0.005%), scaling factors were derived within dilution sets separately
and all SOMAmers within each set were scaled together. Median reference RFU for each
SOMAmer was defined as the median RFU for that SOMAmer within the sample group in the
plate to be normalised. A ratio was calculated by dividing the reference RFU by its measured
RFU of the SOMAmer in sample. Within each dilution set, the median of SOMAmer ratio
defined the sample-based scaling factor for all SOMAmers within that dilution and sample.
A set of control calibrator samples (independent set of pooled human plasma) were used
to derive a calibration factor for each SOMAmer. Calibrator global reference RFU for each
SOMAmer were defined by the median signal measured on a set of samples spanning a
number of independent assay runs. For each SOMAmer, the median RFU signal for that
SOMAmer reagent across all the calibrator samples within each plate defines the local median
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Fig. 2.1 Schematic of the SOMAscan assay data standardisation steps. Figure adapted from SOMAscan
Data Standardization and File Specification Technical Notes, SomaLogic.
calibrator reference RFU. The SOMAmer-based calibration scaling factor was defined by
dividing the calibrator global reference RFU by the local median calibrator reference value.
This scaling factor was applied to all measurements in the plate for that SOMAmer; each
SOMAmer on each plate has a unique scaling factor.
Additionally, plasma from two independent individuals was run as pairs of QC samples
on each plate. The acceptance QC criteria for the hybridization and median normalisation
scaling factors were expected to be in the range of 0.4 to 2.5 based on historical runs. For
each SOMAmer, the calibration scaling factors were expected to be within ±0.4 from the
median. In addition, on the plate level, the median of the calibration scaling factors must lie
within ±0.2 from 1.0 and more than 95% of SOMAmers in the plate must have a calibration
scaling factor within ±0.4 from the median (i.e. less than 5% in the tails of the distribution).
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Additional proteomic QC
INTERVAL pooled plasma samples were used to examine the reproducibility of SOMAmer
measurements and overcome limitations in limited sample volume and effects of biological
sample variation. Within each cohort, variation between the pooled plasma samples can
be used to estimate technical reproducibility of the assay for each analyte. Coefficients of
variation (CVs) for each SOMAmer in each cohort were calculated by dividing the standard
deviation by the mean of the pooled plasma samples. In addition to passing SomaLogic
proteomic QC, each SOMAmer analyte must also have a CV of ≤ 20% for the cohort used in
subsequent analyses. Analytes failing either the SomaLogic proteomic QC or the CV cut-off
were excluded from further analyses. Non-human SOMAmers (n=8) were also excluded.
Baseline-2 year protein correlations
For paired baseline-2 year samples passing QC, Spearman’s correlation was calculated
between baseline and 2-year samples for each SOMAmer analyte.
2.2.4 Technical variability in protein levels
Principal component analysis
PCA is a commonly used dimension reduction method which uses an orthogonal transforma-
tion to project a set of variables into a set of linearly uncorrelated principal components (PCs),
where the first PC accounts for the largest variability in the data with each succeeding PC
explaining progressive less variance. Each PC is a linear combination of original variables.
Post-QC proteomic measurements were first log-transformed, then centred and autoscaled to
unit variance. PCA analysis was performed using the FactoMineR R package [328].
Principal variance component analysis
Principal variance component analysis (PVCA) is an approach which combines PCA with
variance component analysis (VCA) [329, 330] and has been used to estimate contribution of
technical factors to the majority of the variability in gene expression arrays [329–332]. The
proteomic data were first decomposed into a set of PCs and the top PCs explaining 60% of
the overall variance were selected. Technical factors (INTERVAL plate sent for measurement
(categorical), SomaLogic plate for measurement (categorical), donation centre (categorical),
month of attendance (categorical) and duration between venepuncture and processing (binary:
"less than a day" or "a day or more")) were treated as random effects in a linear mixed model
fitted to each PC. The variance components in each model were estimated using restricted
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maximum likelihood (REML) and weighted based on the eigenvalue for each corresponding
PC. The variance attributable to each factor was then standardised across all estimates to
proportion of total variance.
To assess contribution of biological factors (age, sex (binary), BMI, log(estimated
glomerular filtration rate (eGFR)), alcohol use (binary) and smoking (binary)) to protein vari-
ance, the protein data were first adjusted for duration between venepuncture and processing
in a linear model. The residuals were then decomposed into PCs and the protein variance
attributable to each factor was calculated as for technical factors above.
2.2.5 Reproducing non-genetic determinants of protein levels
Protein levels (in RFUs) were natural log transformed and linear regression was performed
using age, sex, BMI, ln(eGFR) and cohort as predictors. Given that a total of 45 proteins
and 40 proteins were previously tested for associations with age and sex respectively in
previous studies using same SOMAscan probes by Ngo et al [333] and Menni et al [334],
Bonferroni-corrected p-thresholds of 1.1×10−3 (0.05/45) and 1.2×10−3 (0.05/40) were
used when considering replication of the previous associations for age and sex respectively.
2.2.6 Genetic measurements and QC
Genotyping, imputation and QC for the whole INTERVAL cohort have been previously
described in detail [322]. Further genetic QC was performed for the INTERVAL subcohorts
who had proteomic measurements. I will briefly describe the INTERVAL-wide genetic
measurement and QC steps (please refer to [322] for additional details) and focus on the
additional QC steps pertaining to the subset of samples with proteomic measurements which
form the basis for subsequent analyses in this thesis.
Genotyping
DNA was extracted from buffy coat aliquots at LGC Genomics (UK) using a Kleargene
method and shipped to Affymetrix (Santa Clara, California, USA) for genotyping. Genome-
wide genotyping was performed on the Affymetrix GeneTitan® Multi-Channel Instrument
according to the Affymetrix Axiom 2.0 Assay Automated Workflow using the UK Biobank
Affymetrix Axiom array which is a customised array assaying 820,967 SNPs and short
indels. The array includes (1) a GWAS scaffold selected to ensure good quality genome-
wide imputation of common (MAF> 5%) and low-frequency (MAF= 1−5%) variants in
European and UK populations, (2) an exome component designed to capture rare variants
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within exonic regions and (3) a selection of variants in regions relevant to various disease
and intermediate phenotypes. Genotypes were called in batches of approximately 50 plates
using the Affymetrix Power Tools software implementing the Axiom GT1 algorithm.
QC of genotype data
Affymetrix implemented standard QC procedures as part of the genotype calling pipeline
excluding samples with poor signal intensity (dish QC< 0.82) and low call rate (< 97%)
based on ∼ 20,000 high quality probesets. Variants were excluded if they had low call rate
(< 95%), had more than three clusters (indicative of off-target measurement), had cluster
statistics (Fisher’s linear discriminant, heterozygous cluster strength, homozygote ratio offset)
indicative of poor quality genotyping or were complicated multi-allelic variants that could not
easily be called. Further variant level QC was performed to exclude variants with potentially
poorly called genotypes and wide MAF ranges across batches - the specific criteria used
are detailed in [322]. Samples with more than 10% sample contamination calculated using
method described in [335], as well as those who had both 3-10% contamination and ten
or more first or second-degree relatives were excluded. Duplicate samples, heterozygosity
outliers (heterozygosity more than three standard deviations away from the mean), samples
with missing phenotypic sex and sex mismatches were also removed. Then in addition,
samples clearly not of European ancestry (ethnic outliers) were also excluded.
Imputation
Prior to imputation, additional variant QC steps were performed to establish a high quality
imputation scaffold. This included a Hardy–Weinberg equilibrium (HWE) filter of p<
5×10−6, call rate filter of 99% over the batches that a variant was not failed in, a global call
rate filter of 75% (effectively ensuring a variant passed in at least 8 of the 10 batches) and
removal of monomorphic and non-autosomal variants. Haplotype phasing was carried out
using SHAPEIT3 [320], in chunks of 5,000 variants with an overlap of 250 variants between
chunks. Imputation was performed using the combined 1000 Genomes Phase 3-UK10K
imputation panel on the Sanger Imputation Server (https://imputation.sanger.ac.uk), which
uses the positional Burrows–Wheeler transform imputation algorithm [336].
Additional genetic QC pertaining to samples with proteomic measurements
The INTERVAL genetic data were first subsetted to samples who have undergone proteomic
measurements and have passed QC. Relatedness between samples was first estimated using
identity-by-descent (IBD). After excluding variants in high LD regions [337], a call rate
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filter of 99%, MAF filter of 5% and HWE filter of p< 5×10−6 were used to establish a high
quality set of genotypes for IBD estimation. The variants were also LD-pruned (r2 < 0.2).
IBD analysis was then performed using PLINK v1.9 [338] and a πˆ cut-off of 0.187 was used
to exclude first or second degree related samples. Of the related pairs of samples, the sample
with the lower call rate was removed. MDS was performed using the high quality set of
genotypes to create components to account for residual relatedness in genetic analyses.
Subsequently QC was performed on the imputed variants in each of the two cohorts
separately. Within each cohort, GCTOOL v1.4 (http://www.well.ox.ac.uk/~gav/qctool) was
used to exclude variants with a minor allele count (MAC)< 8, an INFO score< 0.7, HWE
p< 5×10−6. In addition, for variants with identical genomic positions (Genome Reference
Consortium Human genome build 37 (GRCh37)) and alleles, the variant with the lower INFO
score was removed. Overlapping variants passing in both cohorts were included in the final
set of variants for genetic analyses.
2.2.7 Comparison of GWAS speed and methods
Univariate GWAS using the combined cohort data (n=3,301) was performed on a randomly
generated phenotype drawn from a normal distribution with mean 0 and variance 1. A lenient
variant cut-off of MAF≥ 0.001% and INFO ≥ 0.3 was used leading to ∼ 16.2 million post-
filter variants which were stored as posterior genotype probabilities in "bgen" or "gen.gz"
formats split by chromosomes. Comparison of the time it took to run the GWAS (under the
additive model) was carried out between SNPTEST v2.5.2 (with the "bgen" format) [339],
QUICKTEST v0.95 [340] and RegScan v0.1 (both with "gen.gz" formats) [341]. The first
two are widely used tools for GWAS which handles imputed genetic data and readily accepts
"gen.gz" formats whilst the latter has been recently developed for improved speed compared
to the other two using the "gen.gz" format [341]. The allelic dosages method was tested for
all three tools, score test and maximum likelihood (ML) methods were tested for SNPTEST
and QUICKTEST (as RegScan did not support these two methods).
Details of commands and parameters used for each tool can be found in Appendix A. At
the time of analysis, only SNPTEST supported the newer "bgen" format, which contained
improved storage and data access features (http://www.well.ox.ac.uk/~gav/bgen_format/),
whilst the other two tools used the "gen.gz" format. GWAS for each chromosome for all
methods to compare were sent as a separate job (one job per chromosome) to the CARDIO
cluster (Appendix A), with each job using one core on a single low memory mode. The time
it took to run for each method were summed across all chromosomes. Pearson’s correlation
was calculated between the z-scores obtained from different method and tools.
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2.3 Results
Plasma protein levels of 3,562 healthy individuals from the INTERVAL study were measured
in two separate cohorts (2,731 individuals in cohort 1 and 831 individuals in cohort 2). 4
individuals from cohort 1 withdrew from the study at the time of analysis and were excluded
from subsequent analyses (Fig. 2.2). 51% of participants were male with mean age 44
(range=18-80) and less than 9% were current smokers. Mean BMI is in line with the national
average in England whilst eGFR is slightly higher than the national average [342], which is
likely due to the fact that those with renal disease (hence low eGFR) would not be eligible
for the study. There were no significant differences in baseline characteristics (age, sex, BMI,
eGFR, smoking and alcohol use) between the two cohorts (Table 2.1).
Table 2.1 Baseline characteristics of the study samples.
Characteristic
Combined cohort Cohort 1 Cohort 2
p-value1Mean (SD) Mean (SD) Mean (SD)
or % or % or %
Age (years) 43.7 (14.3) 43.6 (14.3) 44.1 (14.2) 0.37
Sex (% male) 51.0% 51.6% 49.5% 0.31
BMI (kg/m2) 26.3 (4.8) 26.3 (4.8) 26.6 (4.9) 0.15
eGFR (ml/min/1.73m2) 111.5 (16.0) 111.5 (15.9) 111.4 (16.3) 0.85
Current smokers (%) 8.6% 8.6% 8.5% 0.96
Current alcohol use (%) 92.2% 92.6% 91.0% 0.14
1 Age, BMI, eGFR: p-values from two-sided t-test for difference between cohorts. Sex, smoking and alcohol
use: p-values from two-sided χ2 test for difference between cohorts.
2.3.1 Proteomic QC
The proteomics assay (SOMAscan) measured 3,620 unique proteins/protein complexes
assayed using 4,034 SOMAmers. Extracellular proteins (membrane and secreted) are propor-
tionally more represented than intracellular ones compared to the human proteome (Fig. 2.3a).
The proteins assayed cover a wide range of molecular functions (Fig. 2.3b), with the selection
of proteins on the platform reflecting both the availability of purified protein targets and a
focus on proteins known to be involved in pathophysiology of human disease. Some proteins
have multiple SOMAmers targeting them, henceforth I will use the term "SOMAmer" when
referring to SOMAmer probes and "protein" when referring to proteins. Multiple SOMAmers
with dissimilar sequences are included on the platform based on high affinity interactions
with the protein and they may bind to different epitopes on the protein target.
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Fig. 2.2 Flowchart of INTERVAL proteomic sample and genetic QC.
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Fig. 2.3 Characterisation of protein targets measured using the SOMAscan assay by (a) compartment
distribution with annotations of all proteins in the Human Protein Atlas for comparison, and (b) GO
molecular functions.
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SomaLogic technical QC
2,562 of 2,727 individuals from cohort 1 and 825 of 831 from cohort 2 had samples passing
the SomaLogic proteomic QC. 3,680 and 3,807 of the 4,034 SOMAmer targets passed QC in
cohort 1 and cohort 2 respectively with 3,533 SOMAmers passing in both cohorts.
I assessed reproducibility of the proteomic measurements by determining CVs for each
of the SOMAmers from the pooled plasma samples in each cohort separately. The majority
of the SOMAmers showed good reproducibility with 3,847 (95%) and 3,773 (94%) of
SOMAmers having CVs≤ 20% in cohorts 1 and 2 respectively (Fig. 2.4). The median CVs
for the assay platform were 5.3% (4.2-7.7% [1st–3rd quartile]) and 6.9% (5.1-10.2% [1st–3rd
quartile]) for cohorts 1 and 2 respectively.
Fig. 2.4 CVs of proteomic data.
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After both SomaLogic and additional proteomic QC stages, 3,573 and 3,591 SOMAmers
passed in cohorts 1 and 2 respectively with 3,283 SOMAmers, encompassing 2,994 proteins
(or protein complexes), passing in both cohorts.
60 of 71 individuals, where protein levels at both baseline and two-year time points
were measured, had both samples passing QC. I calculated correlation between baseline and
2-year samples using Spearman’s rank correlation to assess longitudinal variation in protein
measurement. 63% of SOMAmers had a Spearman’s correlation greater than 0.5 with a
median correlation of 0.56 across all SOMAmers (Fig. 2.5).
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Fig. 2.5 Baseline-2 year correlation of proteomic data.
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2.3.2 Contribution of various technical and non-technical factors to
proteome variability
PCA of global protein variation
First I looked at whether there were any global differences in protein levels between INTER-
VAL and non-INTERVAL samples (SomaLogic QC samples) using PCA. PCA including all
passed samples (SomaLogic calibrator and QC samples from two independent individuals,
and INTERVAL pooled plasma samples) showed clear separation between INTERVAL and
non-INTERVAL samples in the first 2 PCs (Fig. 2.6). There was also separation between
SomaLogic QC samples from the two separate individuals and between the calibrator and
QC samples. In addition, the INTERVAL pooled samples lie near the centre of the cluster
of INTERVAL samples which is consistent with the pooled plasma being an aggregate of
overall protein levels in INTERVAL participants. Clustering of replicate samples in the biplot
of the first two PC indicates high technical reproducibility across the majority of proteins
measured.
I then looked within the INTERVAL samples to see if there were any obvious clustering
or outlying samples across the main axes of protein variability using PCA excluding the
SomaLogic calibrator and QC samples, and INTERVAL pooled plasma samples. The PCA
biplot showed a rather homogeneous cluster of samples within each cohort and there were no
extreme outlying samples (Fig. 2.7).
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Fig. 2.6 PCA biplot of proteomic data (including SomaLogic calibrator and QC samples and INTER-
VAL pooled plasma samples) mapped to the first two PCs.
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Fig. 2.7 PCA biplot of proteomic data (excluding SomaLogic calibrator and QC samples and INTER-
VAL pooled plasma samples) mapped to the first two PCs.
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Quantifying contributions of technical and non-technical factors to protein variability
I used PVCA [329, 330], which has been previously applied in gene expression datasets
[329–332], to quantify the extent to which technical and sample baseline factors (age, sex,
BMI, renal function (measured via eGFR), smoking and alcohol use) contribute to proteomic
variation (see Section 2.2.4 for details).
Duration between venepuncture and processing contributed the greatest to the total
variance (13% and 14% in cohorts 1 and 2 respectively) (Fig. 2.8 (top)). Other technical
factors contributed little to the total variance. Plate effects, both in terms of the plate which
INTERVAL blood samples were processed and the plate which proteomic measurements
were performed on, contributed less than 3%. The centre where blood was donated also
contributed less than 3% to the variation whilst the month of attendance contributed less
than 2%. Most of the total variance was not explained by the factors examined - residual
variances were 80% and 78% for cohorts 1 and 2 respectively. The extent to which each
factor contributed to the total variance was similar between cohorts 1 and 2. After adjusting
for the duration between venepuncture and processing, the majority of the technical effects on
total variance was removed - residual variances after adjustment were 91% for both cohorts
1 and 2 (Fig. 2.8 (middle)). I also looked at whether if time to sample processing in hours
for samples processed within a day (for participants with non-missing data, 91% in cohort 1
and 96% in cohort 2) had a large contribution to proteomic variance. The number of hours
between venepuncture and processing for samples processed within a day only contributed
1% and 2.4% to proteomic variance in cohorts 1 and 2 respectively, suggesting that time to
blood sample processing beyond a day is the main driver of technical effects on proteomic
variance.
After accounting for the technical effects on protein variance, I also examined the
contribution of several non-technical factors (age, sex, BMI, eGFR, alcohol use and smoking)
to overall proteome variation. Age and sex contributed the most to total variance, although
these two factors only contributed less than 10% to the variation combined (Fig. 2.8 (bottom)).
BMI contributed less than 3% to the protein variance whilst renal function (eGFR), alcohol
use and smoking status each contributed less than 1.5%. Residual variances were 90% and
85% for cohorts 1 and 2 respectively, suggesting that the factors examined here did not have
large contributions to global proteome variation.
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Fig. 2.8 PVCA results of proteomic data. Contribution of each technical factor to overall protein
variation was estimated by PVCA before (top) and after (middle) adjusting for duration between
venepuncture and processing. Bottom panel shows the contribution of various biological factors to
overall variation
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Proteomic variation between cohorts
Proteomic measurements were carried out separately and independently between cohorts 1
and 2. Concentrations were relatively quantified (in RFUs) and calibrated relatively within
each cohort. In addition, due to the different calibrator and standard samples used between the
2 cohorts, RFUs between cohorts were not directly comparable. This can be seen in Fig. 2.9
(left) where there was clear separation of cohort 1 and 2 samples in PC1 using log(RFU)
readouts. Given that the two cohorts were randomly sampled from the same underlying
population and that there were no obviously differences in demographic characteristics
between cohorts (Table 2.1), there should be no systematic differences in mean levels of
majority of the proteins between the cohorts. Therefore, I mean centred and standardised each
SOMAmer separately within each cohort prior to PCA. After centering and standardisation,
there were no obvious differences between cohort 1 and cohort 2 samples within the top PCs
(Fig. 2.9 (right)).
Fig. 2.9 PCA biplot of combined cohort proteomic data (excluding SomaLogic calibrator and QC
samples and INTERVAL pooled plasma samples) mapped to the first two PCs before and after within
cohort centering and standardisation.
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2.3.3 Reproducing previous non-genetic protein associations
I tested the association of protein expression with non-genetic factors (age, sex, BMI and
eGFR) using multiple linear regression. In particular, to examine within platform biological
reproducibility in independent samples, I looked at how many of the previously reported
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associations by Ngo et al [333] and Menni et al [334], using the same SOMAmer probes,
were replicated in this study.
Of the 45 proteins previously associated with age, adjusted for sex [333, 334], 41 (91%)
associations were replicated at p< 1.1×10−3. Whilst of the 40 proteins previously associated
with sex (adjusted for age) [333], 38 were replicated (95%) at p< 1.2×10−3 (Table S1).
Also present were expected highly significant inverse associations of eGFR (a marker of renal
function) with cystatin C (p= 1.7×10−6) and beta-2-microglobulin (p= 4.2×10−6) [343],
positive associations of BMI with leptin (p= 1.1×10−441), insulin ( p= 1.3×10−25), and
inverse association of BMI with ghrelin (p= 1.7×10−17) (Table S2). When also adjusted
for BMI and eGFR, the previous association of 10 additional proteins with age, including
the renal function biomarkers like cystatin C and beta-2-microglobulin, were no longer
significant (at p< 1.1×10−3) (Table S1). This was expected as renal function has been
known to decline with age [344] and may act as a confounder not adjusted for in the two
previous studies [333, 334].
Interestingly, the insulin like growth factor binding protein (IGFBP)-6 association with
age became highly significant after adjusting for BMI and ln(eGFR) (p= 6.3×10−15) but
in the opposite direction to that reported previously [334, 345, 346] and was independently
inversely associated with eGFR (p= 6.0×10−25). Although when the association was
tested with age only, there was a positive and nominally significant effect (p= 0.018). The
associations were similar using the alternate IGFBP-6 SOMAmer probe (Table S2). IGFBP-
6 is part of the IGFBP family of proteins that reduces insulin like growth factors (IGFs)
especially IGF-II [347]. The result here is consistent with previously reported inverse
association seen with eGFR [334, 348, 349]. The previous studies that examined the effect
of age failed to adjust for eGFR. Therefore, the results here suggest that when taking renal
function (eGFR) into account, the plasma IGFBP-6 levels were independently inversely
associated with age and the positive association with age seen in previous studies may have
been confounded by the effect of renal function.
2.3.4 Genetic QC
Genetic sample QC
2,647 of 2,727 and 826 of 831 individuals passed genetic QC in cohorts 1 and 2 respectively
(Fig. 2.2). 19 individuals from cohort 1 and one from cohort 2 failed Affymetrix QC (criteria
detailed in Section 2.2.6). A total of 38 and 4 individuals from cohorts 1 and 2 respectively
failed various subsequent genetic QC criteria (Table 2.2). In addition, 23 individuals from
cohort 1 failed the ethnic outlier QC and were subsequently excluded. 2,487 individuals from
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cohort 1 and 820 from cohort 2 passed both genetic and proteomic QC. Prior to QC of the
imputed variants and subsequent genetic analyses, 6 individuals (incidentally all from cohort
1) who were related at πˆ > 0.187 were also removed (Fig. 2.2).
Table 2.2 Summary of samples failing genetic QC.
QC criteria
Number of samples failing QC
Cohort 1 Cohort 2
Contamination 19 0
Duplicate samples 10 1
Heterozygosity outliers 19 3
Missing/mismatched sex 6 0
Total (unique individuals)1 54 (38) 4 (4)
1 Some individuals had multiple samples sent for genotyping and each sample may fail multiple criteria.
Imputed variant QC
654,966 high quality genotyped variants (defined in Section 2.2.6) formed the imputation
scaffold going into imputation resulting in 87,696,888 imputed variants. After imputation
variant QC, where imputed variants were excluded based on (1) MAC< 8, (2) INFO score<
0.7, (3) HWE p< 5×10−6 and removal of duplicate variants, 12,905,770 and 10,666,876
variants remained in cohort 1 and 2 respectively with 10,572,788 variants passing QC in both
cohorts (Fig. 2.2).
Population stratification
I used MDS implemented in PLINK v1.9 [350], using a LD-pruned set of high quality
genotyped variants excluding regions of high LD (detailed in Section 2.2.6), to visualise
genetic population substructure. There was some clustering in the top dimension suggesting
a small degree of population substructure although there was no obvious clustering of
samples beyond the top dimension (Fig. 2.10a). In addition, there was no distinct separation
between the two cohorts of samples within the top 4 dimensions. Given that the samples
were from a mostly homogeneous white British population, I expected no major population
stratification. Examination of the scree plot showed the inflection point at the third dimension
(Fig. 2.10b). Overall, there was no evidence of significant population structure in the
INTERVAL proteomic data and I will use the top three MDS dimensions as covariates in
subsequent genetic analyses to account for any residual population stratification.
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Fig. 2.10 MDS analysis of INTERVAL samples using high quality genotyped variants.
(a) MDS biplot of genetic data
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2.3.5 Comparison of GWAS method and tools
Due to the large number of phenotypes that will be tested, I needed to optimise the genetic
association analysis pipeline in order to maximise speed and limit false positive findings
when accounting for imputation uncertainty. I compared three commonly used GWAS tools
(SNPTEST, QUICKTEST and RegScan) ran using methods which differ in how they deal
with imputation uncertainty to see which set-up offers the best trade-off between speed and
minimising false positives. The "dosages method" is the simplest and takes the expected
allele count (dosages) for each variant, which is then used for association testing using
logistic or linear regression models. Alternatively, imputation uncertainty can be treated as
missing information and solved using likelihood methods under a logistic or linear regression
framework. The "score test" method uses a quadratic approximation which assumes the
log-likelihood curve is quadratic around the null (β = 0) to maximise the likelihood in one
step [351]. Alternatively the likelihood can be maximised through iterative algorithms ("ML
methods"), such as the expectation–maximisation (EM) algorithm.
Speed comparison between different methods and tools
First I compared three tools using the latest supported genetic format to see which one took
the least time to run one GWAS using a null phenotype (randomly sampled from normal
distribution with mean=0 and variance=1) as specified in Section 2.2.7 using allelic dosages,
score test and ML methods (RegScan only supported the allelic dosages method).
Using the dosages method, SNPTEST (using the "bgen" format) performed the fastest
(mean=5.45 h, SD=0.02 whilst QUICKTEST (using the "gen.gz" format) performed slowest
(mean=7.07 h, SD=0.005) (Fig. 2.11). For the score method, QUICKTEST performed the
quickest (mean=7.18 h, SD=0.31) and SNPTEST performed a lot slower (mean=64.0 h,
SD=0.69). ML methods were significantly slower for both SNPTEST (mean=342.7 h,
SD=41.1) and QUICKTEST (mean=31.8 h, SD=1.85). Overall, SNPTEST using the dosages
method ran using "bgen" format genetic data offered the fastest approach. Given the im-
practicalities in terms of speed of using the ML approach, it was no longer considered in
comparisons described in the next section.
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Fig. 2.11 Comparison of time taken to run a GWAS using different set-ups, using 1 core on 1 CARDIO
cluster node for different methods and tools. Results for SNPTEST score method and ML methods
were not shown for clarity.
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Concordance of results between different methods and tools
All three tools, within practical degrees of precision (to 5 decimal places in the correlation
coefficient), gave fully concordant results for the dosages method with z-scores for all variants
lying along the diagonal, suggesting there were no single/small number of variants with
non-concordant results between the three tools (Table 2.3 and Fig. 2.12a). The score method
in QUICKTEST and SNPTEST were not fully concordant (correlation=0.9924, Table 2.3),
with QUICKTEST having increased spurious associations especially at low MAFs and INFO
scores (0.001%≤MAF < 0.5% and INFO< 0.7). Agreement significantly improved with
increased MAF and INFO score (correlation=0.99996 at MAF≥ 0.5% and INFO≥ 0.7)
although some spurious results still remained. The spurious results were likely a result
of poor imputation quality which gets worse at lower MAFs. The disagreement between
seemingly identical score test methods in SNPTEST and QUICKTEST [352] is likely to
be due to the "falling to EM algorithm" behaviour, switching to the EM ML algorithm,
implemented by SNPTEST at low p-values to reduce false positives [351].
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Table 2.3 Correlation of results obtained using different set-ups. Pearson correlation coefficients
between z-scores computed by SNPTEST, QUICKTEST and RegScan for 16.2 million variants using
allelic dosages or score test methods.
Too
l
SN
PT
ES
T (
d)
QU
ICK
TE
ST
(d)
Re
gS
can
(d)
SN
PT
ES
T (
s)
QU
ICK
TE
ST
(s)
SNPTEST (d) 1.0000
QUICKTEST (d) 1.0000 1.0000
RegScan (d) 1.0000 1.0000 1.0000
SNPTEST (s) 0.9989 0.9989 0.9989 1.0000
QUICKTEST (s) 0.9912 0.9912 0.9912 0.9924 1.0000
Note: SNPTEST used genetic data in "bgen" format, all other tools used "gen.gz" format. (d): allelic dosages;
(s): score test.
Comparing the results of the dosages to the score test method tested on a random (null)
phenotype randomly drawn from a normal distribution (mean=0, variance=1), I found that the
score test (despite SNPTEST’s "falling to EM" behaviour) resulted in excess false positives as
illustrated in Fig. 2.12b by obvious deviations from the straight line in the quantile-quantile
(Q-Q) plot. On the other hand, the allelic dosages method did not show excess false positives.
Comparison of the results obtained by the two methods showed that most of the deviations
occurred for variants with low MAFs and INFO scores (Fig. 2.12c). Reassuringly, the cut-off
of INFO≥ 0.7 and MAC≥ 8 (∼ 0.5% in the smaller cohort 2) implemented during genetic
QC did a reasonably good job of filtering out the spurious associations.
As mentioned above, the score test uses a quadratic approximation to maximise the
likelihood. The robustness of this assumption is reduced if variants have (1) low MAFs
and/or (2) large imputed genotype uncertainty or if the sample size is small leading to
spurious p-values, and this explains the results that are seen here [340, 351]. In addition, the
spurious score test result here is also similar to what has been observed previously [340].
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Fig. 2.12 Comparison of association results using different tools and methods for randomly generated
(null) data.
(a) Scatter plots of z-scores between different tools using
the allelic dosages method.
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(b) QQ plot for score test and allelic
dosages methods.
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(c) Scatter plots of z-scores between score test and allelic dosages methods at various MAF and INFO
thresholds.
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2.4 Discussion
2.4 Discussion
Assessing the quality of data prior to analyses is important to ensure reliable results are
obtained. This applies even more so in large scale genetic association studies where it can
be costly in terms of time and resources having to re-analyse data due to inadequate QC.
Therefore, in the first part of this chapter I assess the quality of the proteomic and genetic
data.
Proteomic measurements for INTERVAL samples show good technical reproducibility
with generally low CVs for most of the proteins measured and close clustering of repeat
samples in PCA. The majority of the proteins measured are relatively stable over time (of
∼ 2 years) consistent with previous evidence [69]. The duration between venepuncture and
sample processing had an reasonable effect on overall proteomic variation. This may be due
to the fact that some proteins may degrade over time whilst certain intracellular proteins may
be released as cells undergo stress ex vivo. The extent to which pre-analytical processing
affects plasma protein levels likely differs between different proteins with some proteins
being inherently more stable than others. Plasma protein levels are largely dynamic, high
frequency serial measurements can be made to investigate protein variation and stability
post-venepuncture. However this may be limited by the infeasibility of repeatedly taking
blood samples from the same person at short intervals.
The INTERVAL samples are mostly homogeneous with no obvious clustering or no-
ticeable outliers. After centering and standardisation, there were no obvious differences
along the main axes of protein variation between cohorts 1 and 2. The majority (>90%) of
previous associations in independent studies with age and sex using the same assay probes
were replicated, providing evidence of robust reproducibility of the assay between studies as
well as within studies. In addition, I find associations with baseline characteristics which
have been robustly seen in previous studies, suggesting that the assay can capture biologically
meaningful outputs. Furthermore, I show using IGFBP-6 as an example, that the association
seen in previous studies may be biased due to unmeasured/unadjusted confounders and can
lead to associations in opposite directions; this area warrants further detailed investigation
across the other proteins which is beyond the focus of this thesis.
Genetic measurements do not show any systematic differences between cohorts 1 and
2. The samples within cohorts are mostly homogeneous beyond the first MDS dimension
and the component plot suggests no significant population structure. This is expected as the
INTERVAL samples are mostly white British individuals from across the UK and they should
be mostly ethnically homogeneous. The combined UK10K and 1000 Genomes reference
panels offer dense genome coverage with improved imputation accuracy especially at lower
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allele frequencies (MAF< 0.5%) [52]. As a result, after variant level QC even at a stringent
INFO score cut-off of 0.7, ∼ 10.6 million variants remain for association testing.
Overall for the QC results, the INTERVAL samples are highly homogeneous with no clear
systematic differences between cohorts 1 and 2. The proteomic assay is highly reproducible
within and between studies as well as being able to capture biologically meaningful signals.
After detailed QC steps, a total of 3,301 samples, 3,283 SOMAmers (encompassing 2,994
proteins/protein complexes) and 10,572,788 genetic variants are retained for genetic analyses
in the subsequent chapters.
Given the scale of the proteomic and genetic data, it is important to optimise the analytical
pipeline prior to embarking on analyses to ensure efficiency in terms of time taken, generation
of manageable file outputs and robustness of the method used to account for imputation
uncertainty especially with respect to limiting false positives. Therefore, in the second part
of this chapter, I compare various widely used approaches and I find that using SNPTEST
running on the newer "bgen" format with the allelic dosages method offers the most optimal
approach in this context. However, at the time of analysis other tools have yet to support
"bgen" formats without converting imputation probabilities into "best-guess" genotypes
(often based on an arbitrary posterior genotype probability threshold (e.g. 0.9)), so I could
not directly compare the performance of the other tools using the "bgen" format, although I
anticipate this to be addressed in newer releases of the these tools. When looking at different
methods, I find that the relative simple approach of analysing allelic dosages perform
better than the more sophisticated score method in terms of controlling false positives.
Although the genetic QC implemented removes many of the false positive findings, this
may not be readily applicable in other phenotypes where they are not from the null. Whilst
newer mixture ML implementations provide better protection against false positives whilst
offering equal or greater power than the dosages approach, this comes at a cost of relatively
higher computational cost [340]. I did not consider using "best-guess" genotypes despite its
computationally efficiency (implemented in PLINK v1.9 [338]), because it offers less power
and higher false positive rates [48, 340]. Overall, the allelic dosage method by far provides
the most optimal approach for analysing the data in the context of this thesis, with much
lower computational cost, superior control of false positives and little sacrifice in power
compared to more sophisticated approaches.
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Chapter 3
Identifying genetic determinants of the
human plasma proteome
3.1 Introduction
The basis for GWAS and their application in pQTL mapping have been discussed in de-
tail in Chapter 1. I highlighted the rationale for looking at the proteome as opposed to
the transcriptome or the metabolome - proteins are the functional units in biological and
pathophysiological processes. Furthermore, most drugs target proteins and identifying causal
associations between proteins and disease risks can inform understanding of disease mech-
anisms and therapeutic targeting. pQTLs can be used to infer causal associations between
proteins and disease through the principles of MR. I discussed previous evidence that proteins
levels are heritable and several genetic associations with protein levels have been discovered
(Section 1.4.5) using mostly affinity-based and sometimes MS approaches. Due to the com-
plexity of the human plasma and technological limitations, studies so far have been limited
in terms of proteome coverage (typically fewer than 100 proteins assayed) or sample size
(typically fewer than 1,000) and hence many of the genetic associations are potentially left
undiscovered.
In this thesis, an expanded aptamer-based multiplex protein assay (see Sections 1.4.3
and 2.2.3 for details) was used to quantify levels of 3,620 unique plasma proteins (approxi-
mately three-fold increase in proteins measured compared to previous aptamer-based studies)
in 3,562 healthy blood donors. After QC in Chapter 2, this chapter looks at the genetic
association between 3,283 SOMAmers (2,994 unique proteins/protein complexed) and 10.6
million imputed variants in 3,301 unrelated European-ancestry individuals. In addition I
perform conditional analysis to identify additional independent associations. Lastly in this
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chapter, I systematically compare findings from this study with previous pQTL studies of
human soluble proteins to see how many of previous associations were replicate and which
associations are novel.
3.2 Methods
3.2.1 GWAS
For each cohort, relative protein abundances (RFUs) were first natural log-transformed
similar to previous studies [95, 250, 251] and then adjusted for age, sex, duration between
venepuncture and processing (binary, within 1 day/> 1 day) and the top three MDS genetic
components. The residuals were then rank-inverse normal transformed (mean= 0 and
variance= 1) prior to association testing similar to previous pQTL mapping approaches
[94–96, 250]. Univariate linear regression assuming additive genetic effects was used to
test genetic association of each SOMAmer separately on each of the 10.6 million post-QC
variants using allelic dosages to account for imputation uncertainty. Association tests for
each SOMAmer were performed for each cohort and for each chromosome separately using
SNPTEST v2.5.2 [339] with GWAS for each protein processed in parallel as a single job
taking up one core on a single node on the in-house CARDIO cluster or Cambridge High
Performance Computing Darwin clusters (http://www.hpc.cam.ac.uk/services/darwin).
3.2.2 Meta-analysis
Association summary results from the two cohorts were combined via fixed-effects inverse-
variance meta-analysis combining the betas and standard errors using METAL [353]. To
account for multiple testing, a conservative Bonferroni-adjusted p-value of 1.5×10−11
(5×10−8/3,283 SOMAmers) in the meta-analysis was used to define genome-wide signifi-
cance. To reduce the possibility of non-random biases within cohorts affecting reproducibility
of results, associations with discordant directions of effect between the two cohorts and those
with a p-value> 0.05 in either cohort were excluded.
Genomic inflation factor (λ ) for each SOMAmer was calculated as the ratio of the median
of the empirically observed distribution of the test statistic to the expected median based on
the χ2 distribution.
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3.2.3 Refinement of significant regions
To identify distinct non-overlapping regions (loci) associated with each SOMAmer, (1) a
1Mb region around each significant variant was defined for each SOMAmer. (2) Starting
with the region containing the variant with the lowest p-value, any overlapping regions gets
merged and this is repeated until no more regions are merged. (2) is repeated with the next
ungrouped region containing the variant with the lowest p-value until no more regions are
merged. The variant with the lowest p-value for each region is assigned as the "(regional)
sentinel variant". Due to the complexity of the major histocompatibility complex (MHC)
region, the extended MHC region (chr6:25.5-34.0Mb) was treated as one region.
To identify whether a locus is associated with multiple SOMAmers, a LD-based clumping
approach was used. Regional sentinel variants that are in high LD (r2 ≥ 0.8) with any other
sentinel variants were combined together into one region. Sentinel variants within the
extended MHC region were treated as one region.
Cis pQTLs were defined as variants lying within 1Mb of the gene(s) encoding the protein
whilst trans pQTLs were variants lying outside this region.
3.2.4 Conditional analysis to identify additional independent signals
To identify conditionally significant signals, conditional analyses were performed for each
SOMAmer using an approximate genome-wide stepwise method implemented in Genome-
wide Complex Trait Analysis (GCTA) with summary data [354] and also using an "exact"
method where stepwise regression was performed using individual level data.
GCTA
Approximate genome-wide stepwise conditional analysis was performed using GCTA v1.25.2
[354] using the "cojo-slct" option for computational efficiency. The same conservative p-
value threshold cut-off of 1.5×10−11 was used. GCTA performs stepwise variant selection
using both a iterative forward and backward selection procedure as follows:
1. Start with the most significant variant in the meta-analysis across the whole genome
with p< 1.5×10−11.
2. Calculate the p-values of all the remaining variants conditional on the variant(s) that
have already been selected in the model. To avoid problems arising from colinearity, if
a variant has a r2 > 0.9 with any of the selected variants, the p-value for that variant is
set to 1.
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3. The variant with the minimum p-value< 1.5×10−11 is selected.
4. Fit all selected variants jointly in a model and the variant with the largest p-value>
1.5×10−11 is dropped.
5. Repeat steps (2)-(4) until no variants are added or removed from the model.
As inputs for GCTA, summary statistics (i.e. betas and standard errors) from the meta-
analysis were used. Correlations between variants were estimated using the cohort-merged
best-guess genotypes (where genotypes were called if they had a posterior probability> 0.9)
and only variants that have passed the univariate significance thresholds (p< 1.5×10−11)
and criteria defined for the meta-analysis were considered for step-wise selection.
As the conditional analyses use different data inputs (summarised rather than individual-
level data), there were some cases (n=28) where the conditional analysis failed to include
sentinel variants that had borderline significant univariate associations in the step-wise
selection. In these instances, the joint model estimation was rerun without step-wise selection
in GCTA with variants identified by the conditional analysis in addition to the regional
sentinel variant. These cases are reported and highlighted in Table S5.
The variants selected by GCTA were fitted as covariates in a multiple linear regression
model adjusting for cohort and the effect sizes were compared to those obtained from GCTA.
Exact method
Stepwise regression was performed using individual level data adjusting for cohort and
considering the same set of variants that passed univariate GWAS thresholds. The iterative
process is similar to the GCTA procedure described above:
1. Start with the most significant variant for each chromosome across the whole genome
with p< 1.5×10−11.
2. Calculate the p-values of all the remaining variants conditional on the variant(s) that
have already been selected in the model using SNPTEST and variant dosages.
3. The variant with the minimum p-value< 1.5×10−11 is selected.
4. Fit all selected variants jointly in a model and if for any variant in the joint model has
a p-value> 1.5×10−11, the new variant is dropped from the conditional analysis.
5. Repeat steps (2)-(4) until no more variants are added to the model.
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3.2.5 Replication of previous pQTLs
To demonstrate the validity of the approach and the data generated, we attempted to identify
all previously reported pQTLs from GWAS and to assess whether they replicated in this
study and identify which of the associations identified here were novel. The NCBI Entrez
programming utility in R (rentrez) was used to perform a literature search for pQTL studies.
The following terms; "pQTL", "pQTLs", and "protein quantitative trait locus" were included
in the search. The search was supplemented by filtering out GWAS associations from the
NHGRI-EBI GWAS Catalog v.1.0.181 (https://www.ebi.ac.uk/gwas/, correct as of April
2016), which has all phenotypes mapped to the Experimental Factor Ontology (EFO) [355],
by restricting to those with EFO annotations relevant to protein biomarkers (e.g. "protein
measurement": EFO_0004747).
Studies identified through both approaches were manually filtered to exclude those not
assessing proteins. Studies were filtered to include only associations reported in European-
ancestry populations. In addition, studies not performed in plasma or serum (e.g. LCLs
and cerebrospinal fluid) were also excluded. Summary data (rsID, protein UniProt ID and
p-values) were then manually extracted for all reported associations from the manuscript or
the supplementary material and the results were curated to update the UniProt IDs, convert
variant genomic locations to build GRCh37 and exclude associations without UniProt IDs
or p-values. The results were then cross-referenced with the pQTL data from this study
matching on UniProt IDs and variant position. Where a variant was not present in the post-QC
imputed data, I looked for the strongest proxy (r2 > 0.6) that was imputed in the INTERVAL
data using PhenoScanner [356]. I defined loci associated with each protein across studies as
described in Section 3.2.3 to determine an approximate number of independent loci for each
protein.
To assess replication, first the set of unique UniProt IDs that were also assayed on the
SOMAscan panel were identified. For previous studies that used the SomaLogic platform, I
refined this match to the specific aptamer used. To avoid confounding due to differences in
p-value thresholds and platforms across studies, a filter of p < 5×10−8 across all studies
was applied before comparing across platforms. I then clumped associations into distinct
loci using the same method applied for the pQTLs in this study (see Section 3.2.3 above).
For each locus, the sentinel variant or the strongest proxy (r2 > 0.6) was cross-referenced to
see if it is associated with the same protein/aptamer in this study at a defined significance
threshold. For the primary assessment, a p-value threshold of 10−4 was used in addition to
p-value thresholds (0.05, 1×10−6, 5×10−8, 1.5×10−11).
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Enrichment for replicated trans associations in chromosomes and the ABO locus (chr9:
136,125,788-137,150,617) was determined by Fisher’s exact test using the sentinel, variants
with different replication p-value thresholds used as sensitivity analyses.
3.2.6 Replication of a subset of genetic associations using alternate as-
say platforms
The reproducibility of the sentinel pQTL variants for a subset of proteins was assessed using
two alternate assay platforms ("Olink" and "Myriad Rules-Based Medicine (RBM)") in a
random subset of ∼ 140 individuals (number of individuals with non-missing measurements
varies slightly for different proteins). Plasma samples were sent to the assay manufacturers
for measurement. The Olink platform (Olink Bioscience, Uppsala, Sweden) uses a PEA-
based affinity assay (see Section 1.4.3 for description of the method) to quantify protein
levels in relative protein abundances, similar to the SomaLogic platform. Three of the Olink
panels of 92 proteins were measured, providing 204 unique proteins when combined. The
Myriad RBM platform (Austin, Texas, USA) is a multiplex proteomics platform that uses
the Luminex™immunoassay technology - a multiplexed immunoassay using the microbead
suspension setup (Section 1.4.3). All 384 proteins available on the DiscoveryMap platform
were assayed, which quantifies protein levels in absolute abundances. For both assays,
proteins that had < 10% missingness were analysed .
The sentinel pQTLs were tested for associations with the corresponding proteins on each
of the two assay platforms (73 overlapping proteins in Olink, 90 in RBM) using the same
approach as described for the SomaLogic platform above (Section 3.2.1).
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3.3 Results
3.3.1 Discovery of genetic determinants of plasma protein levels
After stringent QC of proteomic and genetic data, I performed GWAS comprising 10.6 million
autosomal variants for 3,283 SOMAmers (encompassing 2,994 unique proteins/protein
complexes) in a total of 3,301 unrelated European-ancestry individuals. Analyses were
performed separately in the two measurement cohorts and the results were combined using
inverse variance weighted fixed-effect meta-analysis. Statistical significance of associations
was defined using conservative thresholds as detailed in Section 3.2. I did not adjust the
association results for genomic inflation as the mean inflation factor (λ ) was 1.00 with
standard deviation of 0.01 (Fig. 3.1).
Fig. 3.1 Distribution of inflation factors across proteins that underwent GWAS stratified by cohort and
allele frequency (MAF≥ 5%, MAF< 5%).
Cohort 1 Cohort 2 Combined cohort
0
.9
5
0
0
.9
7
5
1
.0
0
0
1
.0
2
5
1
.0
5
0
0
.9
5
0
0
.9
7
5
1
.0
0
0
1
.0
2
5
1
.0
5
0
0
.9
5
0
0
.9
7
5
1
.0
0
0
1
.0
2
5
1
.0
5
0
0
20
40
60
Inflation factor (λ)
F
re
q
u
e
n
c
y
3.7M variants with MAF<5%
6.9M variants with MAF>5%
All 10.6M variants
In total, 1,927 pQTLs (locus-protein associations) were identified (Fig. 3.2a, Supplemen-
tary File 1, Table S3). 554 of the pQTLs were cis (i.e. the sentinel variant within 1Mb of
the protein-coding gene) and 1,373 were trans (i.e. the sentinel variant >1Mb away from
the protein-coding gene), of which, 1,298 pQTLs were on located on a different chromo-
some to the gene(s) encoding the protein. I found significant associations for 1,478 of the
2,994 proteins (1,561 of 3,283 SOMAmers tested) at 764 genomic regions. I used distance
based clumping (overlapping 1Mb intervals) to define a locus and then used genome-wide
conditional analysis to search for independent associations that may be contained within a
particular region. Of the 764 genomic regions with significant associations, 502 (66%) had
cis associations only, 228 (30%) had trans associations only and 34 (4%) had both cis and
trans associations. The majority of proteins with significant associations (n=1,299; 87.9%)
had either a cis (n=374) or trans (n=925) locus associated while 179 (12.1%) had both cis
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and trans associations. Most of the proteins with pQTLs (n=1,113; 75%) had a single pQTL,
297 (20%) had two and 68 (5%) had three or more loci (Fig. 3.2b). I also compared the
effect sizes between the two measurement cohorts for all significantly associated variants
(Fig. 3.2c). The effects sizes were largely consistent between the cohorts (Pearson’s correla-
tion coefficient 0.987 for the sentinel variants) and there were no systematic differences in
effect sizes between cohorts.
Fig. 3.2 Summary of the pQTL results. (a) Plot of sentinel variants for cis pQTLs (red circles) and
trans pQTLs (blue circles) across the genome. X-axis represents position of genomic locus associated
with the protein. Y-axis represents the position of the gene that encodes the associated protein. The
twelve most associated regions of the genome are annotated above the plot. (b) Histogram of the
number of significantly associated loci per protein. (c) Comparison of association effect sizes between
the two measurement cohorts for all significant associated (p < 1.5×10−11) variants (red) with the
sentinel variants highlighted (blue).
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3.3 Results
Further to the highly conservative significance threshold used to define pQTLs, I also
looked at the number of additional loci detected at the nominal genome-wide significance
threshold of p < 5×10−8 (Table S4). An total of 1,428 additional pQTLs were discovered
at p < 5×10−8, with 1,339 (94%) trans and 89 (6%) cis. I found additional associations
for 1,104 proteins, half of which were proteins without an association at p < 1.5×10−11.
Given that there may be a higher prior on local gene regulation (such as enhancers and
repressors which tend to bind in regions near the gene), one might be more inclined to
believe a marginal association in cis to the gene encoding the protein compared to the rest
of the genome. Therefore, I also looked for additional cis associations at a more liberal
p-value threshold (p < 1×10−6) (Table S4). Additional cis associations for 45 proteins were
identified further to those found at p < 5×10−8.
Conditional analysis to identify secondary association signals
I conducted conditional analysis to identify additional independent associations in any
particular locus. First I performed an approximate stepwise conditional analysis separately
for each analyte implemented in GCTA [354] using summary data due to its computational
speed. The variants selected were then fitted in a joint model using multiple regression with
individual level data and the effect sizes obtained were compared to those obtained from
GCTA (Fig. 3.3a). The effect sizes were largely concordant between the two approaches
(Pearson’s correlation coefficient 0.976) although there was a small number of discrepancies.
Some of the largest discrepancies observed are highlighted in Fig. 3.3a. For example, effect
sizes for a number of variants selected during stepwise selection in GCTA for USP25, C4
and LILRB1 proteins were closer to the null when fitted jointly in the multiple regression
model. Interestingly, the implicated loci resided in the MHC region (USP25, C4) or the
killer cell immunoglobulin-like receptors (KIR) region (LILRB1), both of which are highly
polymorphic regions with complex LD structure [357].
From the "exact" conditional analysis, I identified 2,487 conditionally significant as-
sociations (Table S5). Of the 1,927 locus-protein associations, 363 (15%) had multiple
conditionally significant signals (Fig. 3.3b), of which 234 were from cis pQTLs. For ex-
ample, there were two conditionally significant variants in the cis locus associated with
levels of fibroblast growth factor 7 (FGF7). After conditioning on the top variant, rs7162172
(conditional p = 9.4×10−14, univariate p = 6.8×10−13), I found that rs12899680 (r2 = 0
with rs7162172), lying more proximally downstream to the FGF7 gene, was still signifi-
cantly associated (conditional p = 2.4×10−13, univariate p = 1.7×10−12) with plasma
levels of FGF7 (Fig. 3.4a). No additional significant signals were found after condi-
tioning on both rs7162172 and rs12899680. In the case of the FGF7 association, the
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Fig. 3.3 Conditional analysis results. (a) Comparison between effect sizes obtained from joint model
through GCTA using summary data and effect sizes obtained from multiple regression using individual
level data. Effect sizes for a selection of proteins where there is high discrepancy are highlighted.
(b) Histogram of the number of conditionally significant associations within each associated locus
obtained from stepwise regression using individual level data ("exact method").
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two independent signals may be visually discerned as the peaks lie slightly apart from
each other (Fig. 3.4a (top)), although this may not be obvious in other cases. For in-
stance, there were three independent associations in the cis locus associated with plasma
haematopoietic prostaglandin D synthase (HPGDS) levels which all lie underneath the same
peak (Fig. 3.4b). The top two conditionally significant variants, rs1965049 (conditional
p = 1.5×10−29, univariate p = 1.3×10−71) and rs72665697 (r2 = 0.05 with rs1965049,
conditional p = 9.1×10−40, univariate p = 3.2×10−60) lie within 5kb upstream of the
HPGDS gene, whilst the third, rs28660345 (r2 = 0.12 with rs1965049, r2 = 0.01 with
rs72665697, conditional p = 4.8×10−15, univariate p = 7.8×10−39), is located ∼ 100kb
downstream of HPGDS. After conditioning on all three variants, there were no additional
associations in the locus. Overall, the conditional analysis results indicate that there may be
multiple independent regulation mechanisms within the same locus driving plasma protein
levels.
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Fig. 3.4 Regional associations plots of (a) FGF7 and (b) HPGDS loci at each stage of conditional
analysis.
Whilst conditional analysis can be used to identify independent associations within the
same association peak, it can also be used to assess whether two or more seemingly distant
signals are independent. The significance of the sentinel variants for two loci, rs574174001
for cystatin F (CYTF) and rs541781976 for prostate secretory protein 94 (PSP-94) which
lie 4.7Mb downstream and 5.4Mb upstream of their sentinel cis variants respectively, were
heavily attenuated after conditioning on the cis variants (pCY T F = 0.0067, pPSP−94 = 0.91)
(Table S5). For both cases, the associated regions lie close to the centromeres in gene dense
regions. In the case of CYTF, the "trans" variant lies in high LD with significant variants
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in the cis locus across the other side of the centromere as shown in Fig. 3.5a. For PSP-94,
the "trans" variant lies on the same side of the centromere in low R2 (0.07) (Fig. 3.5b) but
moderate D’ (0.57) LD with the sentinel cis variant. For these two cases, I did not consider
the two loci as trans (Table S3).
Fig. 3.5 Regional association plots of the (a) CYTF and (b) PSP-94 loci with rs574174001 and
rs541781976 as the sentinel variants respectively. Highlighted inside the blue boxes are the genes
encoding the respective proteins.
(a) CTYF
(b) PSP-94
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3.3.2 Replication of published pQTLs
The NHGRI-EBI GWAS Catalog was used, filtering on EFO terms related to protein mea-
surements in addition to a literature search of pQTL studies followed by manual curation,
to obtain a list of previously published pQTLs (see Section 3.2.5 for details). In total, 119
published studies of soluble protein levels (plasma/serum) that employed a range of protein
assays (mostly affinity-based with a small number of MS-based assays) were identified, of
which 57 studies examined proteins that overlap with those measured in this study (Table S6).
In total, 1,723 (89%) of the 1,927 pQTLs identified are reported here for the first time
(Table S3). Previous studies identified pQTLs for a total of 367 proteins of which 269 were
analysed in this study (Table S7). Of a total of 389 associations, 234 (60%) of the associations
were replicated at p < 1×10−4 (0.05/389 loci previously tested) (Table S8). 80% (187)
of the pQTLs that replicated at p < 1×10−4 also reached the genome-wide significance
threshold for this study (p < 1.5×10−11). However, when stratified by cis (175 associations)
and trans (214 associations), I found that cis associations had much higher proportions
replicating compared to trans. For the 175 cis associations, 153 (87%) were replicated at
p < 1×10−4 whilst for the 214 trans associations, 81 (38%) were replicated. Although,
several well established trans associations were also replicated, for example: ABO with
E-selectin (p = 3.1×10−338), P-selectin (p = 5.4×10−36) and ICAM-1 (p = 1.3×10−13)
[165, 166, 190, 191], ZFPM2 with vascular endothelial growth factor A (p = 2.1×10−29)
[242, 243], TMPRSS6 with transferrin receptor protein 1 (p = 1.9×10−16) [358] and SORT1
with granulins (p = 7.8×10−211) [359]. The trans associations that replicated (at p <
1×10−4) were enriched for associations in chromosome 9 (p = 4.1×10−5, p > 0.1 for
all other chromosomes) which consisted mostly of associations (29 of 32) in the ABO
locus. I found that the ABO locus was enriched for trans associations that replicated (at
replication p = 1×10−4 threshold: p = 6.1×10−5) and the enrichment was robust to
sensitivity analyses using alternate p-value thresholds (at p < 5×10−8 threshold: p =
5.8×10−6; at p < 1.5×10−11: p = 2.7×10−5).
I also found that the replication rate depended on the platform used to measure protein
levels. 90% of the associations reported in previous GWAS that used an earlier smaller
version of the SOMAscan platform were successfully replicated (203 of 225 associations
replicated at p < 1×10−4). In contrast, I was only able to replicate associations for 28% of
pQTLs (70% for cis associations, 13% for trans) identified in studies that used other assay
platforms.
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3.3.3 Replication of a subset of genetic associations using alternative
assay platforms
To assess the extent to which the findings here are reproducible across different protein assay
methods, proteins were also assayed using two alternative platforms ("Olink" and "RBM")
in a subset ∼ 140 of the SOMAscan samples. For the Olink panel, I was able to compare
the results for 102 pQTLs. Despite the small sample size, 40 pQTLs replicated at nominal
statistical significance (p < 0.05) with the same direction of effect. The effect estimates for
the Olink analyses were strongly correlated with the SomaLogic effect estimates, whether
for all pQTLs tested (r=0.69) or only those with p < 0.05 (r=0.88, Fig. 3.6a). Similar results
were seen for the RBM panel, where I was able to test 130 pQTLs, of which 55 replicated
at nominal statistical significance. Again, very strong correlations were seen between the
effect estimates from the RBM platform and the SomaLogic results whether overall (r=0.66)
or only those with p < 0.05 (r=0.75, Fig. 3.6b). For 62 associations where I had more than
80% power to detect an association at p = 0.05 in the 140 samples, 43 replicated at nominal
significance in at least one of the alternate platforms.
Fig. 3.6 Scatterplot of pQTL effect size estimates from SOMAscan versus alternate assays. (a) Olink
(b) RBM assays (with p < 0.05 in alternate assays). r = Pearson’s correlation coefficient.
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3.4 Discussion
Genetic studies in yeast, cell lines and soluble proteins in humans have shown that protein
levels are under strong genetic control. I conducted a large scale GWAS of the human plasma
proteome spanning ∼ 3000 proteins in ∼ 3,300 samples across more than 10 million genetic
variants. The results show that common genetic variants influence plasma protein levels in
largely healthy individuals - I find associations for around half of the proteins tested. The
largely healthy cohort minimises the chance of diseases and co-morbidity influencing plasma
protein levels. The large sample size and number of proteins measured allowed the expansion
on the catalogue of existing pQTLs by more than 3 fold. Using a less stringent nominal
genome-wide significance threshold revealed a large number of sub-threshold associations
which may be discovered in larger studies.
Through conditional analysis, I find additional independent associations for around 15%
of the associations. Since I decided to use the same threshold as the univariate analysis (p <
1.5×10−11) for the conditional analyses, I may have missed some additional independent
signals. Whilst GCTA estimates are largely concordant with those from an exact multiple
regression model, discrepancies occasionally occur. This may be likely due to regions with
complex LD structure such the MHC and KIR regions since GCTA uses the LD information,
which in this case, is calculated from hard-call genotype estimates rather than the dosages.
I also highlight one previously overlooked issue when defining loci using distance based
approaches. As exemplified using CYTF and PSP-94 genetic associations, caution needs
to be taken in defining associated regions/loci when the association lies across or near
centromeric regions which tend to have extended LD [27], and where the physical distance
between non-independent associated variants may be exaggerated. Since the vast majority of
associations do not lie near centromeric regions, this problem is often ignored. Many studies
perform conditional analysis within the locus, therefore these may fail to identify that two
apparently independent loci separated by a large distance (e.g. > 1Mb) may not in fact be
independent. Care should also be taken when defining loci for associations in complex or
long LD regions.
I was able to replicate 60% of previously published associations, although, most (87%) of
the cis associations replicated whilst only 38% of the trans associations replicated. However,
trans associations with the ABO locus were enriched for replicated associations possibly
reflecting its large effects on plasma protein levels. The high proportion of the cis associations
that replicated emphasises the robustness of these associations. Lower replication of the
trans associations could be due to the fact that there is a higher chance of any particular
region across the genome exhibiting study specific associations due to study specific factors
such as differences in sample preparation/processing or participant characteristics. However,
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such differences need to exhibit genotype dependent effects (e.g. the effect of difference in
sample processing on a protein’s level is different dependent on the genotype of a variant)
- further investigations with more detailed sample processing factors measured are needed
to assess if this occurs. Another reason that may contribute to lower replication of previous
trans associations could be that many of the previous pQTL studies have been limited in
sample size and have only examined cis associations due to limitations in power. Therefore,
the studies that do test for trans associations tend to be much larger in sample size (103 of the
214 trans pQTL associations were identified in samples greater than 5,000 compared to 15 of
175 cis associations) and this study may be underpowered to replicate those associations. For
example, the cis and the top 3 of the 16 most significant trans associations with CRP levels
found in a previous large scale meta-analysis (n>66,000) [154] were replicated in this study
at p < 1×10−4 (top 5 most significant trans associations replicated at p < 0.05). Of the
remaining 11 trans variants which explained 0.04% to 0.14% of the variance in CRP levels,
I had between 21% to 58% power (although this is likely over-estimated due to "winner’s
curse") to detect an association at nominal significance thresholds, suggesting that many
of the remaining trans associations that were not replicated were likely due to insufficient
power in this study.
The high replication rate (> 90%) of previous pQTLs using the same assay in independent
studies suggest highly reproducible results of the assay platform. The lower replication of
pQTLs, especially for trans association, in studies that used different assay platforms,
suggests there is greater variability of protein measurements between assays which is not
surprising. Inter-platform measurements are more likely to vary compared to measurements
using the same platform due to various technical differences such as sample pre-processing
and assay technologies used (e.g. different capture/detection reagents used). For example,
different assay technologies likely have capture reagents targeted at different epitopes of
the target protein where the epitope for one of the assay reagent may be more readily
available in plasma than the other. The consistency of genetic associations with overlapping
(albeit a subset of) proteins using different assay platforms, suggests that assay platform
variations only partially affect the replication of genetic effects on protein levels, whilst
factors discussed above, in addition to possible differences in sample characteristics and
processing between studies, may also contribute. Currently, there is no single gold standard
method of protein quantification for all proteins apart from clinical-grade immuno-assays
for a very limited handful of proteins (such as CRP). Lastly, the majority of the proteins
measured are low-abundance where there is large variation in quantification which may also
reduce the power for replication.
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The replication of pQTLs across studies found here is comparable to replication of eQTLs
across different studies in the same tissues. Previous eQTL studies have shown that around
two thirds to > 80% of cis eQTLs replicated across independent studies by different groups
[63, 360–362] whilst the proportion of trans eQTLs replicated was much lower and less
robust [360, 361]. It is also interesting to note that there is greater variation in gene expression
quantification between RNA sequencing and microarray technologies [363], analogous to
the variation seen in protein quantification using different proteomic assays.
This chapter presents the vast haul of findings of the pQTL mapping. The subsequent
chapters will focus on characterising the pQTLs in more detail and demonstrate examples
of how the data can be used to highlight biology and disease pathways and inform causal
relationships between protein levels and disease risk.
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Chapter 4
Characterisation of pQTLs
4.1 Introduction
The scale of protein coverage along with the breadth of pQTLs findings allow characterisation
of the genetic architecture of pQTLs previously not possible in small scale studies. Following
on from the discovery findings in the previous chapter, I interrogate the pQTLs discovered in
more detail in this chapter.
First I examine the effect of protein altering variants (PAVs), which could potentially alter
the binding affinity of the reagents to the target, on the cis pQTLs. Although this problem has
been well-described in microarray-based eQTL studies in the form of polymorphism-in-probe
effects [364], it has been overlooked in most pQTL studies to date despite their predominant
focus on only the cis regions. I then proceed to characterising the cis and trans pQTLs in
more detail. I also examine whether the pQTLs are enriched for any functional elements and
the distribution of cis associated variants relative to the gene encoding the protein drawing on
the parallels with eQTL studies. Lastly I overlay pQTLs with published eQTL data and test
to see if cis pQTLs are enriched for eQTLs for their corresponding protein-encoding gene.
4.2 Methods
4.2.1 Candidate gene annotation
Cis pQTLs
Cis pQTLs were defined as variants lying within 1Mb of the gene(s) encoding the proteins
whilst trans pQTLs were variants lying outside this region. When assessing the distance
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of the top cis associated variants to transcription start site (TSS), only analytes that map to
single genes on the primary assembly in Ensembl v83 were considered.
Trans pQTLs
For trans pQTLs, I sought to prioritise candidate genes in the region that might underpin the
genotype-protein association. In addition to reporting the nearest gene to the sentinel variant,
we employed "bottom up" and "top down" approaches, starting from the variant and protein
respectively. The protocol is summarised in Fig. 4.1.
For the "bottom up" approach, the sentinel variant and corresponding proxies (r2 >
0.8) for each trans pQTL were first annotated using Ensembl VEP v83 [324] (using the
"pick" option) to determine whether variants were (1) protein-altering coding variants; (2)
synonymous coding or 5’/3’UTR; (3) intronic or up/downstream; or (4) intergenic. Second,
all sentinel variants and proxies were queried against significant cis eQTL variants (defined
by beta distribution-adjusted empirical p-values using a FDR threshold of 0.05, see http:
//www.gtexportal.org/home/documentationPage for details) in any cell type or tissue from the
GTEx project v6 [365] (http://www.gtexportal.org/home/datasets). Third, promoter capture
Hi-C data in 17 human primary haematopoietic cell types [366] were queried to identify
contacts (with a CHICAGO score > 5 in at least one cell type) involving chromosomal
regions containing a sentinel variant. Gene promoters annotated on either fragment (i.e.
the fragment containing the sentinel variant or the other corresponding fragment) were
considered as potential candidate genes. Using these three sources of information, a list of
candidate genes for the trans pQTLs was generated. A gene was considered a candidate if it
fulfilled at least one of the following criteria: (1) was proximal (intragenic or ±5kb of the
gene) or nearest to the lead variant; (2) contained a non-synonymous proxy (r2 > 0.8); (3)
it had a significant cis eQTL in at least one GTEx tissue overlapping with a sentinel pQTL
variant (or proxy); or (4) it was regulated by a promoter annotated on either fragment of a
chromosomal contact involving a sentinel variant.
For the "top down" approach, all genes with a TSS located within the corresponding
pQTL locus were identified using the GenomicRanges Bioconductor package [367] (http:
//bioconductor.org/packages/release/bioc/html/GenomicRanges.html) with annotation from
the GRCh37 GTF file from Ensembl (ftp://ftp.ensembl.org/pub/grch37/update/gtf/homo_
sapiens/Homo_sapiens.GRCh37.82.gtf.gz [downloaded 06/2016]). Any local genes that had
previously been associated in some way with their corresponding trans-affected protein(s)
were then identified according to the following open source databases: (1) the Online
Mendelian Inheritance in Man (OMIM) catalogue [368]; (2) Kyoto Encyclopedia of Genes
and Genomes (KEGG) [369]; and (3) STRING v10.0 [370]. OMIM data were accessed via
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Fig. 4.1 Candidate gene annotation protocol for trans pQTLs, outlining the combined “bottom-up”
and “top-down” process utilised for candidate gene annotation of trans-pQTL regions
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the HumanMine web tool [371] (http://www.humanmine.org/), whereby all OMIM IDs were
extracted for (i) the trans-affected proteins and (ii) genes local (±500Kb) to the corresponding
trans-acting variant. For KEGG, all human KEGG pathway IDs were extracted using the
KEGGREST Bioconductor package [372] (http://bioconductor.org/packages/release/bioc/
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html/KEGGREST.html). In cases where a trans-affected protein shared either an OMIM ID
or a KEGG pathway ID with a gene local to the corresponding trans-acting variant, these
were taken as evidence of a potential functional involvement of that gene. STRING data
were accessed using the STRING Bioconductor package [373] (http://www.bioconductor.
org/packages/release/bioc/html/STRINGdb.html) whereby all pairwise interaction scores for
each trans-affected protein and all genes local to their corresponding trans-acting variants
were extracted. The default interaction score of 400 was taken as evidence of a functional
relationship between a trans-affected protein and a gene local to the corresponding trans-
acting variant, therefore indicating a possible functional involvement for that local gene.
In addition to using data from open source databases in the top-down approach a guilt-by-
association (GbA) approach utilising the same plasma proteomic data used to identify the
pQTLs was also adopted. A matrix containing all possible pairwise Pearson’s correlation
coefficients between the 3,283 SOMAmers was first generated. The coefficients relating to
the trans-affected analyte and any proteins encoded by genes local to their corresponding
trans-acting variants where available were then extracted. Where the correlation coefficient
was ≥ 0.5 the relevant local gene(s) were prioritised as being potential candidates of the
trans-signal(s) originating at that locus.
The potential candidate genes for the trans pQTLs from both the "bottom up" and "top
down" approaches were reported, highlighting cases where the same gene was highlighted
by both approaches.
4.2.2 Adjusting for effects of PAVs at cis pQTLs
All protein assays that rely on binding (e.g. of antibodies or SOMAmers) are susceptible to
the possibility of aptamer-binding effects, where PAVs (or their proxies in LD) are perceived
to be associated with protein measurements due to differential binding rather than differences
in protein abundance. To account for this potential effect, I performed conditional analysis
at all cis pQTLs where the sentinel variant was in LD (0.1≤r2 ≤ 0.9) with a PAV in the
gene(s) encoding the associated protein. First, variants were annotated with Ensembl VEP
v83 using the "per-gene" option. Variant annotations were considered protein altering if they
were annotated as coding sequence variant, frameshift variant, in-frame deletion, in-frame
insertion, missense variant, protein altering variant, splice acceptor variant, splice donor
variant, splice region variant, start lost, stop gained, or stop lost. To avoid multi-collinearity,
PAVs were LD-pruned (r2 > 0.9) using PLINK v1.9 [338] before including them as covariates
in a conditional analysis using the meta-analysis summary statistics using GCTA v1.25.2
[354] and any variants with a r2 > 0.9 with any of the PAVs were also removed. Coverage
of known common (MAF> 5%) PAVs in the INTERVAL data was checked by comparison
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with exome sequences from ∼ 60,000 individuals in the Exome Aggregation Consortium
(ExAC) [374] (http://exac.broadinstitute.org/ [downloaded 06/2016]).
4.2.3 Functional annotation of pQTLs and enrichment
Functional annotation of variants was performed using Ensembl VEP v83 using the "pick"
option. The enrichment of significant pQTL variants for certain functional classes was
tested by comparing to permuted set of null variants (p> 0.0001 for all proteins). First the
regional sentinel variants were LD-pruned at r2 of 0.1. Each time the sentinel variants were
LD-pruned, one of the pair of correlated variants was removed at random and for each set of
LD-pruned sentinel variants, 100 sets of equally sized null permuted variants were sampled
matching for MAF (bins of 5%), distance to TSS (bins of 0-0.5Kb, 0.5Kb-2Kb, 2Kb-5Kb,
10Kb-20Kb, 20Kb-100Kb and >100Kb in each direction) and LD (± half the number of
variants in LD with the sentinel variant at r2 of 0.8). This procedure was repeated 100 times
resulting in 10,000 permuted sets of variants. An empirical p-value was calculated as the
proportion of permuted variant sets where the proportion that are classified as a particular
functional group exceeded that of the test set of sentinel pQTL variants, and a threshold of
p= 0.005 (0.05/10 functional classes tested) was used to define significance.
4.2.4 Testing for regulatory and functional enrichment
pQTLs were tested to see if they are enriched for functional and regulatory characteristics
using GARFIELD v1.2.0 [375]. GARFIELD is a non-parametric permutation-based enrich-
ment method that compares input variants to permuted sets matched for number of proxies
(r2 > 0.8), MAF and distance to the closest TSS. It first applies "greedy pruning" (r2 < 0.1)
within a 1Mb region of the most significant variant. GARFIELD annotates variants with
more than a thousand features, drawn predominantly from the GENCODE, ENCODE and
ROADMAP projects, which includes genic annotations, histone modifications, chromatin
states and other regulatory features across a wide range of tissues and cell types.
The enrichment analysis was run using all variants that passed the Bonferroni-adjusted
significance threshold (p < 1.5×10−11) for association with any protein. For each of the
matching criteria (MAF, distance to TSS, number of LD proxies), five bins were used. In
total 25 combinations of features (classified as transcription factor binding sites, FAIRE-seq,
chromatin states, histone modifications, footprints, hotspots, or peaks) were tested with up to
190 cell types from 57 tissues, leading to 998 tests. Hence, enrichments with a p < 5×10−5
(0.05/998) were considered to be statistically significant.
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4.2.5 Adjusting trans pQTL effects for blood cell counts
To investigate whether blood cell counts were confounders of the trans pQTL associations,
the sentinel variants for the trans associations were adjusted for blood cell counts measured
in the overlapping participants in a multivariable regression model. The protein residuals
used for the GWAS were adjusted for measurement cohort and regressed against the sentinel
variant dosages, with platelet, red blood cell, reticulocyte, monocyte, neutrophil, eosinophil,
basophil, lymphocyte and white blood cell counts as covariates. The blood cell counts
were QC’d and adjusted for technical factors as in [322] and inverse-rank normalised before
being used as covariates in the regression model. Effect sizes for the univariate variant
associations were re-estimated to account for the participants with missing data across the
blood cell counts (n=368). In addition, to assess the effect of blood cell counts on the genetic
associations under a null model, protein residuals were permuted for each protein and the
same regression model was run using the permuted protein residuals as the outcome.
4.2.6 Cis eQTL overlap and enrichment of cis pQTLs for cis eQTLs
The regional sentinel cis pQTL variants and their strong proxies (r2 > 0.8) were queried
against publicly available eQTL association data using PhenoScanner [356]. Cis eQTL
results were filtered to retain variants with p < 1.5×10−11. Only cis eQTLs for the same
gene as the cis pQTL proteins were retained.
To assess whether the cis pQTLs were more likely to also be cis eQTLs than non-pQTL
variants, I used data from the GTEx project v6, due to the availability of genome-wide
association results across a wide range of tissues and cell-types. GTEx results were filtered
to contain only variants lying in cis (i.e. within 1Mb) of genes that encode proteins analysed
in this study and only variants assessed in both datasets were utilised.
For the enrichment analysis, the cis pQTL sentinel variants were first LD-pruned (r2 >
0.1) and the proportion of sentinel cis pQTL variants that are also significant eQTLs (at
p < 1.5×10−11) for the same protein/gene was compared to a permuted set of variants that
were not pQTLs (p > 0.0001 for all proteins). 10,000 permuted sets of null variants were
generated matched for MAF, distance to TSS and LD (as described in Section 4.2.3 above).
An empirical p-value was calculated as the proportion of permuted variant sets where the
proportion that are also cis eQTLs exceeded that of the test set of sentinel cis pQTL variants.
Sensitivity analyses were performed using a nominal genome-wide significance threshold of
p < 5×10−8 for the eQTLs as well as also using only the sentinel variants at cis pQTLs that
were robust to adjusting for PAVs.
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4.3 Results
4.3.1 Accounting for the effects of PAVs on pQTLs
Genetic variants that change the protein structure may result in apparent cis pQTLs due to
altered reagent (aptamers or antibodies) binding rather than true quantitative differences in
protein levels. A known example is illustrated in Fig. 4.2. Purified low affinity immunoglob-
ulin gamma Fc region receptor IIa (FCGR2A) proteins with either His residue at position
167 (wild-type) or the Arg amino acid substitution (His167Arg, "mutant"), were used to
assess binding to the FCGR2A SOMAmer. The affinity of the SOMAmer for the "mutant"
His167Arg protein is approximately 100 times higher compared to the wild-type.
Fig. 4.2 Example of altered aptamer binding: FCGR2A. Binding characteristics of the FCGR2A
SOMAmer to purified wild-type His167 FCGR2A, "mutant" His167Arg FCGR2A and FCGR2B
proteins showing the fraction of protein bound at increasing concentrations of the respective proteins.
Figure adapted from SOMAscan Assay: A proteomic platform that can also detect SNPs available at
http://www.somalogic.com/resources/presentations-and-posters.
To increase confidence in the cis-associated pQTLs, I annotated them with several lines
of potential evidence against aptamer-binding effects: (1) absence of PAVs (at least at
MAF> 5%) in the gene encoding the protein that are correlated with the sentinel variant
(r2 < 0.1), (2) the pQTL remaining significant after conditioning upon all PAVs in the gene
and (3) overlap with a cis eQTL (in studies which account for the polymorphism-in-probe
effect). Of the 554 cis associations, 93 (17%) were not in LD with a PAV and a further 200
(36%) associations remained significant after adjusting for PAVs (Tables S3 and S9). 224
(40%) were a cis eQTL for the same gene. Taking these evidence together, a total 373 of the
554 (67%) cis pQTLs (91% of all pQTLs) found in this study were unlikely to have been
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influenced by differential aptamer binding. Furthermore, in sub-studies that involved the use
of alternate assay methods (Section 3.3.3), I found strongly concordant genotype-protein
associations for the majority of associations.
4.3.2 Genetic architecture of the plasma proteome
The median variation in protein levels explained by the conditionally significant variants
was 5.8% (in-sample estimate; interquartile range: 2.6%-12.4%, Fig. 4.3a)). For 196
proteins, however, genetic variants explained more than 20% of the variation, such as for
teratocarcinoma-derived growth factor 1 (65%) and haptoglobin (55%). I found a strong
inverse relationship between effect size and MAF (Fig. 4.3b), consistent with previous GWAS
of quantitative traits [322, 376, 377].
There were 25 associations with rare (MAF< 1%) variants and a further 207 associa-
tions with low-frequency (MAF 1-5%) variants. For instance, rs193280350:A (MAF=0.8%)
lying upstream to the gene encoding renin was associated with a 1.2 SD increase in renin
levels per copy of the A allele. Of the 31 strongest pQTLs (per-allele effect size >1.5
standard deviations), 25 were rare or low-frequency variants. For example, rs116475987:C
(MAF=1.5%), located within the intron near the 5’ end of the gene encoding tumor necro-
sis factor receptor superfamily member EDAR (also known as ectodysplasin-A receptor)
(EDAR), was associated with a 1.56 SD per-allele increase in EDAR levels. The sentinel
variant rs189821701 (MAF=0.7%) located 300kb upstream of the gene encoding angiostatin
was associated with a 1.88 SD decrease in angiostatin levels per copy of the rare T allele.
Some of the rare variant associations with protein levels have been previously reported (albeit
not in a GWAS context). The variant rs1799895:G (Arg213Gly, MAF=1.6%, beta=2.30 SD
per-allele) in the heparin-binding domain of Superoxide Dismutase 3 (SOD3) gene has been
previously associated with a 10-fold increase in plasma superoxide dismutase levels [378]
and reduced affinity of the protein for heparin. A missense variant rs11555096:T (Arg341Trp,
MAF=2.1%, beta=-1.88 SD per-allele) in the fumarylacetoacetate hydrolase (FAH) gene has
been previously associated with fumarylacetoacetase pseudodeficiency with reduced levels
of the full length FAH protein [379]. Whilst the effect of the missense variants on aptamer
binding cannot be definitively excluded, the consistent effects seen with the previous findings
in these two examples point to functional effects.
In eQTL studies, the vast majority of cis eQTLs tend to cluster within 200Kb of the gene
TSS [380, 381]. Similarly, 95% and 87% of the sentinel cis pQTL variants were located
within 200kb and 100kb, respectively, of the relevant gene’s TSS (Fig. 4.3c), and 44% were
within the gene itself. The p-values for cis pQTL associations increased with increasing
distance from the TSS, mirroring findings for cis eQTLs in transcriptomic studies [380, 381].
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Fig. 4.3 Genetic architecture of plasma protein levels. (a) Histogram of protein variance explained
(adjusted R2) by conditionally significant variants. (b) Distribution of effect size against minor allele
frequency (MAF) for cis and trans pQTLs. (c) Plot of the statistical significance of the most associated
(sentinel) cis variant for each protein against the distance from the transcription start site (TSS). (d)
Distribution of the predicted consequences of the sentinel pQTL variants compared to matched
permuted null sets of variants. Asterisks highlight empirical enrichment p < 0.005.
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I compared the predicted consequences of the sentinel pQTL variants (LD-pruned at
r2 > 0.1) with permuted sets of null variants matched for MAF, distance to TSS and number
of variants in LD. The pQTLs were strongly enriched for missense variants (empirical p <
0.0001) and were more likely to lie in 3’UTRs (p = 0.0025) or splice regions (p = 0.0004)
(Fig. 4.3d). The enrichment for missense variants was seen for both cis and trans pQTLs
(see Fig. B.1 in Appendix B), indicating that this is not primarily driven by aptamer binding
effects at cis loci.
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To assess whether pQTL were enriched within regulatory elements from a wide range of
cell types and tissues [55, 382, 383], GARFIELD was used [375] (see Section 4.2.4). There
was strong (≥3-fold, p < 5×10−5) enrichment of pQTLs in blood cells - unsurprisingly
given the use of plasma - at features indicative of transcriptional activation (e.g. DNase
I hypersensitivity sites, Fig. 4.4) (Table S10). There was also enrichment at hepatocyte
regulatory elements, consistent with the liver’s role in producing many secreted proteins.
Fig. 4.4 Enrichment of DNase I hypersensitive sites by tissue/cell-type. Circle shows enrichment
for DNase I hypersensitive sites ("hotspots") for each of 55 tissues (183 cell-types) available from
the ENCODE and Roadmap Epigenomics projects, with tissues/cell-types clustered and coloured by
anatomical grouping. Some tissues have multiple values due to availability of multiple cell-type or
multiple tests per cell-type. Radial lines show fold-enrichment, while dots around the inside edge of
the circle denote statistically significant enrichment at p < 5×10−5.
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Of the 764 protein-associated regions, 262 had trans associations with 1,104 proteins.
Unlike cis pQTLs where the protein encoding gene in cis is an obvious candidate for
the association, annotating the candidate gene at trans associations is more difficult. A
combination of "top down" (i.e. using biological databases to link the associated protein
to the trans locus genes) and "bottom up" (i.e. using functional data to try to link trans-
associated variants to the mediating gene(s)) approaches, going beyond using the "nearest
gene" approach, was used to annotate candidate genes at trans loci (Fig. 4.1 and Table S11).
There was additional evidence (where the "top down" and "bottom up" approaches identified
the same gene(s)) for candidate genes for 19% (90 of 470) of the sentinel trans variants, of
which 76 (84%) were annotated with a single candidate gene (Table S11). For 42 of the
90 (47%) sentinel variants the gene(s) identified by both approaches was not the nearest
gene which has been often used to crudely annotate GWAS loci. For example, the trans
association of rs139641769 with transcobalamin-2 (TC-2) was annotated to the CD320
gene, which encodes the receptor for TC-2, instead of the nearest gene annotation KANK3
(rs139641769 is intronic to KANK3). The "top down" approach identified the interaction
between the receptor and its ligand whilst the "bottom up" approach found rs139641769
to be in strong LD (r2 = 0.82) with a non-synonymous variant (rs150384171) in CD320.
Apolipoprotein L1 (APOL1) levels was associated in trans with rs763665 which is located
∼ 100bp downstream to the nearest TXNL4B gene. The "bottom up" approach identified
genes encoding haptoglobin (∼ 10kb downstream) and haptoglobin-related protein (HPR)
(∼ 20kb downstream) as candidates genes, of which HPR was also identified in the "top
down" approach. Both APOL1 and HPR are part of complexes with either HDL3 (known as
trypanosome lytic factor 1) or immunoglobulin M at the core (trypanosome lytic factor 2),
which also have roles in innate protection against African trypanosomes [384]. Incorporating
additional lines of biological evidence can be informative in identifying candidate genes at
the trans loci beyond the crude method of taking the nearest gene.
Most (82%) trans loci were associated with fewer than four proteins. However, there
were twelve regions with more than 20 associated proteins (Fig. 3.2a, Fig. 4.5), including
loci with known pleiotropic functions (e.g. ABO, CFH, APOE, KLKB1). For some loci,
(e.g. the ZFPM2 locus), this was mostly driven by correlation between protein levels, whilst
others, exemplified by the other loci list in this paragraph, appear to be driven by highly
pleiotropic effects in addition to correlation between proteins (Fig. 4.6). Due to limited
coverage of proteins assayed and much smaller sample size using alternate assays, I could
not systematically assess replication at these loci. However, I was able to show directional
concordance for 3 out of 3 associations (Adrenomedullin, CHGA and VEGF-D) for the
KLKB1 locus, 1 (APOB) of 1 association for APOE, 9 (Angiopoietin-1, BDNF, NAP2, PAI1,
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PDGF-BB, SPARC, CCL17, VEGF and DKK1) of 9 associations for ZFPM2, 3 (OPG,
PECAM1 and KLK6) of 5 associations for CFH and 10 (E-selectin, Endoglin, Met, ICAM1,
IL6ST, P-selectin, CCL25, Tie2, KDR, FLT4) of 11 associations for ABO.
Fig. 4.5 Number of proteins associated (p< 1.5×10−11) with each sentinel variant across the genome.
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Given the presence of blood cells in blood from which plasma is obtained, I tested the
hypothesis of whether blood cell counts may confound the trans associations, especially the
pleiotropic ones. After adjusting the trans associations for various types of blood cells (see
Section 4.2.5)), there was no evidence of blood cells affecting the effects of the trans pQTLs
(Fig. 4.7 (left)). Some small fluctuations in effect sizes after adjusting for blood cell counts
were expected by chance as seen for the permuted data (Fig. 4.7 (right)).
Fig. 4.7 Effect sizes (in SD change in protein residuals per-allele) of sentinel variant association
with protein levels before and after adjusting for blood cell counts for trans associations (left) and
permuted protein levels (right).
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4.3.3 Overlap of loci for gene expression and protein levels
A fundamental biological question is the extent to which genetic associations with plasma
protein levels are driven by effects at the transcription level, rather than other mechanisms,
such as altered protein clearance or cleavage of membrane receptor proteins from the cell
surface. I therefore cross-referenced the cis pQTLs with a wide range of publicly available
eQTL studies involving > 30 tissues or cell types using PhenoScanner [356] (Table S12).
40% (n=224) of cis pQTLs had an association with expression of the same gene in at least
one tissue (Table S13), consistent with similar comparisons within human LCLs [249].
The greatest overlaps were found in whole blood (n=117), liver (n=70) and LCLs (n=52),
consistent with biological expectation, but also likely driven by the larger sample sizes for
expression studies of these cell types. Cis pQTLs were significantly enriched (p < 0.0001)
for eQTLs for the corresponding gene (mean 20% versus 2% in the background permuted
set, Table 4.1). The results were robust to effects of PAVs and also to using a more relaxed
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p-value threshold (p < 5×10−8) when selecting eQTLs. To address the converse (i.e. to
what extent do eQTLs translate into pQTLs), I used a subset of well-powered eQTL studies
in relevant tissues (whole blood, LCLs, liver and monocytes) [385–388]. Of the strongest cis
eQTLs (p < 1.5×10−11), 12.2% of those in whole blood were also cis pQTLs, 21.3% for
LCLs, 14.8% for liver and 14.7% for monocytes. Similar proportions were seen using the
relaxed eQTL p threshold (p < 5×10−8; 13.0% for whole blood, 18.7% for LCLs, 17.1%
for liver and 13.4% for monocytes).
Table 4.1 Enrichment of cis pQTLs for cis eQTLs using GTEx data.
Overlap
eQTL p threshold
1.5×10−11 5×10−8 1.5×10−11 5×10−8
(Post-PAV)1 (Post-PAV)1
Lead pQTL-eQTL overlap
(%) - mean (sd) 19.5 (0.3) 28.3 (0.3) 24.9 (0.4) 33.6 (0.5)
Permuted pQTL-eQTL overlap
(%) - mean (sd) 1.8 (0.6) 3.5 (0.9) 1.8 (0.8) 3.7 (1.1)
Empirical p-value
(10,000 permutations) <0.0001 <0.0001 <0.0001 <0.0001
1 Post-PAV: pQTLs that remain significant at p < 5×10−8 after conditioning on protein altering variants.
4.4 Discussion
In this chapter, I characterise the pQTLs identified in Chapter 3. First I look at a previously
under-appreciated issue of potential PAV effects on altered aptamer-binding rather than true
protein abundances; a problem analogous to polymorphism-in-probe effects in eQTL studies
[364]. This problem also applies to other affinity-based protein assays (e.g. ELISAs) and
even MS whereby PAVs can affect the mass-charge ratio of the target protein/peptide. PAVs
may give rise to false positive associations, where the signal is purely due to differential
aptamer/antibody binding affinities or false-negatives, where the effect of differential binding
affinities counteracts true biological effects of the PAV. Cis associations not in LD with
any PAVs are highly unlikely to be affected by this issue. In addition, cis pQTLs that
are also cis eQTLs (in eQTL studies that have adequately controlled for polymorphism-in-
probe effects) for the same gene would also reduce the likelihood that the variant-protein
association is entirely due to differential binding, but this is by no means conclusive. By
conditioning on all PAVs in the gene encoding the protein being measured, pQTL effect
estimates independent of PAV effects can be obtained. However, this method adjusts for
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both the differential binding effect and true biological effect, which would not be rescuable
by conditional analysis. Variants in high LD with the PAVs would also be unrecoverable
using this method. Nonetheless, the signals that do remain after adjusting for PAVs, would
make a high confidence subset of pQTLs not affected by differential binding. Replication
of pQTLs using alternate assays (preferably multiple different assays) would also decrease
the chance of the association being due to differential binding because it is unlikely that the
same PAV(s) would affect binding affinities of two or more different capture ligands to the
same extent and in the same direction. Using a combination of aforementioned approaches, I
was able to show reduced likelihood of differential binding effects for around two-thirds of
the cis pQTLs. In the examples in this and subsequent chapters, I take additional precautions
in ensuring the examples presented are not affected by PAVs. Binding experiments using
purified proteins containing the PAVs would be the definitive evidence in quantifying the
effect of the PAV on binding of capture ligands, however this is infeasible to perform at scale
and is limited by the availability of purified proteins modified with the PAV of interest.
On the other hand, it is also plausible that PAVs have true biological effects on plasma
protein abundance as shown in protein deficiencies due to rare mutations or experimentally
validated effects of more common variants. For example, a cis pQTL association that is
known to be underpinned by differences in plasma protein levels due to a missense variant is
the association of rs4129267 with IL6R levels (Table S3). The variant is strongly correlated
(r2 > 0.95) with rs2228145 (p.Asp358Ala), which has been previously associated with IL6R
levels using other assay methods [246, 252]. This variant has been functionally characterised
and has been shown not to be associated with IL6R gene expression, but to alter cell surface
expression of the receptor [389]. IL6R is cleaved from the cell surface by proteases ADAM10
and ADAM17, and detailed studies have shown that the cleavage site lies between residues
357 and 358 [390]. Carriage of 358Ala has been demonstrated to make the IL6R protein
more susceptible to protease cleavage [391], therefore influencing shedding of the receptor
from the cell surface and hence levels of plasma IL6R. There is also evidence that the variant
may also lead to exon skipping in il6r. Whilst differential binding can be problematic for cis
pQTL mapping, it does however imply that the binding of the aptamer/antibody to protein
targets in such cases are highly specific.
Owing to the large number of proteins assessed, this study enables a more detailed
assessment of the genetic architecture of circulating proteins. I find a similar pattern between
effect size and MAF to other quantitative traits such as gene expression [376], metabolite
levels [377] and blood cell traits [322]. However, statistical power limits the detection of rare
variants with small effects. I show that pQTLs on average explain around 6% of the variance
in protein levels, although this may be lower due to "winner’s curse", or on the other hand,
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higher as the study would be underpowered to detect variants with very small effects (I had
80% power to detect pQTLs that explained ∼ 1.7% of the variance in protein levels at MAF
of 5%). Differential binding effects (assuming they are on average larger than true biological
effects) may also lead to upward bias in the estimate. Taken together, levels of many plasma
proteins are under genetic regulation and are similar to what has been previously reported
[95, 96, 254], although the variance explained differs between different proteins and is also
affected by the sample size. I find a number of trans associations with a small number of
high pleiotropic loci, some of which are partly driven by correlation between proteins and
the associations are unlikely to be driven by blood cell counts. Whilst genes in some of the
loci have established pleiotropic functions, roles of the others still await further elucidation.
Additionally, I also highlight the utility of incorporating publicly available functional data to
annotate candidate genes at trans loci.
In addition, I find parallels between pQTLs and eQTLs where the majority of cis associa-
tions lie within 200Kb of the cis gene [380, 381], suggesting the 1Mb cis window imposed
here may be overly conservative. I find that cis pQTLs are enriched for eQTLs of the cor-
responding protein encoding gene, suggesting plasma protein abundance is often, but not
exclusively, driven by regulation of mRNA. Comparisons between pQTL and eQTL studies
have inherent limitations due to differences in the tissues, sample sizes and technological
platforms used. Even in the same samples, changes in gene expression have attenuated
effects on protein levels and only 35% of pQTLs overlapped eQTLs [67]. Moreover, plasma
protein levels may not reflect levels within tissues or cells. Cis pQTLs without corresponding
cis eQTLs may also be underpinned by effects not captured at the mRNA level, such as
differences in protein stability, degradation, binding, secretion, or clearance from circulation.
In summary, through the scale of this study, I was able to provide novel insights into
the genetic underpinnings of plasma protein levels. The next two chapters will focus on the
biological and disease implications of the findings.
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Chapter 5
Highlighting biological relevance of
pQTLs
5.1 Introduction
Previous chapters have focused on the discovery and general characterisation of pQTLs. This
chapter focuses on more specific examples of how the pQTLs identified can be relevant to
the biological understanding of regulation of plasma protein levels. Unlike cis pQTLs, where
there is a high prior that the locus can be directly linked to the local (cis) gene encoding the
protein, trans pQTLs likely exert their effects on the associated proteins through a biological
intermediate. I first highlight how some of the associations at trans loci have obvious
biological connections with their associated proteins. Then I use mediation analysis to test
whether any of the highly biologically plausible trans associations act through the proteins
associated with the locus in cis (Fig. 5.1). I make the reasonable assumption that there is a
directed effect going from the variant to the proteins and from the cis associated protein to
the trans associated protein.
The pleiotropy at the ABO and FUT2 regions led me to explore the biologically-motivated
hypothesis of effect modification of O blood group status by fucosyltransferase 2 (FUT2)
secretor status on circulating protein levels. The ABO gene is expressed on the surface of red
blood cells and numerous other tissues throughout the body and encodes a glycosyltransferase
with three main variant alleles giving rise to the "A", "B" and "O" blood groups [104]
(Fig. 5.2). Variants responsible for the "A" and "B" blood groups lead to transferases that
catalyse the transfer of modified monosaccharides to a protein backbone called "H antigen",
converting it to "A" and "B" antigens respectively. Those with the "O" blood group variant
lack the functional transferase and hence express only the H antigen.
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Fig. 5.1 Simplified framework for mediation of trans pQTLs by cis proteins. (a) Cis-mediated effect:
the causal variant affects the protein levels in cis (locally) which in turn affects the levels of the distal
(trans) protein. (b) The causal variant affects levels of measured protein (ProteinX) and unmeasured
protein (ProteinY) in cis. The unmeasured ProteinY in turn affects levels of the protein in trans 1⃝,
whilst the measured ProteinX has no effect. It is also possible, although much less likely, for cis
and trans associations on the same chromosome, that the variant has a long-range genetic effect that
directly affects trans protein levels 2⃝.
Fig. 5.2 ABO blood group system.
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The enzyme FUT2, also known as secretor type α1,2-fucosyltransferase, encoded by the
FUT2 gene, allows for expression of ABH antigens in mucal and gastrointestinal secretions.
About 80% of Caucasian individuals carry at least one functional allele (rs601338, Trp154Ter)
of FUT2 (known as secretors) while the remaining 20% (non-secretors) are homozygous for
the protein truncating variant [392]. Therefore, it can be envisaged that modified antigens
may have different effects on plasma protein abundance and that their effects may be modified
by whether the modified antigens are expressed or not. Since both the ABO system and
secretor status are genetically determined and the two genes lie on different chromosomes
(ABO is located on chromosome 9, FUT2 is located on chromosome 19), this also serves
as an example of long range gene-by-gene interaction. Both blood group and secretor
status are not solely determined by additive effects at a particular variant, thus using this
functional distinction may be more reflective of the underlying mechanism compared to the
variant-by-variant analysis in pQTL mapping.
5.2 Methods
5.2.1 Mediation of the biologically plausible trans pQTL by proteins
associated in cis
Examples of biological plausible trans pQTLs were manually extracted by combining
the trans annotation results from Section 4.2.1 with manual literature searches using the
associated protein and candidate genes at the trans loci as inputs. Those with additional
literature support were retained and the results were confirmed by an independent investigator.
To assess whether biologically plausible trans pQTLs were mediated by protein levels
associated in cis, I performed mediation analysis through multiple regression using the
inverse-rank normalised protein levels (used for GWAS) associated in trans adjusted for
measurement cohort as the outcome variable. The sentinel variant (allelic dosages) along
with any proteins (residuals used for GWAS) with cis association at the trans locus at
p < 5×10−8 were used as covariates in the model. The expectation was that trans pQTLs
would be mediated by protein levels associated in cis at the locus, assuming the mediator
protein(s) has been measured. Where this is true, adding the levels of the mediator protein to
the multiple regression model would significantly decrease or abolish the trans pQTL effect.
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5.2.2 Interaction between blood groups and secretor status
Determination of ABO blood groups and secretor status
ABO blood groups were determined by haemagglutination assay at NHS Blood and Trans-
plant centres (UK) according to standard procedures. ABO blood groups were dichotomised
based on whether the person had absence of expression of modified antigens (type A or B
antigens, i.e. those of blood type O) or not (i.e. presence of A [blood type A] or B [blood
type B] antigens or both [blood type AB]). Participants’ secretor status was determined by an
inactivating mutation (rs601338, Trp154Ter) common in Caucasians [392], with secretors
carrying GG or GA genotypes and non-secretors carrying AA defined using hard-called
genotypes (genotypes were called if the posterior probability for a genotype is ≥ 0.8) from
imputed data (INFO∼1.0, missing call=0.03%). 3,298 of 3,301 individuals had ABO blood
groups and secretor status successfully determined.
Statistical test for interaction
I tested for the interaction between O blood type (where there is an absence of modified
blood antigens in those of type O, Fig. 5.2) and secretor status using linear regression.
Rank inverse transformed residuals for each protein measurement used for the GWAS were
regressed against O blood group status and secretor status, with and without their interaction
term, adjusting for measurement cohort. I used a Bonferroni-corrected p-value threshold of
1.5×10−5 (0.05/3,283 analytes tested) to define statistical significance.
Enrichment of proteins associated with O blood group and secretor status for high
expression in gastrointestinal tracts
Data on tissue expression (RNA expression) of proteins across 37 tissues was extracted from
the Human Protein Atlas [327] (http://www.proteinatlas.org/about/download, downloaded
November 2016) and cross-referenced with those overlapping the SOMAscan assay by gene
name and Ensembl ID. I defined high expression from non-high expression of genes in
GI tract by whether the abundance was labelled as "high" or not. GI tract included the
following tissues: salivary gland, oesophagus, stomach, duodenum, small intestine, colon.
I defined whether the protein was significantly associated with O blood group or secretor
status (regression against O blood group status and secretor status adjusted for cohort) or not
using the following p-value thresholds: 0.00001, 0.0001, 0.001, 0.01, to see if the proteins
defined as associated were robust to the choice of p-value thresholds.
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I tested for enrichment of proteins significantly associated with O blood group/secretor
status for high expression in the GI tract using Fisher’s exact test. As sensitivity analyses
to see if the results were robust to correlation between proteins, I also pruned correlated
proteins, prior to enrichment testing, at the following absolute correlation coefficient cut-offs:
0.2, 0.3, 0.4, 0.5, using the "findCorrelation" function from the "caret" R package [393]. I
did not test enrichment for proteins at absolute correlation coefficient cut-off of 0.1 or lower
due to small sample numbers (≤ 1) in the significantly associated group.
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5.3 Results
5.3.1 pQTLs linking plausible biological pathways
I identified a number of novel trans associations with strong biological plausibility linking the
associated protein with the gene in the trans loci (Table 5.1). For example, an intronic variant
(rs7787942) in C1GALT1 was associated for the first time with levels of C1GALT1-specific
chaperone 1 (C1GLC or C1GALT1C1) (p = 1.0×10−28), consistent with suggestions that
C1GLC is a probable molecular chaperone for C1GALT1 [394]. As mentioned in the
previous chapter, the HPR gene in the trans locus and the associated protein APOL1 are
both part of a multiprotein complex (TLF1 and TLF2), involved in innate host defence
against trypanosomes. I also found three trans associations which were all implicated in the
coagulation cascade: rs10800453 in factor V with tissue factor pathway inhibitor; rs559054
in factor X (12kb upstream of Protein Z) with Protein Z-dependent protease inhibitor which
inhibits factor X; and rs36229204, 1kb upstream of urokinase-type plasminogen activator
(uPA) receptor, with its ligand uPA (Table 5.1).
Another example alluded to in the previous chapter is the trans pQTL (rs139641769,
p = 1.0×10−23) for soluble TC-2, which is in strong LD (r2 = 0.82) with rs150384171
leading to an in-frame deletion of the glutamine residue at position 88 in the TC-2 receptor
CD320. CD320 binds cobalamin (also known as vitamin B12) bound TC-2 with high
specificity and affinity, allowing endocytic uptake of cobalamin into cells [395]. The deletion
in CD320 (associated with higher plasma levels of TC-2) overlaps a disulphide bond within
the LDL-receptor class A1 domain, a known endocytic catalyser, that interacts with TC-2, but
structural analysis on CD320 showed that the deletion has little effect on its protein structure
and no difference in TC-2 binding affinity [396]. Taking these observations together, it can be
hypothesised that the deletion (rs150384171) affects the endocytic activity of CD320, leading
to reduced cellular uptake of cobalamin-bound TC-2, which in turn results in the increased
plasma levels of TC-2 (Fig. 5.3). In addition, recent genetic association studies have identified
a non-synonymous variant in CD320, rs2336573 (p.Gly220Arg), to be associated with serum
cobalamin levels [397, 398]. This variant is in LD with rs150384171 (r2 = 0.30), and both
variants remained at least nominally significant in the association with TC-2 levels in the joint
model containing both variants (rs150384171, p = 1.1×10−8; rs2336573, p = 1.3×10−4).
Therefore, the Gly220Arg variant may have an effect independent of Glu88del on circulating
TC-2 levels. Functional studies looking at the effect of these variants on CD320 function and
studies in larger samples looking at the effect of both variants conditionally on TC-2 levels
are needed to test these two hypotheses and elucidate the mechanism behind the genetic
associations in more detail.
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Table 5.1 Table of highly biologically plausible trans pQTLs.
Sentinel variant Chr Target Trans gene(s) Biological connection
rs10800453 1 TFPI F5 TFPI and F5 are part of the coagulation cascade. F5 deficiency has been associated
with lower TFPI levels and F5 immunodepletion experiments in normal plasma and
surface plasmon resonance analysis evidence of F5-TFPI complex [399]. Ligand blot
experiments also demonstrate F5 binding to TFPI [400].
rs7787942 7 C1GLC C1GALT1 C1GLC (C1GALT1C1) is the molecular chaperone for C1GALT1 and is required for
C1GALT1 activity in mammalian cell lines [394].
rs11607100 11 BMP-6 CHRDL2 CHRDL2 is a BMP-binding inhibitor and mouse Chrdl2 co-immunoprecipitates with
human BMP6 [401].
rs559054 13 protein Z
inhibitor
F10, PROZ Protein Z-dependent protease inhibitor is a serpin inhibitor of F10 dependent on PROZ
binding [402, 403].
rs763665 16 Apo L1 HPR APOL1 and HPR are two primate-specific proteins part of two multiprotein complexes
involved in trypanolysis, with either HDL3 (TLF1) [404] at the core or IgM (TLF2)
[405]. HPR is involved in targeting TLF1 to trypanosomes whilst APOL1 acts as the
pore-forming lysin [384].
rs11079936 17 GDF-11/8 WFIKKN2 WFIKKN2 binds and inhibits GDF8 and GDF11 [406–408].
rs139641769 19 TC-2 CD320 TCBLR (CD320) is the receptor for TC-2 which binds cobalamin and reponsible for the
celluar uptake of the TC2-cobalamin complex [395].
rs36229204 19 uPA PLAUR PLAUR (uPAR) is a well-established receptor for PLAU (uPA) [409].
rs855791 22 TR CYTH4, IL2RB,
TMPRSS6
Both matriptase-2 (TMPRSS6, a serine protease) and TfR (TR) are involved in iron
regulation. The missense variant has previous been related to various iron-related and
haematological traits including soluble TfR levels [410, 411].
TFPI: Tissue factor pathway inhibitor; F5: Factor V; C1GALT1: Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1; C1GLC: C1GALT1-
specific chaperone 1; BMP: Bone morphogenetic protein; CHRDL2: Chordin-Like Protein 2; F10: Factor 10; PROZ: Protein Z; ApoL1: Apolipoprotein L1;
HPR: Haptoglobin-related protein; TLF: Trypanosome Lytic Factor; GDF: Growth/differentiation factor; WFIKKN2: WAP, Follistatin/Kazal, Immunoglobulin,
Kunitz And Netrin Domain Containing 2; TC-2: Transcobalamin-2; TCBLR: Transcobalamin Receptor; uPA: Urokinase-type plasminogen activator; PLAUR:
Plasminogen Activator, Urokinase Receptor; TR/TfR: Transferrin receptor protein 1; CYTH4: Cytohesin-4; IL2RB: Interleukin-2 receptor subunit beta;
TMPRSS6: Transmembrane Protease, Serine 6. Note: the SOMAmer probe on the assay binds both GDF-11 and 8, which are considered together as GDF-11/8.
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Fig. 5.3 Proposed mechanism of CD320 ∆88 effect on TC-2 levels. The deletion of Glu at residue 88
in CD320 may act to inhibit endocytosis of the bound TC2-Cbl complex leading to increased TC-2
levels in plasma.
5.3.2 Mediation of biologically plausible trans associations
I looked at whether the highly biologically plausible trans associations may be mediated
by levels of the proteins associated in cis with the trans pQTLs, by adjusting the trans
associations in Table 5.1 for proteins with cis associations in the locus at nominal genome-
wide significance (p < 5×10−8). Two of the trans associations, growth differentiation factor
(GDF)-11/8 with rs11079936 and bone morphogenetic protein (BMP)-6 with rs11607100,
became null (p > 0.05) after adjusting for protein levels in cis at their respective loci
whilst the trans association for APOL1 showed obvious attenuation but remained significant
(Fig. 5.4). However, for 4 of the trans associations, none of the proteins encoded by the
candidate annotated gene(s) was assayed (F5 for TFPI, C1GALT1 for C1GLC, HPR for
APOL1, CD320 for TC-2). Whilst the APOL1 association partially attenuated after adjusting
for haptoblogin levels, this may have occurred downstream of the effect on the unmeasured
HPR. For the trans association with protein Z inhibitor, F10 was measured but PROZ was
not, and adjusting for F10 levels did not lead to changes in the trans association. For the
association with TR, CYTH4 and IL2RB were measured but TMPRSS6 was not, and there
was no change in the trans association after adjusting for the two proteins. Adjusting for
PLAUR levels led to a small but not significant attenuation in the trans association between
rs36229204 and uPA (PLAU). I proceeded to examine the two regional associations at the
trans associations that attenuated to the null in more detail below.
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Fig. 5.4 Forest plot of highly biologically plausible trans associations adjusting for proteins with cis
associations in the trans loci.
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Mediation of the GFD-11/8 trans association by WFIKKN2
GDF-11 and 8 are part of the transforming growth factor-beta superfamily of secreted proteins
with key roles in development and tissue homeostasis [412]. GDF-11 (also known as BMP-
11) and in particular GDF-8 (commonly known as myostatin) have roles in regulating muscle
mass [413]. The SOMAmer probe on the assay binds both GDF-11 and 8 which share a high
level of homology and are considered together here. The common allele (rs11079936:C) near
the WFIKKN2 gene on chromosome 17 was associated in trans with lower levels of plasma
GDF-11/8 (p = 7.9×10−12), as well as in cis with lower levels of plasma WFIKKN2 (p =
6.9×10−136) (Table S3 and Fig. 5.5a). The trans association attenuated completely across
the region upon adjustment for levels of WFIKKN2 (pad j = 0.67), whilst the cis association
remained significant after adjustment for GDF-11/8 (pad j = 7.2×10−113), suggesting that
WFIKKN2 regulates GDF-11/8 (Fig. 5.5b). This observation is supported by in vitro and
murine in vivo evidence suggesting that WFIKKN2 has high affinity for GDF-8 and GDF-11
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[407, 408, 414]. In vitro studies have shown that GDF-11 and GDF-8 bound to WFIKKN2
have reduced binding to their receptors and thus inhibits the activity of the two GDFs [407,
408, 414]. This may seem to be opposite in direction to the findings here (Fig. 5.5b), but it
is important to note that the proteomic assay used here does not distinguish free GDF-11/8
from those bound to WFIKKN2, and reduced WFIKKN2 levels may proportionally decrease
levels of the bound, non-active GDF-11/8 compared to their free counterparts. Additional
studies using an assay that distinguishes free from bound GDF-11/8 can help elucidate the
mechanism further.
Fig. 5.5 GDF11/8 trans pQTL on chromosome 17 mediated by genetic control of WFIKKN2 levels.
(a) Regional association plots of the trans pQTL (sentinel variant rs11079936) for GDF11/8 before and
after adjusting for levels of WFIKKN2 (upper panels), and the WFIKKN2 cis pQTL after adjusting
for GDF11/8 levels (bottom panel). (b) Proposed mechanism of how the trans pQTL for GDF11/8 is
mediated by WFIKKN2 levels. Solid arrows indicate the direct effects whilst dashed arrows indicate
the indirect effect.
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In addition to the GDF-11/8 trans pQTL at the WFIKKN2 locus, there is another trans
pQTL (rs1815739) for GDF-11/8 in the Cathepsin F (CTSF or CATF) region on chro-
105
Highlighting biological relevance of pQTLs
mosome 11 (p = 8.1×10−12). There were two proteins in the region with pQTLs in cis
(Table S3), CTSF with rs1791679 (p = 2.5×10−18) and Cystatin M (CST6) with rs3825068
(p < 4.0×10−14). After adjusting for CTSF and CST6 levels, the trans association remained
significant and was similar to pre-CTSF adjusted results (pad j = 5.7×10−12, Fig. 5.6a), sug-
gesting CTSF and CST6 levels do not mediate the association. However, the sentinel variant
is known to encode for a premature stop codon in Actinin Alpha 3 (ACTN3) (Arg577Ter)
leading to deficiency of the protein product [415], and both ACTN3 and myostatin are
involved in skeletal muscle function [413, 416]. Unfortunately, ACTN3 was not assayed in
this study. The trans association at this locus may likely be mediated by ACTN3 or possibly
one of the other unmeasured proteins in the region (Fig. 5.6b).
Fig. 5.6 (a) Regional association plots of the trans pQTL (sentinel variant rs1815739) for GDF11/8
before and after adjusting for levels of CTSF and CST6. (b) Possible mechanism of how the trans
pQTL for GDF11/8 on chromosome 11 may be mediated by unmeasured proteins in the locus
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Mediation of the BMP-6 trans association by CHRDL2
BMP-6, similar to the GDFs, belongs to the same superfamily of proteins and has a positive
regulatory role in bone development [412] as well as being a key modulator in iron home-
ostasis [417]. The variant rs11607100, located in the intron of the Chordin-like protein 2
106
5.3 Results
(CHRDL2) gene on chromosome 11, was associated in trans with BMP-6 (p = 1.8×10−12)
levels and in cis with CHRDL2 levels (p = 5.8×10−26). After adjustment for CHRDL2
levels, the trans association attenuated to the null (pad j = 0.14) whilst the cis association with
CHRDL2 remained highly significant (pad j = 2.5×10−15) after adjusting for BMP-6 levels
(Fig. 5.7a). The mediation mechanism is similar to that for GDF-11/8 association on chromo-
some 17 described above with the BMP-6 trans association mediated by CHRDL2 levels
(Fig. 5.7b). CHRDL2 was characterised recently in 2004 and there was in vitro evidence
of mouse Chrdl2 interaction with human BMPs including BMP-6, thereby competitively
inhibiting their interaction with BMP receptor [401]. The results here provide support that
human CHRDL2 binds and regulates BMP-6 levels ex vivo in human plasma.
Fig. 5.7 BMP-6 trans pQTL on chromosome 11 mediated by genetic control of CHRDL2 levels. (a)
Regional association plots of the trans pQTL (sentinel variant rs11607100) for BMP-6 before and
after adjusting for levels of CHRDL2 (upper panels), and the CHRDL2 cis pQTL after adjusting
for BMP-6 levels (bottom panel). (b) Proposed mechanism of how the trans pQTL for BMP-6 is
mediated by CHRDL2 levels. Solid arrows indicate the direct effects whilst dashed arrows indicate
the indirect effect.
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5.3.3 Interaction between O blood group and secretor status
The distribution of blood groups seen in this study (Table 5.3) is similar to that of healthy
blood donors within the National Health Service Blood and Transplant in England (https:
//www.blood.co.uk/why-give-blood/the-need-for-blood/blood-groups/). 26% of the individ-
uals are secretors, which is slightly higher than the generally reported proportion of 20%,
but is line with what has been previous reported within individuals from the UK population
[418]. There was not sufficient evidence against independence between ABO blood group
and secretor status (p = 0.06, Table 5.3). Likewise, neither blood group nor secretor status
was dependent on sex or proteomic measurement cohort (all p > 0.05, Table S14).
Table 5.3 Distribution of INTERVAL proteomic samples by ABO blood group and secretor status.
Secretor status Total (%)
Blood group Secretor Non-secretor
A 360 955 1,315 (39.9%)
AB 19 91 110 (3.3%)
B 89 228 317 (9.6%)
O 387 1,169 1,556 (47.2%)
Total (%) 855 (25.9%) 2,443 (74.1%) 3,298
Two-sided χ2 test p = 0.060.
First I tested the association of plasma protein levels with O blood group status (which
stratifies those with modified antigens or not) and secretor status as covariates adjusting for
proteomic measurement cohort. 54 and 19 proteins were associated (p < 1.5×10−5) with O
blood group and secretor status respectively (Table S15). In particular, the levels of E-selectin,
P-selectin, ICAM-1 and F8 stratified by ABO blood groups closely mirrored the pattern
reported previously [165, 166, 190, 191, 419] (Fig. 5.8). The pleiotropy of associations
with O blood group status and secretor status were not driven by strong correlation between
proteins as shown in Fig. 5.9, although there were some weak to moderately correlated
clusters of proteins.
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Fig. 5.8 Boxplot of protein levels stratified by ABO blood groups for selected proteins previously
reported.
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Proteins significantly associated with secretor status were enriched for high expression
in the GI tract consistent with their role in these tissues [392] (Fig. 5.10 (left)). The results
were robust to the choice of p-value significance thresholds and were unlikely to be biased
by correlation between proteins (at least at a correlation pruning threshold of 0.2). On the
other hand, I found no evidence of enrichment of GI expression for proteins associated with
O blood group status (Fig. 5.10 (right)).
There was evidence of interaction (p < 1.5×10−5) between O blood group status and
secretor status affecting levels of five proteins (FAM3D, GOLM1, FAM3B, C1GLC and
MIP-1α (also known as CCL-3)) (Table 5.4). There was also evidence of interaction, close
to the p < 1.5×10−5 significance threshold, for ALPI levels (p = 2.1×10−5), which has
been recently reported in serum samples from a Japanese cohort [420]. For the five proteins
with significant interactions, higher plasma levels were seen in secretors compared to non-
secretors in non-O blood group participants, but the effect was diminished or abolished in
those of O blood group (Fig. 5.11). On the other hand, higher plasma levels of ALPI were
seen in secretors compared to non-secretors in the O group whilst the effect was largely
abolished in those in the non-O group. Within those who are both non-O blood group and
secretors, higher protein levels, except for ALPI, were seen in those with type A alleles
(blood type A or type AB, Fig. B.2). In secretors, ALPI protein levels were higher in those
without type A alleles (type B or O) compared to those who carry the type A allele (type A
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Fig. 5.9 Correlation heatmap of proteins associated (p < 1.5×10−5) with O blood group status,
secretor status and the interaction between O status and secretor status.
A
L
P
I
C
C
L
3
G
O
L
M
1
C
1
G
A
L
T
1
C
1
F
A
M
3
D
F
A
M
3
B
F
A
M
3
B
ALPI
CCL3
GOLM1
C1GALT1C1
FAM3D
FAM3B
FAM3B
A
L
P
I
G
N
S
C
A
S
C
4
C
A
S
C
4
F
T
H
1
IC
A
M
1
IC
A
M
2
F
L
T
4
K
D
R
IL
3
R
A
S
E
L
E
A
D
G
R
F
5
T
P
S
T
2
C
1
G
A
L
T
1
C
1
F
A
M
2
0
B
G
L
C
E
K
IN
S
E
L
P
C
C
L
2
8
C
H
S
T
1
1
D
H
F
R
S
P
O
C
K
2
B
4
G
A
L
T
2
C
H
S
T
1
5
C
H
S
T
1
5
IS
L
R
2
L
IF
R
IC
A
M
5
IC
A
M
5
F
A
M
1
7
7
A
1
D
P
E
P
2
L
1
C
A
M
M
E
T
IN
S
R
T
L
R
4
F
8
C
D
H
1
C
L
IC
5
B
3
G
N
T
2
P
L
X
N
B
2
B
4
G
A
L
T
1
D
S
G
2
B
C
A
M
C
D
H
5
T
IE
1
S
T
6
G
A
L
N
A
C
1
G
O
L
M
1
C
D
2
0
9
Q
S
O
X
2
A
B
O
M
B
L
2
F
A
M
3
D
F
A
M
3
B
F
A
M
3
B
T
H
S
D
1
T
U
F
T
1
C
T
S
S
C
C
L
2
5
C
C
L
2
5
ALPI
GNS
CASC4
CASC4
FTH1
ICAM1
ICAM2
FLT4
KDR
IL3RA
SELE
ADGRF5
TPST2
C1GALT1C1
FAM20B
GLCE
KIN
SELP
CCL28
CHST11
DHFR
SPOCK2
B4GALT2
CHST15
CHST15
ISLR2
LIFR
ICAM5
ICAM5
FAM177A1
DPEP2
L1CAM
MET
INSR
TLR4
F8
CDH1
CLIC5
B3GNT2
PLXNB2
B4GALT1
DSG2
BCAM
CDH5
TIE1
ST6GALNAC1
GOLM1
CD209
QSOX2
ABO
MBL2
FAM3D
FAM3B
FAM3B
THSD1
TUFT1
CTSS
CCL25
CCL25
M
L
N
G
O
L
M
1
F
A
M
3
D
F
A
M
3
B
C
1
G
A
L
T
1
C
1
B
3
G
N
T
2
F
U
T
3
C
C
L
2
5
C
C
L
2
5
T
C
N
1
H
H
L
A
2
L
C
T
A
L
P
I
P
V
R
L
2
P
R
K
C
S
H
S
E
C
T
M
1
C
C
L
1
5
C
C
L
1
5
F
G
F
1
9
B
P
IF
B
1
F
A
M
1
7
7
A
1
MLN
GOLM1
FAM3D
FAM3B
C1GALT1C1
B3GNT2
FUT3
CCL25
CCL25
TCN1
HHLA2
LCT
ALPI
PVRL2
PRKCSH
SECTM1
CCL15
CCL15
FGF19
BPIFB1
FAM177A1
●
●
−1
−0.8
−0.6
−0.4
−0.2
0
0.2
0.4
0.6
0.8
1
! "#$#%" &'()'#*) "#$#%"
! "#$#%" + "'()'#*) "#$#%"
Note: Some proteins appear multiple times due to multiple SOMAmer probes targeting the same protein. Please
see Table S15 for details.
Fig. 5.10 Enrichment of proteins significantly associated with secretor status (left) and O blood
group status (right) for high expression in the GI tract. Log odds ratio (OR) of the Fisher’s test, with
lines indicating 95% confidence intervals, were plotted for proteins associated at different p-value
thresholds. Colours represent the sensitivity tests using proteins after pruning at various absolute
correlation thresholds. Mean absolute correlations of post-pruned proteins are shown in brackets.
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or AB). A graded effect between blood types A, AB, B and O among secretors was most
apparent for FAM3D, whilst for C1GLC, presence of type B alleles in the absence of type
A alleles (type B) did not lead to elevated protein levels compared to those of type O in
secretors (Fig. B.2).
Table 5.4 Proteins with significant interactions (p < 1.5×10−5) between O blood group and secretor
status.
SOMAmer ID Target beta SE p
FAM3D.13102.1.3 FAM3D -1.29 0.058 8.9×10−103
GOLM1.8983.7.3 GOLM1 -0.72 0.072 1.1×10−23
FAM3B.9177.6.3 FAM3B -0.54 0.078 3.1×10−12
C1GALT1C1.5735.54.3 C1GLC -0.52 0.076 1.5×10−11
FAM3B.5618.50.3 FAM3B -0.45 0.079 1.3×10−8
CCL3.3040.59.1 MIP-1α -0.37 0.079 3.2×10−6
ALPI.10463.23.31 Alkaline phosphatase, intestine 0.33 0.078 2.1×10−5
1 Interaction with ALPI previously reported but is marginally below the multiple testing corrected p threshold.
FAM3D: Family With Sequence Similarity 3 Member D; GOLM1: Golgi membrane protein 1; FAM3B: Family
With Sequence Similarity 3 Member B; C1GALT1C1: C1GALT1 Specific Chaperone 1; CCL3: C-C chemokine
ligand; MIP: Macrophage inflammatory protein; ALPI: Intestinal-Type Alkaline Phosphatase.
Fig. 5.11 Boxplot of protein levels (normalised residuals) by O blood group status and secretor status
for proteins with significant interactions (p < 1.5×10−5).
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Note: Two boxplots are shown for FAM3B as there are two SOMAmers used to assay FAM3B. Association
with ALPI previously reported but is marginally below the multiple testing corrected p threshold
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5.4 Discussion
This chapter highlights examples of the biological relevance of pQTLs discovered in this study.
I find strong biological links between some of the trans pQTLs and their associated proteins
suggesting that levels of some plasma proteins are strongly regulated by "complementary"
proteins such as that of "receptor-ligand" pairs. Given that some of these pairings have only
been discovered relatively recently (e.g. C1GALT1 and its chaperone C1GLC in 2002) [394,
421], it is possible that further undiscovered interactions may be located within some of the
trans pQTLs. Meanwhile, the TC-2 example demonstrates how the data from this study can
be integrated with existing knowledge to provide hypotheses for functional/epidemiological
follow up to elucidate the cobalamin pathway mechanisms in more detail.
Through the GDF-11/8 and BMP-6 examples, I show that trans pQTLs may be mediated
by levels of proteins in cis to the locus. Unmeasured mediators may explain the lack of
mediation at the other trans loci considered although increased proteome coverage in future
assays will address this. Insufficient myostatin has been shown to result in excessive muscle
growth [422], therefore myostatin has emerged as a promising therapeutic target for treatment
of conditions characterised by muscle weakness, such as muscular dystrophy [423]. BMP-6
is a positive regulator of osteogenesis and has recently been shown to upregulate hepcidin (a
key regulatory protein involved in inhibiting iron transport from cells) expression in mice
[417]. As a result, BMP-6 is a potential drug target for diseases related to iron metabolism
such as anaemia, and also possibly osteoporotic diseases [424]. The results here suggest
that WIFKKN2 and CHRDL2 are potential additional pharmaceutical targets in regulating
myostatin and BMP-6 levels respectively and illustrate how delineation of mediating proteins
at trans-associated loci may help identify additional drug targets in regulating a particular
target. The result also reveals the need to distinguish between free and bound-forms of a
protein, especially in the context of drug targeting. For example, targeting (inhibiting) the
bound-form (inactive) of a protein (assumed to have a activatory effect) will not have an
efficacious inhibitory effect as opposed to targeting the free (active) form. Despite the lack
of distinction of the assay between free and bound-forms of a protein, it is still nonetheless
a useful first step in identifying proteins that regulate the target of interest as leads for
downstream follow up using more specific assays.
Lastly I looked at the effects of O blood group (those who do not express modified
A or B antigens), secretor status and their interaction on plasma protein levels. Further
to reproducing previous associations with ABO blood groups and secretor status, I find
additional novel associations, further highlighting the biological pleiotropic effects at these
loci which likely reflect impact on a range of distinct biological modules rather than a result
of high correlation between the proteins measured. In particular I find that proteins associated
112
5.4 Discussion
with secretor status are more likely to be those highly expressed in tissues of the GI tract,
suggesting secretion of ABH antigens may affect plasma levels of these proteins directly
through interactions with ABH antigens in blood and/or indirectly, for example through
modulating the uptake of transport proteins from GI or mucal secretions into blood. I also
find evidence for effect modification between O blood group by secretor status on levels
of five proteins, all of which are novel findings, in addition to replicating the only such
interaction effect (ALPI) seen previously [420]. Taking into account the effects of FUT2
secretor genotype on biomarker levels (e.g. CA19-9, a marker for pancreatic cancer) when
deciding their clinical cut-off values can improve sensitivity and reduce false positives [425].
The findings here suggest that effect of blood group status as well as its interaction with
secretor status should also be considered. This relates in particular to GOLM1 (also known as
GP73) which has been proposed as a biomarker for prostate cancer and chronic liver disease
[426–428].
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Chapter 6
Disease relevance of pQTLs and their
application in MR
6.1 Introduction
The previous chapter has focused on the implication of pQTLs in biological pathways. This
chapter will focus on how pQTLs can be used to provide insights into pathways implicated
clinically in disease. Although GWAS of complex traits have yielded many associations,
most of these associations have resided in non-coding regions [54]. The disease causing
genes in GWAS loci are often based on biological priors such as variants in regulatory regions
of plausible genes and associated eQTLs assuming changes in expression translates to protein
level changes. A stronger case can be made with pQTLs which provides direct evidence
of alterations in protein levels due to variation in the genome. Whilst eQTLs have been
shown to be enriched amongst disease GWAS associated variants and have contributed to
prioritisation of causal genes in a GWAS locus (see Section 1.3.4), linking pQTLs to disease
associations have mostly been at an ad hoc basis in small scale pQTL studies. Therefore,
the first part of this chapter involves cross-referencing the discovered pQTLs with published
disease GWAS and testing whether disease associated variants are enriched for pQTLs.
In Chapter 1, I discussed the principles of MR in causal inference and how pQTLs can
make suitable genetic instruments for MR studies. The second part of this chapter uses
two distinct examples to highlight ways in which pQTLs and MR can be used to help with
causal evaluation of proteins in disease. I apply a combination of extensions to traditional
MR approaches to overcome some of the limitations with traditional univariate MR (see
Section 1.5 for details). In particular, the presence of horizontal pleiotropy, where the genetic
instrument(s) used may be associated with more than one protein in cis (e.g. in the case
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of variants in the IL1RL1-IL18R1 locus described in this chapter; Fig. 6.1a) will lead to
violation of univariate MR assumptions (Section 1.5). In these scenarios, multivariable MR,
(Fig. 6.1b) which uses multiple instruments associated with several measured risk factors
to simultaneously estimate the causal effect of each of the risk factors on the outcome (see
Section 6.2.5 for details) [315], can be used to account for potential horizontal pleiotropy.
The multivariable method has also been extended to take into account the correlation between
genetic instruments and utilises summary association statistics under a two-sample MR
framework, where the results for the genetic variants with protein levels and disease risk are
obtained from two independent samples.
Fig. 6.1 Schematics comparing univariate and multivariable MR. (a) Left: univariate MR assumptions
for genetic instrument, G, associated with outcome, Y , through risk factor, X . Confounders represented
by U . Right: Presence of horizontal pleiotropy shown by associations between the genetic instrument
with both risk factors X1 and X2. (b) Multivariable MR assumptions for genetic instruments, G1 to G3,
associated with the outcome through risk factors X1 and X2. It is not necessary for each variant to be
associated with every risk factor in the set. Causal estimates from multivariable MR represent direct
causal effects, representing the effect of intervening on one risk factor in the model while keeping
others constant.
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6.2 Methods
6.2.1 Disease annotation
To identify disease phenotypes that the pQTLs have been associated with, I queried the
sentinel variants and their strong proxies (r2 ≥ 0.8) against publicly available disease
GWAS data using PhenoScanner [356]. A list of datasets queried is available at http:
//www.phenoscanner.medschl.cam.ac.uk/information.html. For disease GWAS, results were
filtered to p< 5×10−8 and then manually curated to retain only the most statistically sig-
nificant entry per disease end-point. Non-disease endpoints such as anthropometric traits,
intermediate biomarkers and lipids were excluded manually.
6.2.2 Enrichment of disease associations for pQTLs
Disease-associated variants from published GWAS were downloaded from the NHGRI-EBI
GWAS Catalog v1.0.1 [429] (https://www.ebi.ac.uk/gwas/ [downloaded April 2016]). Ge-
nomic positions were converted to GRCh37 and variants not in the INTERVAL post-QC
imputed genetic data were excluded. Associations in non-Europeans were then filtered out,
as were associations that were not genome-wide significant (p≥ 5×10−8). 2,846 disease-
associated variants were retained by filtering on the "disease" EFO term (EFO_0000408)
and its children. Associations were further subsetted into major disease subclasses us-
ing the following EFO terms and their children: EFO_0000319 (cardiovascular disease
[n=242]), EFO_0000405 (digestive system disease [n=538]), EFO_0000589 (metabolic
disease [n=323]), EFO_0000540 (immune system disease [n=905]), EFO_0000618 (nervous
system disease [n=549]) and EFO_0000616 (neoplasm [n=678]).
Enrichment was assessed using a permutation-based approach previously described by
Nicolae et al [57]. To avoid bias due to LD, variants in the extended MHC region were first
removed due to its complex LD structure. I then LD-pruned the disease-associated variants
at r2 of 0.1. This procedure was repeated 100 times, each time randomly selecting which
correlated variant(s) to remove. For each LD-pruned set, 100 variant sets with the same
number of variants as the LD-pruned variants were randomly sampled, without replacement,
from the imputed genome-wide variants (excluding the extended MHC region) matched on
MAF (in bins of 0.05). For each variant set, I counted the number of variants that were
also pQTLs at the Bonferroni-adjusted threshold of p< 1.5×10−11 and the conventional
genome-wide threshold of p< 5×10−8. The proportion of the randomly permuted sets where
the pQTL overlap exceeded the disease overlap was used to obtain an empirical p-value.
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6.2.3 Selection of genetic instruments for MR
6.2.4 IL-1Ra and CHD
To replicate the previous univariate MR finding of IL1RA association with CHD and RA
[306], I used the same genetic variants from the study, rs6743376 and rs1542176, as genetic
instruments for IL1RA levels. Summary associations for CHD and RA were obtained
through PhenoScanner. CHD associations were from a recent large-scale 1000 Genomes-
based GWAS meta-analysis which consists mostly (77%) of individuals of European ancestry
[430]. RA associations were from the European cohort results in a large-scale trans-ethnic
meta-analysis [431].
MMP-12 and CHD
To test the hypothesis of whether plasma matrix metalloproteinase (MMP)-12 levels have
a causal effect on risk of CHD I used genetic variants in the MMP12 gene region to select
variants to act as IVs. I constructed a genetic score comprising of 17 variants that had a
cis association with MMP-12 levels at p< 5×10−8 and that were not highly correlated
with each other (r2 ≤ 0.2). To perform multivariable MR, I used association estimates for
these variants with other MMP proteins in the locus (MMP-1, MMP-7, MMP-8, MMP-10,
MMP-13). Summary associations for variants in the score with CHD for variants in the score
were obtained through PhenoScanner as described above.
Proteins in the IL1RL1-IL18R1 locus and AD
To identify the likely causal proteins that underpin the previous genetic association of the
IL1RL1-IL18R1 locus (chr11:102.5-103.5Mb) with atopic dermatitis (AD) [432, 433], I used
a multivariable MR approach. For each protein encoded by a gene in the IL1RL1-IL18R1
locus (IL18R1, IL1RL1, IL1RL2, IL1R1, IL1R2, IL18RAP), I took variants that had a cis
association at p< 1×10−4 and LD-pruned them at r2 of 0.1. I then used these as instrumental
variables for their respective proteins in univariable MR. For multivariable MR, association
estimates for all proteins in the locus were extracted for all instruments. European-ancestry
summary associations with AD for the selected variants were obtained from a recent large-
scale GWAS meta-analysis [432] through PhenoScanner. Where the relevant variant was not
available, the strongest proxy with r2 ≥ 0.9 was used.
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6.2.5 MR analysis
Univariate MR
Two-sample univariate MR was performed for each protein separately using summary
statistics using the inverse-variance weighted (IVW) method [266, 267] adapted to account
for correlation between variants [268]. In detail, for each of G genetic variants (g = 1, ...,G)
with estimate of the association with protein βˆXg and its standard error σXg , and estimate
of the association with risk of disease (AD or CHD) βˆYg and standard error as σYg , the IV
estimate (βˆIV ) is:
βˆIV =
∑Gg=1 βˆXg βˆYgσ
−2
Yg
∑Gg=1 βˆ 2Xgσ
−2
Yg
(6.1)
The variance of the estimate of the causal effect for a variant, var(βˆIVg), can be calculated
using the delta method [434], which including first and second-order terms, is:
var(βˆIVg) =
σ2Yg
βˆ 2Xg
+
βˆ 2Ygσ
2
Xg
βˆ 4Xg
− 2θβˆYgσYgσXg
βˆ 3Xg
(6.2)
where θ is the correlation between estimates βˆXg and βˆYg . βˆXg and βˆYg are assumed to be
independent (i.e. θ = 0) as they were estimated from non-overlapping samples. In addition,
the second (and higher) order terms can be assumed to be negligible as the estimate of βˆXg
is more precise than βˆYg and the leading term will dominate [267]. Therefore, using the
first-order term of the delta method, the approximate standard error of the causal estimate,
se(βˆIV ), can be calculated as[266]:
se(βˆIV ) =
√
1
∑Gg=1 βˆ 2Xgσ
−2
Yg
(6.3)
The method above can be extended to account for correlation between IVs [268] where
the MR estimate, βˆIVc , is obtained from generalized weighted linear regression of the genetic
associations with the outcome (βˆY ) on the genetic associations with the protein (βˆX ) weighting
for the precisions of the genetic associations with the outcome and accounting for correlations
between the variants according to the regression model:
βˆY = βˆIVc βˆX + ε,ε ∼ N(0,Ω) (6.4)
where βˆY and βˆX are vectors of the univariate (marginal) genetic associations, and the
weighting matrix Ω has terms Ωg1g2 = σYg1σYg2ρg1g2 , and ρg1g2 is the correlation between
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the g1th and g2th variants. The IV estimate from this method is:
βˆIVc = (βˆ
T
X Ω
−1βˆX)−1βˆTX Ω
−1βˆY (6.5)
and the standard error is:
se(βˆIVc) =
√
(βˆTX Ω−1βˆX)
−1
(6.6)
where T is the matrix transpose. This is the estimate and standard error from the regression
model fixing the residual standard error to 1 (equivalent to a fixed-effects model in a meta-
analysis).
Multivariable MR
To account for potential effects of horizontal pleiotropy [261], I performed multivariable MR
using the weighted regression-based method proposed by Burgess et al [435]. For each of
K risk factors (proteins) in the model (k = 1, ...,K), the weighted regression-based method
is performed by multivariable generalized weighted linear regression of the association
estimates, βˆY , on each of the association estimates with each risk factor, βˆXk , in a single
regression model:
βˆY = βˆIV1 βˆX1 + βˆIV2 βˆX2 + · · ·+ βˆIVK βˆXK + ε,ε ∼ N(0,Ω) (6.7)
where βˆX1 is the vector of the univariable genetic associations with risk factor 1, and so
on. This regression model is implemented by first pre-multiplying the association vectors
by the Cholesky decomposition of the weighting matrix, and then applying standard linear
regression to the transformed vectors. Estimates and standard errors are obtained fixing the
residual standard error to be 1 as above.
MMP-12 genetic score sensitivity analyses
I performed two sensitivity analyses to determine the robustness of the MR findings. Plasma
levels of MMP-12 were measured using a PEA-based affinity assay (Olink Bioscience,
Uppsala, Sweden) (see Section 1.4.3 for description of the method) in a sub-sample of 141
individuals, and were used to derive genotype-MMP12 effect estimates for the 17 variants in
the MMP-12 genetic score. Second, I obtained effect estimates from a pQTL study based on
SOMAscan assay measurements in an independent sample of ∼ 1,000 individuals from a
German cohort [257].
119
Disease relevance of pQTLs and their application in MR
6.3 Results
6.3.1 Using pQTLs to inform biological pathways underlying disease
susceptibility loci
GWAS have identified thousands of loci associated with common diseases, but the pathways
by which most variants influence disease susceptibility await further elucidation. To identify
intermediate links between genotype and disease, I overlapped pQTLs with disease-associated
genetic variants identified through GWAS (p < 5×10−8). 152 of the sentinel pQTLs were
strongly correlated (r2 ≥ 0.8) with variants significantly associated with disease (Table S16),
including 38 with cis associations, 109 with trans associations and 5 with both. For example,
rs10993994 associated with Beta-Microseminoprotein (also known as "Prostate Secretory
Protein Of 94 Amino Acids", encoded by the MSMB gene) levels (p= 4.2×10−589), was also
associated with prostate cancer susceptibility (p = 9×10−29) [436]; rs2271893 associated
with "Lectin, Mannose Binding 2 Like" protein (also known as VIP36-like, encoded by the
LMAN2L gene) levels (p = 4.4×10−24), was also associated with bipolar disease risk [437,
438]. Using autoimmune diseases as examples below, I illustrate how the findings here can
provide new insights into disease pathways.
Previous association studies have identified a missense allele (rs3197999:A, p.Arg703Cys)
in Macrophage Stimulating 1 (MST1) on chromosome 3 that increases risk of inflammatory
bowel disease (IBD) (Fig. 6.2) [439, 440], and decreases plasma MST1 levels [256]. I
show that this polymorphism acts in trans to reduce abundance of B-Lymphocyte-Induced
Maturation Protein 1 (BLIMP1), encoded by PR/SET Domain 1 (PRDM1) on chromosome 6
(Fig. 6.2, Table S3). BLIMP1 is a transcriptional master regulator that plays a critical role in
the terminal differentiation of immune cells. Intriguingly, there is another IBD association
signal in the intergenic region adjacent to PRDM1 on chromosome 6 (Fig. 6.2) [440]. Both
PRDM1 and its neighbour Autophagy Related 5 (ATG5), which encodes a protein involved
in autophagy, are plausible candidate genes at this locus. The data here implicate BLIMP1
as a previously unidentified mediator of the IBD association in MST1 on chromosome 3. In
addition, the results provide indirect support for the hypothesis that PRDM1 is the causal
gene underlying the chromosome 6 association.
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Fig. 6.2 Trans pQTL for BLIMP1 at an IBD associated genetic variant in MST1. (a) Missense variant
rs3197999 in the MST1 region on chromosome 3 is associated with IBD (top) and BLIMP1 levels
(bottom). (b) Regional association plot of the IBD susceptibility locus on chromosome 6 adjacent to
the PRDM1 gene, which encodes BLIMP1. IBD association data are for European participants from
Liu et al, 2015. (c) Boxplot for relative plasma BLIMP1 levels (normalised residuals) by rs3197999
genotype, stratified by the two subcohorts used in this analysis.
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The pQTL data can also be used to elucidate pathogenic mechanisms. Anti-neutrophil
cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease characterised by
autoantibodies to the neutrophil proteases proteinase-3 (PR3) or myeloperoxidase (MPO).
Clinico-pathological features mirror antibody specificity, with granulomatous inflammation
typically correlating with anti-PR3 antibodies (PR3+ AAV). GWAS have identified signals
in PRTN3 (gene encoding PR3) and SERPINA1 (gene encoding α1-antitrypsin, an inhibitor
of PR3) specific to PR3+ AAV [441]. I identified a cis pQTL immediately upstream of
PRTN3 (Table S3, Fig. 6.3). By linking the risk allele at PRTN3 to higher plasma levels of
the autoantigen PR3, the data strongly suggest a pathogenic role of anti-PR3 antibodies in
this disease.
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Fig. 6.3 Regional association plot of the cis PR3 pQTL. A similar association pattern was seen for the
alternate SOMAmer PR3 target (see Fig. B.3 in Appendix B).
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The vasculitis risk allele at the SERPINA1 locus (rs28929474:T, also known as the ‘Z’
allele) is a missense variant (p.Glu366Lys) resulting in defective secretion of α1-antitrypsin,
which clinically also leads to early onset emphysema and liver cirrhosis. I found that
the Z allele was not only associated with lower plasma α1-antitrypsin, but was also a
pQTL "hotspot" associated with 13 proteins using the conservative significance threshold
(p < 1.5×10−11) (Fig. 6.4 (top)) and 19 at p < 5×10−8. This finding illustrates how a
single mutation can lead to widespread perturbation of downstream proteins. There was weak
to moderate correlation between the proteins but the pleiotropic associations at this locus
were not driven by high correlations between proteins (Fig. 6.4 (bottom)). The associated
proteins cover a range of biological functions (Table S17) and there was no functional
evidence to suggest that any of these proteins interact with each other. One of these proteins
was Neutrophil Cytosolic Factor 2 (NCF2), which plays a key role in neutrophil oxidative
burst involving nicotinamide adenine dinucleotide phosphate-oxidase dependent superoxide
production. Mutations in NCF2 which prevents formation of reactive oxygen species can
result in a rare condition known as chronic granulomatous disease, which like PR3+ AAV
exhibits granulomatous inflammation. Therefore, the results here suggest NCF2 may mediate
this characteristic feature of PR3+ AAV. Other associated proteins did not have obvious
implications in vasculitis, although 4 of the proteins have been implicated in congenital
disorders (Table S17).
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6.3 Results
Fig. 6.4 Missense variant rs28929474 in SERPINA1 is a trans pQTL hotspot. (Top) Circos plot of
the trans associations. Numbers (outermost) indicate chromosomes. Interconnecting lines link the
genomic location of rs28929474 and the genes encoding significantly associated (p < 1.5×10−11)
proteins. Line thickness is proportional to the effect size of the associations with red positive and blue
negative. (Bottom) Correlation heatmap of the trans associated proteins.
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Disease relevance of pQTLs and their application in MR
The FUT2 locus which determines the secretor status described in the previous chapter
has been previously associated with a range of (primarily autoimmune) diseases [442]
and I explored the extent to which the novel protein associations (C-C chemokine ligand
(CCL)-15, CCL-25 and fibroblast growth factor 19 (FGF19)) implicated candidate pathways
underpinning two of these disease associations - Crohn’s disease and primary sclerosing
cholangitis (PSC). Boxplot of the protein levels by genotype of the variant (rs601338)
encoding secretor status showed non-additive effects with decreased protein levels only in
those homozygous for the A (non-secretor) alleles (Fig. 6.5), strongly supporting the view
that this is the causative biological effect underlying the association at this locus. Crohn’s
disease (a type of IBD, characterised by inflammation of the GI tract) has been associated
with secretor status [443] and I showed that secretor status was associated with CCL-25
and CCL-15 levels (Table S15, Fig. 6.5), two chemokines strongly expressed in intestinal
cells and previously suggested to play a role in IBD [444, 445]. PSC, a disease associated
with Crohn’s disease characterised by inflammation and fibrosis of bile ducts, has also been
associated with secretor status [442]. CCL-25 has also been implicated in the recruitment
of C-C chemokine receptor (CCR)-9-positive lymphocytes to the liver in PSC. In addition,
secretor status was associated with levels of FGF19 (Table S15, Fig. 6.5), which is involved
in regulation of bile acid synthesis and cholestatic liver disease [446]. A recent study showed
that engineered FGF19 analogue reduced liver injury and reversed sclerosing cholangitis in
mice models of cholangiopathy [447]. Hence FGF19 is a strong candidate for the effector
gene underlying the association between secretor status and PSC specifically, CCL-15 the
candidate underlying the secretor status association with Crohn’s disease and CCL-25 the
candidate underlying the common pathway behind secretor status association with both
diseases.
6.3.2 Enrichment of disease GWAS associations for pQTLs
To test whether the disease GWAS associations were enriched for pQTLs, I employed a
permutation-based enrichment approach [57] (Section 6.2.2). As sensitivity analyses, I ran
the enrichment test using pre and post PAV conditioned summary results, as well as using
the conventional genome-wide threshold of p < 5×10−8. I found that disease associated
variants are on average more than two and a half times more likely to be pQTLs compared
to the background MAF-matched variants randomly drawn from the genome (p < 0.0001,
Table S18). In addition I found evidence of enrichment across all disease subclasses except for
"neoplasm". I saw little effect of PAVs on the significance of the enrichment for all diseases
and disease subclasses, except for "nervous system diseases" where enrichment p attenuated
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Fig. 6.5 Boxplot of FGF19, CCL15 and CCL25 protein levels by rs601338 genotypes.
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Note: Two boxplots are shown for CCL15 and CCL25 as there are two SOMAmers used to assay CCL15 and
CCL25.
but remained nominally significant. I found similar results using both p < 1.5×10−11 and
p < 5×10−8 thresholds (Table S18).
6.3.3 Causal evaluation of candidate proteins in disease through MR
This section uses two examples to illustrate different ways in which pQTLs can be used
to assess evidence of causal association between plasma protein levels and disease risk
through two-sample multivariable MR, using summarised data and accounting for correlation
between the genetic instruments.
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MMP-12 levels and CHD risk
Various MR studies have shown various lipids and inflammatory cytokines to be causally
implicated in CHD, one of the world’s leading cause of mortality and morbidity [448] (see
Section 1.5.2). A recent study showed that a risk score based on levels of 9 proteins can be
used to predict cardiovascular events [449]. For one of the 9 proteins, MMP-12, there was a
cis associated locus where the variants can act as suitable genetic instruments. MMP-12 is
an elastase enzyme involved in the breakdown of extracellular matrix and its levels have also
been associated with atherosclerotic burden in those with T2D. Therefore, I used multiple
cis-associated variants to evaluate whether plasma MMP-12 plays a causal role in CHD
(Table S19, Fig. 6.6).
Fig. 6.6 Regional association plot of the MMP12 cis locus. The variants selected as genetic instruments
through LD-pruning are highlighted in green.
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6.3 Results
First I attempted to replicate the previous MR association with CHD using protein
measurements made in this study as a positive control before testing the association between
plasma MMP-12 levels and CHD risk. A previous study, which showed IL1RA levels to
be causally associated with CHD risk, measured IL1RA in a similar sized sample as this
study (n=3,081) [306]. Using the same two independent variants from [306] as instruments
(rs6743376 and rs1542176), I found IL1RA levels also to be positively associated with
CHD risk (p = 8.8×10−4, Fig. 6.7). I also replicated the inverse association with RA
(p = 1.8×10−3), where summary results for the disease association [431] were also publicly
available.
Fig. 6.7 MR results for the effect of plasma IL1-Ra levels on CHD and RA risks. Forest plot of
univariate MR estimates for IL1-Ra and risk of CHD.
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Observational studies report associations of higher levels of plasma MMP-12 with
recurrent cardiovascular events [449, 450]. In contrast, the multi-allelic genetic score, which
explains 14% of the variation in plasma MMP-12 levels, showed that genetic predisposition
to higher MMP-12 levels is associated with decreased coronary disease risk (p = 2.8×10−13,
Fig. 6.8). The multivariable MR approach adjusts for the effects of other MMPs in the region
(MMP-1, 7, 8, 10 and 13) and showed no independent effects the other proteins on CHD
risk (Table S19). However, the MMP-3 SOMAmer did not pass QC in the assay. The results
were robust to the two sensitivity analyses (using an alternate assay ("Olink") and MMP-12
estimates from an independent sample ("Suhre")) used (Section 6.2.5, Fig. 6.8b). In addition,
the allele (rs2276109:T, r2 = 1.0 with the sentinel MMP-12 pQTL variant rs28381684)
associated with higher plasma MMP-12 levels (p = 8.7×10−111) has also been shown to be
associated with increased MMP12 promoter activity, increased binding of transcription factor
AP-1, increased mRNA expression and lower fibrinogen levels [451, 452]. Other alleles
associated with higher MMP-12 levels, have also been robustly associated in GWAS with
decreased risk of large artery atherosclerotic stroke [453], but poorer pulmonary function
and increased risk of chronic obstructive pulmonary disease (COPD) [454, 455].
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Disease relevance of pQTLs and their application in MR
Fig. 6.8 MR results for the effect of plasma MMP-12 levels on CHD risk. (a) Scatter plot of changes
in CHD risk against changes in MMP-12 levels with 95% confidence intervals. Red line represents
the MR estimate. (b) Forest plot of univariate and multivariable MR estimates for MMP-12 and risk
of CHD. Olink and Suhre in parentheses indicate the MR results using MMP-12 measured using the
Olink assay and data from Suhre et al respectively (Section 6.2.5).
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6.3 Results
Disentangling multiple related candidates causally associated with AD risk
In the second example, I use the multivariable MR approach to distinguish causal genes
in a complex locus harbouring multiple genes with similar functions. The IL1RL1-IL18R1
locus on chromosome 2 contains a cluster of genes in the interleukin 1 receptor family
(IL1RL1, IL1RL2, IL18R1, IL1R1, IL1R2 and IL18RAP). I identified four proteins that each
had cis pQTLs at this locus (Table S3, Fig. 6.9), which has been associated with a range of
immune-mediated diseases including AD [432, 433].
Fig. 6.9 Regional association plots of the IL1RL1-IL18R1 region showing the cis pQTLs and atopic
dermatitis (AD) GWAS locus.
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AD, is a common form of eczema, characterised by chronic inflammation of the skin.
The regional association plots showed obvious overlap of signals with the AD association
for IL18R1 and IL1RL1, whilst the overlap was less clear for IL1RL2 and IL1R2 pQTLs
(Fig. 6.9). The functional similarities between the interleukin family proteins in this locus
make it difficult to suggest the likely causal candidate(s) based on biological roles alone. I
created a genetic score for each protein using multiple protein-increasing alleles (Table S19).
Initial "one-protein-at-a-time" analysis (univariate MR unadjusted for the effects on other
proteins in the locus) identified associations of the scores for IL18R1 (p = 9.3×10−72) and
IL1RL1 (p = 5.7×10−27) with AD risk Fig. 6.10). In addition, I found a weak associa-
tion for IL1RL2 (p = 0.013). I then mutually adjusted these associations for one another
(multivariable MR) to account for the effects of the variants on multiple proteins. While the
association of IL18R1 remained significant (p = 1.5×10−28), the association of IL1RL1
(p = 0.01) was attenuated. In contrast, the association of IL1RL2 (p = 1.1×10−69) became
much stronger, suggesting that IL1RL2 and IL18R1 are the causal proteins influencing risk
of atopic dermatitis at this locus.
Fig. 6.10 Forest plot of univariate and multivariable Mendelian randomisation (MR) estimates for
proteins in the IL1RL1-IL18R1 locus and risk of atopic dermatitis (AD). No univariate MR estimates
available for IL1R1 and IL18RAP due to no significant pQTLs to select as a genetic instrument.
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6.4 Discussion
This chapter uses bioinformatic approaches to link pQTLs to disease GWAS loci and high-
lights the utility of pQTLs in linking protein candidates to disease GWAS loci to help suggest
potential pathways connecting the loci to disease. I find that the secretor status has pleiotropic
associations with both protein levels and risk of several diseases/pathopysiological endpoints.
The findings also reveal the possibility that different pathways may be mediating the associa-
tion between secretor status and different diseases. Although functional studies are needed to
elucidate and experimentally test how disease loci are connected to disease susceptibility, the
data here nonetheless generate hypotheses to be tested that may not be obvious previously.
Whilst disease associated variants have been shown to be enriched for eQTLs, there have
been no analogous analysis looking at pQTLs, possibly as a result of limited number of
pQTLs identified due to small number of proteins tested or limited sample size in previous
studies. Leveraging on the large scale of this study, I show for the first time that variants
associated with risk of disease and various subclasses of diseases are enriched for pQTLs.
This observation is perhaps unsurprising given that proteins are expected to be the functional
units that drive the association at a particular disease locus. Thus, in addition to using eQTLs
and epigenetic annotations, pQTLs, at least for proteins reflecting those on this assay, can
also help to inform biological interpretation at disease GWAS loci. Future studies using
non-targeted proteomic approaches with large coverage would shed light on whether the
enrichment of GWAS loci for pQTLs can be generalised to the entire proteome, although the
bias towards more abundant proteins where sensitivities are higher needs to be accounted for.
In the third part of this chapter I show how cis pQTLs can be used as genetic instruments
in MR to assess evidence for causal associations between plasma protein levels and disease
risk. Through the IL1RL1-IL18R1 locus example, I show how using instruments for multiple
proteins in a locus via multivariable MR can be used to account for potential horizontal
pleiotropic effects and help disentangle causal proteins in a complex locus. In univariate
MR, where the effect of the genetic instruments on each protein was considered in isolation,
IL18R1 and IL1RL1 are likely considered as strong candidates for having causal effects on
AD risk. However, by adjusting for the effects of the genetic instruments on other interleukin
1 receptor family proteins in the locus (a potential source of horizontal pleiotropy that violates
one of the assumptions of univariate MR (Section 1.5.1)) in multivariable MR, I would de-
prioritise IL1RL1 and consider IL1RL2 as a stronger candidate than IL1RL1. Some studies
have only considered the effect of genetic variants on a single protein (e.g. IL1RL1) in the
locus or effect of a single protein in isolation with disease [206, 456–459]. The findings here
emphasise the importance of considering effects of the other proteins in the locus, at least
those that are functionally related (i.e. the other interleukin 1 receptor family proteins in
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this example), which can act as highly plausible confounders. Otherwise, the results would
fail to take into account the effect of the confounders and potentially lead to biased effects
being estimated (e.g. the univariate vs multivariable MR estimates for IL1RL1 and IL1RL2,
Fig. 6.10).
The example of MMP-12 and CHD demonstrates how the pQTL data can be used
to inform drug targeting. MMP-12 (also known as macrophage metalloelastase) is an
elastase secreted by macrophages which is involved in the break down of the extracellular
matrix. Studies in vitro and in model organisms have not established conclusive evidence
for whether the role of MMP-12 is cardioprotective or not [460, 461]. The MR results here
show that higher plasma MMP-12 reduces the risk of CHD. Although the multivariable
approach adjusts for the effects of the MMP-12 score on MMP-1, 7, 8, 10, 13 levels on
CHD risk, the unmeasured proteins, in particular MMP-3 could potentially be a source of
horizontal pleiotropy. Incorporating the effect of the genetic score on MMP-3 from other
studies may resolve this limitation. As MMP-12 is released from macrophages in response to
cardiovascular injury [462, 463], it is possible that higher MMP-12 levels are cardioprotective
and could explain the observational association of higher circulating MMP-12 levels in those
with existing CHD [449]. The results here are consistent with the fact that variants associated
with higher MMP-12 are also associated lower fibrinogen levels (a well-known correlate of
CHD risk, see Section 1.5.2) [452] and with reduced risk of several CHD related phenotypes:
advanced carotid atherosclerotic lesions [452] and large artery atherosclerotic stroke [453,
464]. Since MMP-12 is known to play a role in lung damage, MMP-12 specific inhibitors
are being tested in COPD [465]. The opposing direction between the effect of MMP-12
increasing alleles on CHD and COPD risk suggests a potential, long-term cardiovascular
safety concern for MMP-12 inhibitors (currently aimed primarily at treating airway diseases
such as COPD [465]), particularly as patients with COPD are at high baseline cardiovascular
risk due to smoking history.
In summary, this chapter shows the utility of pQTLs as an additional data source in anno-
tating disease loci and demonstrates how the pQTL data can be used to uncover intermediate
molecular pathways that connect the genome to disease endpoints. Previous investigation has
focused on genes in the vicinity of disease susceptibility loci. By contrast, advances are made
here through the use of trans pQTLs to implicate previously unsuspected proteins encoded
by distant genes. Furthermore, I used pQTLs for multiple proteins in MR to disentangle
candidate causal proteins at complex disease loci and assess causal associations between
soluble protein levels and disease risk, both of which can help inform drug targeting. Proteins
provide an ideal paradigm for MR analysis because they are under proximal genetic control.
Whereas MR studies of plasma proteins have been constrained by availability of few suitable
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genetic instruments, the data here alleviate this limitation through furnishing an extensive
catalogue of instruments.
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Chapter 7
Discussion and conclusion
7.1 Introduction
This chapter first summarises the work carried out in this thesis with overarching discussions
from chapters 2-6. Specific discussion points are contained within the discussion sections
of each corresponding chapter. I will then discuss the general limitations of the work and
suggest future directions to extend the body of knowledge in this field further.
7.2 Summary of work
In this thesis, I have identified many novel genetic variants that regulate human plasma protein
levels and exemplified ways in which pQTLs can be used to further the understanding of
biology and disease. The work presented in this thesis highlights three key novel contributions
to the scientific literature: (1) significant advances on existing knowledge of genetic regulation
of the human plasma proteome, (2) helps to generate biological hypotheses for further follow
up and (3) provides a valuable resource for functional annotation and MR. Prior works
focusing on pQTLs have been limited in scope in terms of sample size or proteome coverage
and there has only been a handful of multi-protein pQTL studies performed at the start of
this project (see Section 1.4.5). This was mainly due to technical challenges in large-scale
multiplex measurements of human plasma proteins, in addition time-consuming and cost
factors. Whilst multi-protein pQTL efforts making use of recent advances in affinity-based
proteomic technologies have been garnering attention in the last two years, the work in this
thesis is the most comprehensive to date. I found many novel pQTLs and in the process
replicated many of the existing ones in the literature. Owing to an unprecedented combination
of sample size and proteome coverage, I was able to shed light on the genetic architecture
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of the plasma proteome, drawing parallels with what has been seen in the eQTLs literature.
This was an area which has only been briefly touched on previously where studies rarely
went beyond dividing pQTLs into cis and trans. Interestingly, some of the loci with trans
associations in previous single protein GWAS (e.g. ABO) have pleiotropic associations
with many proteins, once again highlighting the power of proteomic compared to single
protein approaches in elucidating the genetic underpinnings of plasma protein levels. I
have demonstrated, through various examples, the biological relevance of pQTLs such as
how trans pQTLs highlight potential plasma protein-protein interactions and application
of pQTLs in enhancing understanding of biological pathways. This should pave way for
further functional follow up at many of the novel associations to elucidate the mechanisms
underlying the other pQTLs, especially trans ones where the biological connection is less
well understood. In addition, the work presented here also serves as a valuable resource for
the wider scientific community for functional annotation of GWAS loci, complementing the
wealth of currently available molecular QTL data (e.g. eQTLs, mQTLs and epigenetic QTLs)
and helping researchers to illuminate molecular pathways linking the variant to complex
traits, especially for signals located in non-coding regions. Furthermore, pQTLs also reflects
effects not captured at the transcription level. MR is also a field gaining traction in the last few
years allowing researchers to look at the causal effect of certain protein biomarkers on disease
risk at epidemiological scales (see Section 1.5). However, there have been limitations in
terms of high quality genetic instruments and horizontal pleiotropy. The cis pQTLs generated
here provide a "catalogue" of quality genetic instruments due to their favourable properties
for MR (see Section 1.5.3) and greatly alleviate the current bottleneck. For complex regions
with multiple similar functional genes and higher potential for horizontal pleiotropy, the
broader proteome coverage here allows potential pleiotropic effects to be accounted for
through multivariable MR approaches.
Chapter 2 introduced the INTERVAL cohort used for this thesis. INTERVAL participants
are composed of healthy blood donors with no specific focus on any targeted sub-populations
and therefore proteomic measurements in samples from these individuals are unlikely to
be affected by disease processes or confounded by specific subgroups (e.g. specific age
groups). Furthermore, the proteomic measurements made in INTERVAL represent baseline
levels of a healthy population, which is something often under-appreciated and previously
under-explored as many studies tend to focus on specific disease subgroups with a limited
number of controls.
A multiplex affinity-based proteomic assay was used to measure plasma levels of more
than 3,000 proteins which is at least twice the proteome coverage of previous studies,
challenging the current limitations to plasma proteomic measurements (Chapter 1). I showed
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that the proteomic measurements were highly reproducible, with CVs in-line with other
affinity-based assays. In addition, I find that the assay can produce biological meaningful
signals - reproducing many of the expected associations (e.g. with age, gender, BMI and
eGFR).
Genotyped variants were imputed to a recent large scale reference panel with higher
imputation quality compared to using previous reference panels, especially for low-frequency
variants, improving on genetic resolution of previous studies. Due to the large scale of data
(analysing∼ 10.6 million variants per trait for more than 3,000 traits in∼ 3,300 individuals),
I first optimised the analysis pipeline prior to genetic association analyses, comparing across
several commonly used GWAS tools and methods. I find that the simple method of using
"allelic dosages" is the most efficient approach with adequate control for false positives
compared to more sophisticated methods.
After stringent QC in Chapter 2, I proceeded to performing the GWAS in Chapter 3.
I found a total of 1,927 associations with 1,478 proteins across 764 genomic regions, sig-
nificantly expanding the repertoire of known pQTLs. The pQTLs identified indicate that
many plasma protein levels are partly under genetic control. In the process, I also replicate
many previous pQTLs, suggesting that pQTLs, especially cis ones, are often robust across
studies. Chapter 4 characterised the discovered pQTLs in more detail. First I made a
systematic attempt to address the commonly overlooked issue of PAVs which may affect
aptamer binding. I find that more than two-thirds of cis pQTLs are unlikely to be subject to
this problem. In terms of the genetic architecture, I find that the majority of cis pQTLs are
concentrated around the gene encoding the protein, suggesting they are heavily under local
regulation similar to what has been observed in eQTL studies. Enrichment of pQTLs for
missense variants suggests that functional variants are likely to have a larger effect on protein
levels compared to non-coding variants. Furthermore, results from overlap with eQTLs
suggest plasma protein abundance is often but not exclusively driven by gene expression,
consistent with similar observations made previously.
Further to the discovery and broad level characterisation of pQTLs, Chapters 5 and
6 illustrate novel biological and disease implications of pQTLs. In Chapter 5, I showed
examples of plausible biological interactions linking trans pQTLs and how trans pQTLs
can be mediated by the protein in cis to the trans locus, highlighting the role of protein-
protein interactions. Through integrating with evidence from other studies, the data here
also provide hypotheses for further functional follow-up. In addition, I also find evidence
of interaction between genetically determined blood groups and secretor status on protein
levels, suggesting that modified blood antigens and their secretion combine to affect plasma
protein abundance. This also suggests that gene-by-gene interactions can also play a role
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in regulating plasma protein levels. In Chapter 6, I cross-referenced the pQTL results with
published disease GWAS variants and I show that disease associated variants are enriched for
pQTLs, highlighting their relevance and utility in biological interpretation of disease GWAS
loci. Using autoimmune diseases as examples, I demonstrated how the pQTLs can be used to
provide insights into possible mechanisms linking disease loci.
Lastly in Chapter 6, two examples were used to illustrate ways in which cis pQTLs can
be used to evaluate the causal association between protein levels and disease risk through the
MR paradigm. By measuring multiple functionally related proteins simultaneously within
the Il1RL1-IL18R1 locus, I am able to dissect the effect of individual protein levels on the risk
of AD adjusting for the effects of other related proteins in the locus through multivariable
MR. The results suggest that univariate analyses which fail to account for the effect of
other proteins can lead to confounded estimates. The MMP-12/CHD example tested the
causal association between a candidate protein and disease risk and I find increased MMP-12
levels lead to decreased CHD risk. The results are consistent with previous evidence of
MMP-12 increasing alleles on MMP-12 gene expression, decreased levels of CHD marker
and decreased risk of related atherosclerotic disease. Interestingly, the genetic evidence
points to an opposite effect of MMP-12 levels on COPD risk, revealing a potential long-term
safety concern for MMP-12 inhibitors currently developed to treat COPD. The pQTL data
here present an extensive catalogue of genetic instruments for MR studies.
7.3 Limitations of work and recommendations for future
research
Specific limitations have been discussed in the relevant chapters. This section will focus on
general limitations of the work in this thesis.
The strengths and limitations of the aptamer-based platform are in principle largely
similar to all affinity-based assays as discussed in Chapter 1. Whilst the aptamer-based
platform used here by far has the largest proteome coverage compared to other approaches,
there has been limited evidence on assay performance as a whole in the literature. In addition,
there is also the question of specificity of the aptamers to the protein target which has
only been tested on an ad hoc basis. This potential problem also affects antibody assays
although there are more data available on antibody specificities for a range of antibody
probes due to their wide usage. The results of this study which reproduces many of the
previous biological (e.g. age and sex) and genetic associations suggest that the assay is
highly reproducible. The cis pQTLs in particular also lend support to the specificity of
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aptamers, at least for those targeting the proteins with the cis associations. Studies in the
literature which compared aptamer-based with antibody-based assays for a limited set of
overlapping proteins showed comparable performance between aptamer and antibody-based
approaches although agreement also varied depending on the proteins examined [466, 467].
In addition, comparisons and follow-up with mass spectrometry and gene transcript levels
have demonstrated specificity for many of the aptamers as well as complementarity with
MS-proteomics and transcriptomics platforms [333, 468]. However, the specificity of the
remaining aptamers requires additional albeit time consuming investigations such as MS with
aptamer pull-downs or affinity capture experiments with other proteins. Similar to antibody
approaches, aptamer-based assays may not able to differentiate bound versus free-forms of
a protein (see Chapter 5) and post-translational modifications such as phosphorylation and
glycosylation. Nonetheless, the assay is still useful as a first step to short-list candidates for
more detailed follow-up with more specific methods.
Despite significantly improving on proteome coverage of previous human soluble pro-
teomic studies, the current largest coverage proteomic technology, such as the one used
here, still only measures up to around one tenth of the entire human proteome. However,
it is unlikely that the entirety of the human proteome is present in plasma. Many of the
intracellular proteins are under-represented on the assay used in this study, where probe
selection is driven by the available of purified proteins in addition to proteins known to be
involved in pathophysiology of disease. Therefore, enrichment of disease variants for pQTLs
seen in this study may not be generalisable to the entire human proteome. On the other hand,
the selection of proteins for the assay should not have systematically different effects on
genetic regulation and eQTL enrichment compared to the rest of the proteome. On a smaller
note, the aptamer assay used here provides relative quantification. This is not problematic in
pQTL mapping as the focus is on the relative differences in protein levels between people of
different genotypes. However, absolute quantification becomes more important in studies
under pathophysiological or clinical contexts.
This study has discovered many novel pQTLs and further additional discoveries are
expected in larger studies with more power to detect novel loci and additional independent
associations within loci. Unfortunately, current proteomic assays are costly and prohibit
large-scale studies (in the tens of thousands). The SOMAscan assay costs around $1,000 per
sample, which is prohibitively expensive for biobank sized measurements despite a relatively
cheap per-data point cost of < $0.3 per sample. Similar to the falling cost of genotyping and
sequencing measurements, the cost for proteomic measurements could follow in the same
footsteps in future to facilitate their wider uptake. Nonetheless, additional power can be
achieved presently through GWAS meta-analysis of pooled data from other sources that have
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proteomic and genetic measurements. The approach has been previously successfully applied
for specific proteins such as CRP [154] and for various disease traits [46]. The pooling
of proteomic data from different sources that used different assay methods would not only
increase the power to detect additional pQTLs but also help to establish a subset of robust
pQTLs across assay methods as well as across cohorts. Furthermore, pooled analyses will
also help distinguish study-specific pQTLs, allowing for further investigation into why they
occur. In parallel, additional efforts into more extensive characterisation of different assay
technologies will provide additional information on assay performance for an increasing
number of proteins on multiplex assay platforms, as exemplified in [333, 468]. There are
some challenges distinct from those experienced when combining data from multiple disease
GWAS that need to be addressed when combining proteomic data. One major challenge is
that quantification differs between proteomic technologies; some use relative quantification
with calibrators such that the units are not comparable between studies whilst some use
absolute quantification. Harmonising across different units of quantification across assays
will require additional normalisation steps to ensure systematic biases are accounted for prior
to combining the data together. Furthermore, protein levels are also driven by environmental
factors such as diet where Western diets with higher fat contents may influence plasma lipid
related proteins differently to those from Asia. Different prevalences of infections across
different regions may also influence levels of certain plasma proteins such as inflammatory
markers. Non-genetic factors along with pre-analytical blood sample processing which may
have systematic differences across studies and assay platforms need to be properly accounted
for when pooling together data to avoid spurious results.
Most of pQTL studies so far, including this one, have been performed predominantly
in those of European ancestry and therefore may not be representative of effects in other
ethnic populations. Trans-ethnic GWAS meta-analyses have been successfully applied in
various disease and non-disease contexts [469]. Performing pQTL studies in samples from
other ethnic populations will be able to establish pQTLs shared across different populations
and those that are specific to certain ancestries. Moreover, under some circumstances, pQTL
mapping in multi-ethnic cohorts can significantly increase power to detect associations, as
genetic drift may elevate allele frequencies of some variants in different populations, thus
increasing the power to detect an association [470]. However, care needs to be taken to avoid
population stratification giving rise to spurious associations. More sophisticated approaches
in addition to adjusting for global ancestry through principal components such as linear mixed
models or admixture mapping may be required to sufficiently account for confounding due
to population structure [469]. Moreover, differences in genetic architecture across ethnicities
may affect replication rates across populations. A review of the literature found that although
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replication of individual variants may be low, when nearby markers are also considered, the
replication rate is high [471].
The emergence of next generation sequencing and newer, larger reference panels would
also increase the genetic resolution of future pQTL studies and facilitate fine-mapping of
pQTLs. Advances in this area will improve the accuracy of variants on the rare end of
the frequency spectrum, facilitating interrogation effects of rare variants on protein levels.
However, rare variants with large effects are also more likely to have protein-altering effects,
which as discussed in Chapter 4, can complicate their interpretation. Nonetheless, it would
also be interesting to assess any rare variants that affect protein levels via non-coding effects.
Plasma was used as the tissue of choice due to its various favourable properties discussed
in Chapter 1. However, soluble protein levels may not be reflective of tissue specific protein
expression and localisation. The complexity of blood plasma where many proteins are bound
to other proteins such as albumin, may affect the generalisability of genetic effects on protein
levels to other tissues. Previous studies have revealed tissue specific eQTLs (Section 1.3.4),
to what extent pQTLs in plasma are also seen in other tissues is currently unknown. An
additional complication is that some proteins may be expressed and produced in one tissue
but are then transported and accumulate in tissues at distal sites in the body. Tissue/cell-
type specific pQTL studies would be valuable in assessing pQTLs that are shared versus
those that are tissue specific. Analogous efforts such as the GTEx project have significantly
improved our understanding in this area in the the context of eQTLs. However, there are
still many technical challenges in optimising proteomic assays for other sample matrices and
affinity-based assays are mostly geared for soluble matrices (e.g. blood or urine).
The scale of the dataset and output of results (> 3×1010 association results) in this
study posed significant computational, data storage and access burdens, and this is also
the case when analysing other "omic" data. As a trade-off, which has also been made in
most omic QTL studies so far, I used a simple univariate linear model and analysed each
phenotype individually, in parallel through a computing cluster. More integrative approaches
such as multivariate models could be used to increase power to detect associations in the
context of correlation between proteins, reduce the amount of multiple testing and account
for pleiotropy across proteins. Although various multivariate GWAS have been developed,
they each had variable performance under different contexts and some have results that are
less straightforward to interpret [472, 473]. Furthermore, current methods are limited in
the number of phenotypes that can be feasibly analysed simultaneously and are sensitive to
model specifications [473]. Therefore, another area for future work would be developing
computationally feasible multivariate methods to account for correlation structure of high-
dimensional "omic" data as well as methods to select a relevant subset of proteins, statistically
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and/or biologically, for multivariate analyses. It should also be noted that meta-analysis
of summary results using univariate methods is much more straightforward compared to
multivariate methods where model specification between studies could vary significantly
and differences in effects conditional on other covariates cannot be assumed to be negligible
across studies. Lastly, whilst genetic data formats have mostly been optimised for storage
and access, summary association results have been less standardised in this regard despite
largely similar output parameters from regression. With the significant rising volume of
summary results from omic studies, optimising the storage and speed of access to specific
subset of results would make downstream data logistics more efficient.
As we enter the multi-omic era, another area of future focus should be developing
novel formal mathematical methods integrating various types of omic data (e.g. genomics,
transcriptomics, proteomics, metabolomics, epigenomics, and phenomics) to give a more
comprehensive view of biological and disease processes not apparent when looking at each of
the datasets in isolation. For example, methods have been developed to assess co-localisation
between summary association signals for two different traits (e.g. disease and eQTL) [474]
and active efforts are in progress to extend the method to analysing multiple traits thereby
allowing integration of additional endo-phenotypes (e.g. eQTLs, pQTLs, mQTLs and disease
loci).
7.4 Conclusion
Advances in genomic and proteomic technologies over the last decade have allowed data
capture at ever increasing coverage and resolution. This thesis combines high density genetic
measurements with protein measurements of unprecedented scope to reveal genetic control
of the human plasma proteome, significantly expanding on current knowledge. The scale
of the study also allows for extensive characterisation of the genetic architecture of pQTLs.
The discoveries enabled identification of important consequences of natural perturbations
in the plasma proteome and demonstrates their utility in uncovering intermediate molecular
pathways in biology and disease. The data generated here also complement generation of
hypotheses for further experimental and epidemiological follow up. Proteins provide an
ideal paradigm for MR analysis because they are under proximal genetic control. Whereas
MR studies of plasma proteins have been constrained by availability of few suitable genetic
instruments, the data generated here remedy this bottleneck by furnishing an extensive toolkit
for the scientific community and highlight the power of using proteomic data to account for
pleiotropic effects. To conclude, this study foreshadows major advances in post-genomic
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science through increasing application of novel bioassay technologies to major population
biobanks.
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Appendix A
Technical details of parameters used in
tools for GWAS testing
CARDIO cluster technical specification
The CARDIO cluster consists of 3 nodes:
• 1 high-memory node consisting of: 32 processors, 4 NUMA zones with 8 processors
within each zone, 1TB RAM.
• 2 low memory nodes each consisting of: 24 processors, 2 NUMA zones with 12
processors within each zone, 256GB RAM.
Commands used for comparison of different GWAS tools
genetic_data = genetic data used; pheno_regscanformat = phenotype file containing randomly
generated phenotype in RegScan format; pheno.sample = phenotype file containing randomly
generated phenotype in SNPTEST format; random_pheno = coloumn name of randomly
generated phenotype.
SNPTEST
Dosages
time snptest
-data genetic_data.bgen pheno.sample
-pheno random_pheno
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Technical details of parameters used in tools for GWAS testing
-method expected
-frequentist 1
-use_raw_phenotypes
-o snptest_output_dosages.tsv
Score test
time snptest
-data genetic_data.bgen pheno.sample
-pheno random_pheno
-method score
-frequentist 1
-use_raw_phenotypes
-o snptest_output_score.tsv
ML test
time snptest
-data genetic_data.bgen pheno.sample
-pheno random_pheno
-method em
-frequentist 1
-use_raw_phenotypes
-o snptest_output_ml.tsv
QUICKTEST
Dosages
time quicktest
--snptest
--geno genetic_data.gen.gz
--pheno pheno.sample
--npheno random_pheno
--method-mean
--no-progress
--ignore-ties
--out quicktest_output_dosages.tsv
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Score test
time quicktest
--snptest
--geno genetic_data.gen.gz
--pheno pheno.sample
--npheno random_pheno
--method-score
--no-progress
--ignore-ties
--out quicktest_output_score.tsv
ML test
time quicktest
--snptest
--geno genetic_data.gen.gz
--pheno pheno.sample
--npheno random_pheno
--method-ML
--no-progress
--ignore-ties
--out quicktest_output_ml.tsv
RegScan
Dosages
time regscan
-M gwas
-gfile genetic_data.gen.gz
-pfile pheno_regscanformat
-buffer 500
-out regscan_output_dosages.tsv
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Appendix B
Fig. B.1 Distribution of the predicted consequences of the sentinel pQTL variants compared to
matched permuted null sets of variants, stratified by cis and trans. Asterisks indicate empirical
enrichment p < 0.005.
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Fig. B.2 Boxplot of protein levels (normalised residuals) by ABO blood group and secretor status for
proteins with significant interactions (p < 1.5×10−5) from Fig. 5.11. Two boxplots are shown for
FAM3B as there are two SOMAmers used to assay FAM3B on the SOMAscan platform.
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Fig. B.3 Regional association plot of the cis PR3 pQTL for the alternate SOMAmer target.PRTN3.13720.95.3
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